The design of a synthetic, bioactive dermal scaffold to assist the healing of chronic, non-healing wounds by Gilmartin, DJ
  
 
The design of a synthetic, bioactive 
dermal scaffold to assist the healing 
of chronic, non-healing wounds
 
 
 
Daniel John Gilmartin 
 
 
A thesis submitted for the degree of 
  
Doctor of Philosophy 
 
UCL 
 
  
2 
 
Declaration 
I, Daniel John Gilmartin, confirm that the work presented in this thesis is my own. Where 
information has been derived from other sources, I confirm that this has been indicated in the 
thesis. 
 
Signed:        Date: 
 
Acknowledgements 
I would like to express my greatest thanks to the members of my laboratory who provided 
both scientific discussion and moral support throughout my PhD. Thank you to Nikki 
Davis, Jessica Sutcliffe, Katie Heath, Ming Hou and Beverley Bright. 
I would also like to extend my gratitude to members of the data analysis team at the UCL 
Confocal Imaging department at UCL for their much valued support during my use of the 
equipment in the facility. This includes Tim Robson, Chris Thrasivoulou, Daniel Ciantar 
and Jane Pendjiky. 
I also appreciate the scientific input and direction provided by my supervisors Prof David 
Becker and Dr Suwan Jayasinghe throughout the course of my PhD, as well as from 
Anthony Phillips of CoDa Therapeutics Inc. in New Zealand. 
Lastly, I would like to extend my sincere gratitude to all of my family and friends, without 
whom I could have never made it this far! 
 
  
3 
 
Abstract 
Chronic ulcers are painful, hard-to-heal wounds. To assist the healing of full-thickness 
ulcers and burns, engineers have designed scaffolds; synthetic skin substitutes intended to 
act as a temporary structure to support cell growth and wound regeneration. Remarkably 
few studies have investigated the effect of scaffolds on healing at the cellular level, 
however. Owing to the lack of clear evidence, the initial project aim was to investigate the 
function of scaffolds in vivo, with the hypothesis "scaffolds do not promote healing of full-
thickness wounds." After applying fabricated collagen scaffolds to full-thickness wounds, 
scaffolds appeared to integrate with the wound edge poorly. Wound edge keratinocytes 
were found to express markedly elevated levels of the gap junction proteins connexin 43 
(Cx43) and Cx26, surprisingly similar to chronic wounds. In an effort to improve 
integration, scaffolds were bioactivated through local application of a Cx43 antisense 
sequence (asODN). This significantly reduced wound edge Cx43 expression, epithelial 
thickening and inflammation of the surrounding tissue compared to using ordinary 
scaffolds, yet healing still occurred underneath scaffolds without matrix integration. An 
alternative hypothesis was formulated; that "scaffolds could instead be used to deliver 
drugs to render them beneficial in ulcer treatment." To achieve this, scaffolds were polymer 
coated with Cx43 asODN using an emulsion technique, and asODN elution was 
confirmed in vitro to occur over several days using UV spectrophotometry. Application of 
coated Cx43 asODN scaffolds significantly improved wound re-epithelialisation, even over 
untreated wounds, and prevented scaffold-associated adverse effects. Incorporation of 
novel Cx26 antisense sequences also significantly reduced wound edge Cx26 levels and 
improved re-epithelialisation. Wounds treated with combined Cx26 and Cx43 asODN 
scaffolds typically re-epithelialised further still, such that using both sequences may be 
synergistic. These findings support the use of coated scaffolds as drug delivery mechanisms 
that could be developed to treat chronic wounds.  
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1.1 – The structure and function of skin 
The skin is the largest organ in the body and serves an essential role to protect against 
stresses such as desiccation, injury and infection (Margadant et al., 2010). It is comprised of 
multiple distinct layers, each providing the skin with a number of different properties. 
1.11 – Epidermis 
The epidermis comprises the topmost layer of skin and the predominant cell type present 
in it is the keratinocyte. The primary role of keratinocytes is to form a tightly adherent layer 
of cells that has the important role of establishing a stratified squamous epithelial barrier 
(Figure 1. 1). Keratinocytes in the epidermis can be segregated into 4 distinct layers, each of 
which differs in shape and function. From the bottom layer upwards, keratinocytes in the 
epidermis can be categorised as belonging to the basal, spinous, granular or cornified layers 
(Haake et al., 2001). Many keratinocytes in the lowermost basal layer are capable of 
proliferation and are cuboidal in shape. Basal keratinocytes are a single layer and have the 
important function of anchoring the epidermis to the underlying basement membrane as 
well as supplementing the epidermis with additional keratinocytes (Martin, 1997). The 
former is achieved through the expression of cell-matrix junctional proteins termed 
hemidesmosomes on the cell membrane of basal keratinocytes, which bind to anchoring 
filaments contained within the underlying basal lamina (Figure 2. 1, top left). As new cells 
are produced, existing keratinocytes can delaminate from the basement membrane and 
progress upwards throughout the layers in a process termed terminal differentiation (Fuchs 
and Byrne, 1994). As well as keratinocytes, around 5-10% of cells in the basal layer of adult 
human skin are melanocytes. Melanocytes are responsible for the production of melanin, 
necessary to absorb UV radiation to afford a level of protection against DNA damage 
(Costin and Hearing, 2007). This is demonstrated in albino individuals, who are deficient in 
melanin production and prone to sun-mediated skin damage. Merkel cells are also prevalent 
within the basal layer of mammalian epidermis, and are associated with light touch 
discrimination of shape and texture. As such, they are more common in touch-sensitive 
areas such as the fingertips (Maricich et al., 2009). 
The layer directly above the basal layer is the spinous layer, and is usually around 8-10 rows 
of keratinocytes thick (Haake et al., 2001). Interspersing these keratinocytes are  
1. Introduction 
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Figure 1. 1 – The structure of human skin 
The skin is comprised of multiple layers of functionally distinct cells, and each layer can 
differ in the types of cells and cell junctions present. The structure of skin is shown both at 
a low power (bottom) and high power (middle). The major membrane bound channels 
present on keratinocytes are illustrated in the topmost illustration (image adapted from 
Colledge et al., 2010 using Goliger and Paul, 1995). 
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Langerhans cells. Langerhans cells are dendritic cells that function as antigen-presenting 
cells in the case of infection (Cella et al., 1997). The epidermal region of skin also 
contributes to the development of hair follicles, an appendage exclusive to mammals. 
These epithelial organs project downwards into the territory of the dermis and are 
accompanied by arrector pili muscles which can contract to elevate hair, as well as 
sebaceous glands to secrete sebum to lubricate and waterproof the skin (Paus and 
Cotsarelis, 1999). Keratinocytes in the spinous layer additionally express desmosome 
junctions on the surface of the cell membrane. Unlike hemidesmosomes, the extracellular 
domain of desmosomes anchors the cells to desmosomes of adjacent cells, while the 
intracellular domain binds to the intracellular keratin filaments within the cell cytoplasm 
(Green and Jones, 1996). Desmosomes are formed by an aggregation of adhesion 
associated cadherin proteins, and function primarily to mechanically adhere cells to one 
another. Formation of a barrier is also assisted by the presence of adherens junctions. 
These are assembled from transmembrane proteins of the cadherin family. Cadherins also 
bind to each other on neighbouring cells, while the internal domain bind to members of 
the catenin family of proteins. Catenins then anchor the cell to the actin cytoskeleton 
within the cell cytoplasm, resulting in a strong mechanical attachment between cells 
(Niessen, 2007). The closest contact formed between keratinocytes is due to the presence 
of tight junctions on the surface of the cell membrane. These are multiprotein complexes 
found only in epithelial cells and anchor the apical region of cells to one another. Tight 
junctions prevent the liberal diffusion of molecules between cells, thus allowing the 
establishment of distinct compartments. This is particularly important in the case of a 
lumen, such as in a blood vessel wall, and plays a crucial role in establishing apical to basal 
cell polarity. Three main protein families form tight junctions: occludins, claudins and 
junctional adhesion molecules (Niessen, 2007).  
Directly above the spinous keratinocyte layer is the granular layer. This is usually around 3-
5 rows of flattened keratinocytes thick and the cells are highly differentiated from those in 
the basal layer. Granular keratinocytes contain keratohyalin granules filled with histadine- 
and proline-rich proteins, resulting in classification of the layer as ‘granular’ (Haake et al., 
2001). These proteins are considered responsible for binding keratin filaments to one 
another. While being displaced from the granular to stratum corneum layers, keratinocytes 
secrete lamellar bodies that contain lipids and proteins to create a hydrophobic lipid barrier 
of protection for the skin (Schmitz and Muller, 1991). Additionally, during the process of 
1. Introduction 
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keratinocyte displacement in an upwards direction, the stratum corneum cells flatten 
further, enucleate and lose their cytoplasmic organelles and water. These terminally 
differentiated flattened cells, termed corneocytes, form the thick stratum corneum layer of 
skin which can comprise several layers (Candi et al., 2005). The number of layers depends 
on the location within the body; thick-skinned areas such as the soles of feet and palms 
contain the most layers (Caspers et al., 2003). Corneocytes, while biologically dead, are still 
filled with water-retaining keratin bundles. Corneocytes lie within a cornified protein 
envelope and are responsible for many of the barrier-related functions of skin (Kalinin et 
al., 2002). Corneocytes in the bottom layers of the stratum corneum attach to one another 
through corneodesmosomes, which are variants of regular desmosomes (Haftek et al., 
1998). As lower layers of corneocytes are displaced, protease degradation of these junctions 
allows dead skin cells to be shed through desquamation (Caubet et al., 2004). The total time 
taken between generation of a basal keratinocyte to it shedding from the stratum corneum 
is approximately 6 weeks (Haake et al., 2001). The shedding of skin is a finely tuned 
process where skin shedding occurs at approximately the same rate as keratinocyte 
replenishment. This balance is particularly important, since perturbations to the cycle have 
been frequently noted in painful hyperproliferative skin conditions (Bauer and Boezeman, 
1986, Weinstein et al., 1984).  
1.12 – Gap junctions 
Also embedded in the membranes of multiple cells throughout the epidermis and dermis in 
skin are gap junctions. Gap junctions are crucial for cell to cell communication and are 
formed by proteins of the connexin (Cx) family. These are structurally related four-pass 
transmembrane proteins found throughout a diverse number of cell types (Makowski et al., 
1977). Connexins have a cytoplasmic loop and two extracellular loops, as well as 
cytoplasmic facing C and N termini (Figure 1. 2). There are currently 21 known connexins 
in humans and 20 in mice, and the naming of connexin proteins refers to the molecular 
weight of the protein (Sohl and Willecke, 2004). In invertebrates, a group of proteins called 
innexins instead form gap junctions, which share homology with mammalian pannexins. 
Unlike connexins, pannexins are not thought to form gap junctions (Bauer et al., 2005, 
Panchin et al., 2000). In mammals, six Cx subunits assemble to form a connexon 
hemichannel embedded within the plasma membrane of a cell (Goodenough, 1975, 
Makowski et al., 1977). Individual connexon hemichannels on a cell surface can alone 
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function to allow the transport of ions between the cell and the environment 
(Goodenough, 1975). However, connexons on opposing cells can also dock to form a gap 
junction. Gap junctions formed by docking of two connexons can either be homotypic 
(both connexons are composed of the same connexin proteins), heterotypic (individual 
connexons are composed of one type of connexin, but the connexin in question is different 
between the two connexons), or heteromeric (an asymmetrical assortment of 6 connexin 
proteins makes up each connexon) (Sosinsky, 1995). Direct cell communication through 
gap junctions that cluster as plaques on cells can then be achieved through the passage of 
ions, metabolites and second messengers under 1 kDa in size (Yeager and Nicholson, 
1996). Gap junctions are found throughout multiple tissues and have been demonstrated to 
function across a number of processes, including heart contraction (Sohl and Willecke, 
2004), corneal homeostasis (Yuan et al., 2009) and wound healing (Coutinho et al., 2003). 
The prevalence of different connexin proteins differs between cell types and species, as 
well as the different layers of the epidermis, and this expression can change during 
processes such as wound healing (connexins are described in detail in section 2.3) 
(Coutinho et al., 2003).  
 
 
Figure 1. 2 – Vertebrate connexin structure and gap junction assembly 
Left: the simplified structure of a single connexin transmembrane protein. Middle: six 
connexin subunits group to form an active connexin hemichannel that can function to 
transport small molecules under 1 kDa in size. Right: hemichannels on neighbouring cells 
can dock to form a gap junction, allowing transport to take place between cells (figure 
created using information from Wagner, 2008). 
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1.13 – Dermis 
In humans and pigs, keratinocytes in the epidermis protrude into the underlying dermis as 
finger-like projections referred to as rete pegs. These strengthen the attachment of the 
epidermis to the dermis, although through the process of ageing the protrusions flatten and 
the epidermis thins, reducing skin resistance to shearing (Bank and Nix, 2006). In contrast 
to the epidermis, the dermis is a considerably thicker layer yet has a much lower cell 
density. The dermis functions as the connective tissue component of the skin and provides 
skin with elasticity and tensile strength (Vogel, 1974). The most common cell type in the 
dermis is the fibroblast. Fibroblasts are responsible for synthesis of many of the connective 
tissue components of the skin, the most abundant of which are collagen and elastin. In the 
case of the latter, elastin is often lost as the individual ages, resulting in a loss of elasticity 
and wrinkling (Narayanan et al., 1989, Sephel and Davidson, 1986). Collagen is the most 
prevalent protein, and in fact accounts for 75% of the dry weight of the human body. 
There are around 20 genetically distinct collagens, but the majority found within native 
dermal tissue belongs to type I, III and V. Of this, approximately 80-90% is type I and 8-
12% is type III (Weber et al., 1984). The various collagen species differ in the makeup of 
the 3 chains that form each collagen molecule. Collagen is synthesised through chain 
glycosylation, assembly into procollagen molecules and bonding to rough endoplasmic 
reticulum, where it is then destined for secretion into the extracellular space (Lodish H et 
al., 2000). There it is proteolytically cleaved by matrix metalloproteinase (MMP) enzymes, 
resulting in the formation of banded collagen fibrils and filament networks. 
 
Within the dermis, glycosaminoglycans, glycoproteins and proteoglycans together form a 
gel referred to as ‘ground substance’ through which migration can occur over, and it also 
provides a structure for the embedding of fibrous components. Skin proteoglycans are 
large molecules of around 100-2500 kDa in size and can bind up to 1000 times their own 
volume and regulate dermal volume (Archer, 2008). Glycosaminoglycans such as 
hyaluronan, on the other hand, are polymers that are formed of repeating disaccharides and 
provide a link to components of the overlying basement membrane (Brown et al., 2001). 
The glycoproteins present in the extracellular matrix include fibronectin, thrombospondin, 
tenascin and vitronectin, and similar to the other components of the dermis like collagen, 
they provide a substrate for cell adhesion and interaction through integrin receptors 
(Midwood et al., 2004). Many of the components in the dermis are not distributed evenly, 
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however, leading to the establishment of distinct layers within the dermis. The topmost 
layer of the dermis is labelled the papillary dermis. This contains the rete peg protrusions 
from the epidermis as well as small bundles of fine collagen fibrils and immature elastic 
fibres (Fore, 2006). The structural properties of the papillary dermis confer the ability to 
resist mechanical stress upon the skin. The layer also contains a large proportion of active 
fibroblasts that have the ability to synthesise proteoglycans to regulate dermal volume (Imai 
et al., 1992, Midwood et al., 2004). The papillary dermis also contains capillaries extending 
from the subpapillary plexus, which project into and terminate at the dermal rete pegs. 
These capillaries are necessary for nutrient exchange to both dermal and epidermal layers 
(Pasyk et al., 1989). Below the papillary layer is the significantly thicker reticular layer. 
Unlike the papillary dermis, this layer contains a far greater proportion of mature, large 
diameter collagen fibrils that are woven into a mesh network. Elastic fibres wrap around 
the collagen fibrils to form a combined structure, and provide the skin with a considerably 
strong level of mechanical stress resistance and elasticity (Silver et al., 2001). 
1.14 – Hypodermis 
Also referred to as subcutaneous tissue or subcutis, the hypodermis resides below the 
dermis and above tissue and bodily organs. The hypodermis is responsible for insulating 
the body as well as providing a shock resistant cushion to the skin (Tobin, 2006). The 
predominant tissue in the hypodermis is adipose tissue, and is often referred to as 
subcutaneous fat. The numerous adipocytes in this layer provide the body with an energy 
reserve for the body under starving conditions. The layer of fat is not present in all tissues, 
however; it is absent from multiple regions of the body including the scalp, eyelids and 
foreskin. (Hausman et al., 1981). The hypodermis is also highly vascularised, such that the 
layer is often selected for drug injection (Dominguez-Delgado et al., 2010). Also within the 
layer are apocrine and eccrine sweat glands responsible for release of sweat, as well as hair 
follicles that can extend deep into the hypodermis (Wilke et al., 2007). Unique to the 
hypodermis in certain areas of the body is the panniculus carnosus. This is a continuous 
striated sheet of muscle found in areas such as the scalp, face and hand, and is responsible 
for twitch contractions, and in the face allows the performance of certain facial 
expressions. In animals such as mice and rats the panniculus carnosus is considerably more 
extensive and covers larger areas of the body such as the back (Treuting et al., 2012). 
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1.2 – Acute wound healing 
In order to maintain the highly organised structure of skin following injury a complex series 
of events are triggered to restore the epithelial barrier and tensile strength of the tissue. 
1.21 – Haemostasis and inflammation 
When the skin is wounded a cascade of events to halt blood loss and repair the wound is 
initiated (Nurden et al., 2008, Figure 1. 3). In order to halt blood loss platelets are drawn to 
injury-induced extravasated blood and deposit a temporary fibrin-rich clot to plug the 
wound. Platelets also secrete platelet-derived growth factor (PDGF) and transforming 
growth factor ß1 (TGF-ß1) (Grainger et al., 1995). PDGF acts as a powerful 
chemoattractant, recruiting neutrophils, monocytes and macrophages, as well as the 
fibroblasts required for deposition of new ECM proteins (Hosgood, 1993). TGF-ß1 
stimulates macrophages to secrete inflammatory cytokines such as interleukin-1 (IL-1) 
 
 
Figure 1. 3 – Haemostasis and the early inflammatory response in acute wound 
healing 
Shortly after wounding, platelets are recruited and form a fibrin blood clot to prevent 
blood loss. Platelets secrete factors to attract neutrophils within the first 24 h, which are the 
first line of defence against infection (image derived from Stein and Kuchler, 2013). 
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and tumour necrosis factor α (TNFα), as well as additional PDGF to promote further 
chemotaxis of fibroblasts (Nurden et al., 2008). Characterisation of inflammation in 
response to a wound has been documented as far back as the Romans, who noted the signs 
of rubor (redness), tumor (swelling), calor (heat) and dolor (pain) (Shah, 2011).  
Within the first 24 h of injury, neutrophils that have been activated by pro-inflammatory 
cytokines undergo diapedesis to exit the capillaries close to the wound and begin to 
phagocytose dead cells, bacteria and debris (Lingen, 2001, Figure 1. 3). Neutrophil 
diapedesis is dependent on expression of various adhesion molecules on endothelial cells 
including endothelial P- and E-selectins as well as ICAM-1 and -2. In turn, these interact 
with integrins on the neutrophil surface, including CD18, CD11b and CD11c (Abbassi et 
al., 1993, Jones et al., 1993, Smits et al., 2000). Neutrophil recruitment is also promoted 
through the degranulation of mast cells to release a cocktail of pro-inflammatory cytokines. 
Indeed, studies of mast cell deficient mice indicated a decreased level of neutrophil 
recruitment (Egozi et al., 2003). As well as polymorphonuclear neutrophils, monocytes 
arrive at the wound site and are activated by TGF-ß1 as well as the ECM to develop into 
macrophages (Figure 1. 4). Neutrophil recruitment typically subsides after 2-3 days, while 
macrophages appear from around 2-3 days onwards. As monocytes mature, they can be 
differentially activated to become either M1 or M2 macrophage subtypes. M1 macrophages 
adopt a pro-inflammatory role, secreting inflammatory cytokines such as interferon gamma 
(IFN-γ), IL-1, IL-6, and IL-23, as well as reactive oxygen species (ROS). These are 
responsible for the targeted destruction and phagocytosis of pathogens and spent 
neutrophils (Diegelmann and Evans, 2004). M2 macrophages, on the other hand, instead 
express mediators that promote angiogenesis and tissue regeneration. These include IL-10, 
TGF-ß1 and low levels of IL-12. Macrophages are also responsible for the release of 
various mitogens, including PDGF and vascular endothelial growth factor (VEGF) 
(Mosser and Edwards, 2008, Strassmann et al., 1994). For this reason, some have argued 
that macrophage recruitment and function is crucial for efficient wound healing to occur, 
and macrophage depletion has been reported to result in a reduced wound healing capacity 
(DiPietro and Polverini, 1993). However, further evidence suggests that macrophages, and 
even neutrophils, may not be essential to wound healing. Wounds made in neonatal PU.1 
knockout mice that are deficient in macrophages and neutrophils re-epithelialise faster with 
an absence of fibrosis (Martin et al., 2003). While macrophages and neutrophils are 
important in targeting pathogens it is possible that beyond this, their main function is to 
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regulate scarring and fibrosis, as opposed to wound re-epithelialisation. If this is the case, 
anti-inflammatory therapies could improve the healing of even acute wounds (Martin and 
Leibovich, 2005). 
1.22 – Re-epithelialisation 
The re-epithelialisation stage consists of the proliferation and outward migration of 
epidermal keratinocytes to cover the open wound (Figure 1. 4). This step is initiated within 
24 h and coincides with the inflammatory phase (Winter, 1962). Re-epithelialisation is first 
triggered by TGF-ß1 release from activated macrophages, keratinocytes and macrophages 
which acts to drive keratinocyte integrin expression (Gailit et al., 1994). Desmosome and 
hemidesmosome adhesion complexes dissolve and peripheral cytoplasmic actin forms, 
allowing cell migration to take place (Chen et al., 1993). Re-arrangement of these actin 
bundles confers cell polarity and allows for the formation of a protruding lamellipodia used 
for migration. E-cadherin, required for adherens junction formation, has also been noted 
 
Figure 1. 4 – The late inflammatory, re-epithelialisation and proliferation phases of 
acute wound healing 
A few days into wound healing, monocytes are recruited that differentiate into 
macrophages. Macrophages release a number of factors that promote angiogenesis, 
fibroblast recruitment and ECM deposition, resulting in granulation tissue formation. 
Throughout wound healing and usually up to 7 days, keratinocytes at the wound edge 
become migratory to restore the epithelial barrier (image derived from Stein and Kuchler, 
2013). 
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to vanish from the leading edge keratinocytes in mouse wounds (Kuwahara et al., 2001). 
The expression of various integrins prior to re-epithelialisation prepares keratinocytes for 
migration and adhesion to the temporary wound matrix, consisting of fibronectin, 
vitronectin, tenascin and collagen (Gailit et al., 1994). Since keratinocytes are required to 
migrate through granulation tissue they enzymatically convert plasminogen at the clot to 
plasmin, which degrades a pathway for cell advancement (Pepper, 2001). Around 24-72 h 
after migration commences, a dramatic increase in the proliferation of keratinocytes behind 
the migratory leading edge occurs (Usui et al., 2005). This, alongside contributions from 
epidermal stem cells in hair follicles, supplies keratinocytes to repair the broken epidermis. 
Migrating keratinocytes also deposit laminin to help reconstitute the basal membrane 
(Nguyen et al., 2000). Once the epithelial barrier is restored at around 5-7 days, 
keratinocytes once again adopt a flattened morphology and reform cell-cell junctions. Re-
stratification then occurs, leaving behind an epidermis similar to that in uninjured tissue. 
This re-epithelialisation process is affected by dynamic changes in Cx43. Cx43 
downregulation at the wound is necessary in keratinocytes and fibroblasts in order to adopt 
a migratory phenotype (discussed in further detail in section 1.32; Goliger and Paul, 1995, 
Coutinho et al., 2003, Mendoza-Naranjo et al., 2012a).  
 
1.23 – Granulation tissue formation 
Around three to five days after injury granulation tissue rich in vascular endothelial cells, 
macrophages and fibroblasts is formed at the wound (Tonnesen et al., 2000, Figure 1. 4). 
The proliferation and subsequent migration of fibroblasts into the tissue is due to the 
release of cytokines and growth factors from active macrophages and platelets, including 
PDGF and TGF-ß1 (Schreier et al., 1993). Fibroblasts adhere to and migrate along the 
fibrin matrix laid down by platelets and monocytes, into the wound space. The main 
function of fibroblasts in the early proliferative phase is to rapidly synthesise collagen III, 
providing structural support to the wound (Klinge et al., 2000). This is largely regulated by 
TGF-ß1, which increases fibroblast transcription of collagen- and protease-related genes, as 
well as the downregulation of MMP activity by inducing expression of tissue inhibitors of 
metalloproteinases (TIMPs) (Hall et al., 2003). 
Newly formed tissue must obtain a blood supply. Components of the recently deposited 
ECM, particularly fibrin, have been shown to promote angiogenesis (Knighton et al., 1982). 
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Macrophages and fibroblasts also secrete cytokines that promote proliferation and 
chemotaxis of vascular endothelial cells, such as fibroblast growth factor 2 (FGF2), TGF-α, 
vascular endothelial growth factor (VEGF) angiopoietin and TNFα (Li et al., 2003). 
Expression of the αVß3 integrin on cells has also been linked to promotion of migration and 
blood vessel elongation (Brooks et al., 1994). Localised hypoxia is also an important trigger 
of angiogenesis. Hypoxia Inducible Factor (HIF)-1, a heterodimeric transcription factor, 
accumulates under hypoxic conditions (Semenza, 2001). Accumulated HIF-1 subsequently 
assembles as heterodimers which then go on to drive transcription of pro-angiogenesis 
factors such as VEGF.  
1.24 – Wound closure and remodelling 
Re-epithelialisation is not the only contributor to wound closure. Fibroblasts at the wound 
edge can also differentiate into specialised contractile cells termed myofibroblasts, and are 
most numerous around 4-14 days after wounding (Darby et al., 1990, Figure 1. 5). This 
differentiation can be induced by various soluble factors including TGF-ß1, PDGF, TNFα 
and IL1. Myofibroblasts primarily differ from fibroblasts by their accumulation of large 
bundles of alpha smooth muscle actin along the cytoplasmic face of the plasma membrane  
 
Figure 1. 5 – The remodelling phase of acute wound healing 
From around 5 days onwards, fibroblast differentiation into myofibroblasts results in a 
contractile cell capable of promoting wound closure. Newly deposited ECM fibres are 
continuously crosslinked and processed through activity of matrix metalloproteinases for 
up to 2 years (image derived from Stein and Kuchler, 2013). 
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(Thannickal et al., 2003). These bundles function to allow contraction in conjunction with 
ongoing re-epithelialisation to pull the wound margins together. Initially appearing close to 
the wound margins, myofibroblasts eventually reside close to the centre of wounds around 
7-14 days after wounding. Interestingly, targeted knockdown of Cx43 has been shown to 
advance the differentiation of fibroblasts to myofibroblasts by around 1-2 days, resulting in 
acceleration of wound closure and loss of myofibroblasts from the edge of wounds (Mori 
et al., 2006). In contrast to this, a different study made use of skin implants that release 
lithium chloride, a known gap junction intercellular communication (GJIC) inducer, and 
found that there was an increased amount of granulation tissue deposited, and that collagen 
fibres were more mature (Moyer et al., 2002). After the two migrating epithelial sheets have 
fused many myofibroblasts show signs of apoptosis (Desmouliere et al., 1995). This may be 
necessary for optimal healing, as persistence of myofibroblasts has been found in keloid 
scars where collagen deposition is extreme (Ladin et al., 1998). The ECM is then 
remodelled for up to 2 years to enhance the tensile strength of the new skin (Gurtner et al., 
2008, Figure 1. 5). During this time the type III collagen deposited by fibroblasts is 
gradually degraded by MMPs and replaced with the more versatile type I collagen (Klinge 
et al., 2000). MMP activity reduces the collagen density found in the provisional matrix, 
after which a fine balance between synthesis and degradation of further collagen is 
established (Witte et al., 1998). The most time-consuming stage of remodelling is the 
continuous crosslinking of matrix proteins, resulting in an end restoration of about 70-80% 
of the original tissue tensile strength (Diegelmann and Evans, 2004). In adults, this method 
of remodelling results in formation of a fibrous scar (Stadelmann et al., 1998). This is not 
the case in the developing embryo where healing is privileged and occurs without scarring 
(Martin, 1997). This is in part due to healing occurring solely by actin contraction in cells at 
the wound in a purse string method (Redd et al., 2004).  
 
1.3 – Connexins in wound healing 
The structural components of gap junctions, connexins, have been implicated throughout 
development and a number of other biological processes. These include heart contraction 
(Jalife et al., 1999), CNS signalling (Dermietzel et al., 1991), mammary gland differentiation 
(El-Sabban et al., 2003), inflammation (Mori et al., 2006) and wound re-epithelialisation 
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(Wang et al., 2007, Qiu et al., 2003). The variations between different connexins occur 
primarily through variations in the cytoplasmic loop and the C-terminus of the protein 
structure, and have given rise to the 21 different connexin proteins in humans. Specifically 
in skin, expression profiling of these individual connexin proteins in both intact and 
wounded skin reveals distinct localisation and function of the different connexin types. 
1.31 – Connexins in intact skin 
In rodents there are at least 4 connexins that are differentially expressed in the skin during 
the wound healing process; Cx43, Cx26, Cx30 and Cx31.1 (Risek et al., 1992, Goliger and 
Paul, 1995). Cx43 is the most ubiquitous connexin and also the most studied. It has been 
implicated in a number of processes including inflammation, wound re-epithelialisation, 
differentiation and proliferation (Becker et al., 2012, Mori et al., 2006, Qiu et al., 2003). In 
intact skin, Cx43 is expressed in the epidermis, dermal fibroblasts, hair follicles, vascular 
smooth muscle cells and sebaceous glands (Table 1. 1). In rodent epidermis Cx43 
expression tends to be localised to the basal layer, while in humans Cx43 is also present  
Structure Human Rodent 
Stratum corneum none none 
Granular layer 31.1++, 26low, 31++, 37, 30.3+++, 40++ 26low, 30low, 31.1+, 31, 37 
Spinous layer (upper) 30+, 31.1+, 26low, 37, 31+, 30.3+, 45low 31, 37 
Spinous layer (lower) 43++, 30+, 31.1+, 37, 31 31, 37 
Basal layer 43+, 32+ 43++, 37, 40 
Fibroblasts 43+, 40low, 45low 43+ 
Blood vessels 43+++, 26++, 30+ 43+++, 26++, 30+ 
Sebaceous glands 43++ 43+ 
Hair follicles 43+++, 26++, 30+, 31.1low 43+++, 26++, 30+, 31.1low 
 
Table 1. 1 – Connexin expression in the uninjured skin of humans and rodents  
The expression of a number of different connexins is localised to specific regions of the 
skin. In the order of highest relative expression to lowest: +++ > ++ > + > low. 
Connexins whose levels of expression have not accurately been determined for individual 
compartments have not been assigned a symbol (table constructed using information from 
Richard, 2000 and Coutinho et al., 2003). 
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within the lower and upper rows of keratinocytes within the spinous layer (Di et al., 2001). 
While Cx43 expression is strongly expressed in the epidermis, both Cx26 and Cx30 are 
expressed at barely detectable levels in the granular layer of rodent skin as well as at 
moderate levels in the hair follicles and blood vessels (Coutinho et al., 2003, Goliger and 
Paul, 1995). In the thicker human skin, both connexins are also present at low levels within 
the upper spinous layer of keratinocytes. Cx31.1 is detectable at low levels within the 
granular layer in rodents, as well as at very low levels within hair follicles. As Cx31.1 
appears to be confined to the granular layer in which keratinocytes undergo apoptosis to 
produce dead cells in the cornified layer, Cx31.1 may have a role in co-ordinating cell-death 
signals between these cells (Coutinho et al., 2003, Goliger and Paul, 1995). Indeed, in 
ovarian follicles undergoing atresia through apoptosis, Cx31.1 expression is restricted to 
atretic follicles, lending credence to the possibility that Cx31.1 can mediate the 
communication of apoptotic signals (Wright et al., 2001). While around 10 connexin genes 
are found to be expressed in human adult skin (Table 1. 1), it is unclear exactly how each 
one is involved in maintenance of the skin physiology. Of these connexins, Cx43, 26, 30 
and 31.1 have been linked to the process and resolution of wound healing, and are 
dynamically regulated following injury (Coutinho et al., 2003, Goliger and Paul, 1995). 
 
1.32 – Connexins in acute wounds 
Following injury, within the first 6-24 h there is a strong downregulation of Cx43 as well as 
Cx31.1 in leading edge keratinocytes of the basal layer in rodent skin (Table 1. 2). At 
around 1-2 days the level is reduced to the extent that it is almost undetectable (Coutinho 
et al., 2003, Goliger and Paul, 1995). At the same time, keratinocytes flatten, extend 
lamellipodial protrusions and migrate outwards across the wound bed. These two 
occurrences have been linked, as knockdown of Cx43 experimentally has been found to 
accelerate cell migration while overexpression has found to slow it (Mendoza-Naranjo et 
al., 2012b, Qiu et al., 2003). There are a number of possibilities as to why Cx43 
downregulation may be necessary during wound healing. The cytoplasmic tail of Cx43 is 
capable of interacting with cytoskeletal proteins both directly through a PDZ domain as 
well as through adhesion associated proteins like ZO-1, Cadherins and both α- and β-
catenin. The cytoplasmic tail has also been found to interact with actin and microtubules 
(Butkevich et al., 2004, Giepmans et al., 2001a, Shaw et al., 2007, Theiss and Meller, 2002, 
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Wei et al., 2005). Indeed, a wide array of protein interactions with Cx43 have been 
reviewed, including those mediated by the C-terminus of Cx43 (Herve et al., 2012). While 
this could affect adhesion and cell migration directly, the sequestration of transcription 
factors such as β-catenin could also influence gene expression. In this way it has been 
suggested that Cx43 may form a nexus, acting as a regulator of other genes in a separate 
capacity to its role in forming gap junctions (Iacobas et al., 2007, Spray et al., 2002). Cx43 
expression in the dermis also changes following wounding. Cx43 downregulation occurs in 
dermal fibroblasts at around 24-48 h and this has been shown to result in enhanced 
migration both in vitro and in vivo (Mendoza-Naranjo et al., 2012b, Mori et al., 2006). This 
enhancement may be due to a decrease in fibroblast adhesion since Cx43 downregulation 
was observed in conjunction with activation of the small GTPases Rac1 and RhoA. RhoA 
has a role in regulation fibroblast lamellipodial protrusion, while Rac1 can help stabilise 
newly extended protrusions (Machacek et al., 2009, Mendoza-Naranjo et al., 2012a). In  
 
Table 1. 2 – Changes in rodent connexin expression in injured keratinocytes, wound 
fibroblasts and proximal epidermal appendages up to 7 days after acute wounding  
The table illustrates the expression of connexin proteins at the leading edge in the case of 
epidermal keratinocytes. Connexin levels increase (green), decrease (red) or do not differ 
from the level of intact cells (yellow). Grey is used where a particular connexin is never 
expressed in that particular compartment (table constructed using immunofluorescence 
staining data from Coutinho et al., 2003). 
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contrast, Cx43 levels increase in blood vessels surrounding the wound within the first few 
hours as they become leaky due to inflammation. This leakiness results in blood 
extravasation, which delivers additional inflammatory cells and platelets to the site of 
damage (Coutinho et al., 2003, Cronin et al., 2008). While Cx43 is downregulated in the 
leading cells, just a short distance away cells are actively proliferating and around 4 days 
post wounding they overexpress Cx43 (Coutinho et al., 2003). This raises the possibility 
that during wound healing, keratinocytes at the wound edge may form a communication 
compartment distinct from cells in the same layer that are just a short distance away. 
 
This concept is further supported by the role of Cx26 and 30 during wound healing. Unlike 
Cx43, Cx26 and 30 are expressed at almost undetectable levels in the granular layer of 
epidermis in rodent skin. However, during wound healing the keratinocytes at the wound 
edge undergo rapid upregulation of these connexins throughout the granular and spinous 
layers (Coutinho et al., 2003). The exact function of Cx26 and 30 in wound healing is 
unclear; although it has been shown that ectopic overexpression of Cx26 is associated with 
hyperproliferative conditions and a delay in barrier reformation (Djalilian et al., 2006). As 
previously discussed, gap junctions can be either heterotypic or heteromeric and thus can 
be comprised of more than one type of connexin subunit. However, Cx43 cannot form 
channels with Cx26 and 30 due to differences in coupling properties (Marziano et al., 
2003). This presents a scenario in which the leading edge keratinocytes express connexins 
that are incompatible with connexins a short distance back, such that leading edge cells may 
not be able to communicate in a manner such as receiving signals relating to adhesion.  
 
1.4 – Chronic and diabetic wound healing 
A small wound will typically re-epithelialise within 5-7 days; at which point the migrating 
keratinocytes fuse to restore the epithelial barrier. In some situations, however, hard-to-
heal wounds may develop in which the normal series of events leading to restoration of the 
epithelial barrier is perturbed. These chronic ulcers commonly appear on the feet of 
diabetics (diabetic foot ulcers; ‘DFUs’), as venous ulcers on the legs of the elderly (venous 
leg ulcers; ‘VLUs’) and also as pressure ulcers on bedbound patients (‘PUs’). Chronic ulcers 
place a huge burden on healthcare organisations and result in a significant deterioration of 
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patient quality of life. A conservative estimate made for the 2005-2006 period projected the 
cost of ulcer management in the UK to be £2.3-3.1 billion, accounting for 3% of total 
health expenditure. Around 200,000 patients in the UK were estimated to have a chronic 
ulcer at any one time, the majority of which are VLUs. These figures are expected to 
increase considerably due to the ulcer risk factors of age and diabetes. In the US, the World 
Health Organisation (WHO) anticipates that one third of all US adults will be diabetic by 
2050. Of these, around 2.5-10.7% of diabetics are likely to develop a DFU. DFUs can be 
particularly detrimental to quality of life since in 1.8% of diabetics the lead to foot 
amputation (Centers for Disease Control & Prevention, 2011, Hunt, 2011). The ageing 
population is also a factor, with the worldwide population of over 60s expected to exceed 2 
billion by 2050 (WHO, 2011). PUs alone amount to an annual £1.4 – 2.1 billion cost, over 
90% of which is spent on nursing (Bennett et al., 2004). 
1.41 – Ulcer aetiology 
Diabetic foot ulcers 
The development of effective chronic wound treatments requires investigation into the 
aetiology of chronic ulcers. The causes of chronic ulcers vary between VLUs, DFUs and 
PUs. In diabetic individuals, the presence of neuropathies allows minor abrasions to remain 
unchecked by the patient, such that they can develop into larger non-healing DFUs. 
Neuropathies also prevent the release of neuropeptides such as nerve growth factor, which 
promote cell chemotaxis and growth factor production (Galkowska et al., 2006). Once 
wounds have been formed, diabetics are at a disadvantage compared to normal individuals. 
Under hyperglycaemic conditions, excess glucose is converted to sorbitol at the cost of 
NADPH (Yagihashi et al., 2007). NADPH is necessary for the production of antioxidant 
reducing equivalents nitric oxide and reduced glutathione. With reduced levels of 
antioxidants at the wound the balance between reactive oxidant species (ROS) and 
antioxidants in the wound is lost, resulting in accumulation of ROS that can cause tissue 
harm and prolong the duration of healing (Vincent et al., 2004). Fibroblasts derived from 
hyperglycaemic patients have also been found to divide more slowly, while the ability of 
leukocytes to phagocytose and destroy bacteria was markedly reduced (Loots et al., 1999, 
Mowat and Baum, 1971). Capillary blood flow is also reduced in diabetic individuals and 
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can contribute to hypoxic damage of tissue and a poor healing environment (Jorneskog et 
al., 1995). 
Venous leg ulcers 
In contrast to DFUs, the underlying causes of VLUs relate to venous insufficiency in the 
legs. In healthy individuals, the hydrostatic pressure in the deep veins of the leg when 
standing approximates to 80 mm Hg (Falanga, 1993). Movement of the leg causes the calf 
muscle to contract, causing deep veins to compress and transiently elevate blood pressure 
in order to propel blood in an anterior direction. As pressure rises in the deep veins, valves 
close to prevent retrograde flow of blood. As the deep vein system empties, deep vein 
pressure drops to between 0-10 mm Hg, allowing valves to re-open and for blood to re-
enter the deep vein system (Gourdin and Smith, 1993). Venous hypertension, which 
precedes development of VLUs, occurs as a result of perturbation to this series of events. 
This can be caused either by valvular incompetence resulting in retrograde blood flow, or 
calf muscle dysfunction which results in insufficient clearance of blood (Gourdin and 
Smith, 1993, Falanga, 1993). In either case, the fall in pressure normally experienced 
following deep vein emptying is not achieved, resulting in the condition described as 
venous hypertension. Ultimately, this results in the pooling of hypoxic blood in the legs, 
which in turn promotes the death of tissue and the development of an inflammatory 
response. 
Pressure ulcers 
PUs occur as a result of mechanical stress and subsequent ischaemia reperfusion damage, 
commonly in bedridden individuals (Berlowitz and Brienza, 2007). They commonly form 
as localised areas of necrosis in response to compression of soft tissue between a bony 
prominence and an external surface for prolonged periods. Typical sites where PUs can 
occur are the heels, back and elbows, due to prolonged resting on these areas in a setting 
such as a hospital or nursing home. The constant resting on one particular area can raise 
the interstitial pressure of capillaries in that region. Normal capillary pressure ranges 
between 12-32 mm Hg (Kosiak et al., 1958). Pressures over 32 mm Hg result in 
compromises to oxygenation and circulation, which is of particular concern since lying on a 
hospital bed can generate pressures of up to 150 mm Hg (Daniel et al., 1981). Studies also 
suggest that considerable durations of hypoxia followed by repeated reperfusion events can 
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in fact cause more damage than hypoxia alone (Peirce et al., 2000). While just 2 hours of 
constant pressure at 70 mm Hg on a single region can cause cell death, intermittent relief of 
pressure can avoid damage to the tissue that would otherwise occur (Kosiak, 1959). The 
likelihood of developing PUs can also be promoted through friction, shearing forces and 
moisture (such as in patients with urinary incontinence) (Herman and Rothman, 1989). As 
such, the prevention of PUs in many cases is dependent on the effective management of 
bedbound patients in hospitals and care homes. 
1.42 – Shared features of chronic ulcers 
While the underlying causes of the three main types of ulcers differ, a number of features 
are present in all cases. Chronic ulcers are invariably associated with an elevated 
inflammatory response that does not typically resolve within the usual 1 week associated 
with acute wounds. One common cause of inflammation is the excessive colonisation of 
wounds with bacteria and sometimes fungi. Regardless of the type of bacteria present, a 
level greater than 106 organisms per gram of tissue is associated with impaired healing 
(Bendy et al., 1964). Chronic ulcers are also frequently found to develop biofilms 
containing the bacteria P. aeruginosa. Biofilms are complex communities of bacteria that 
envelope within a self-secreted polysaccharide matrix. This protects bacteria from 
neutrophils and may also explain the failure of some antibiotics to heal chronic wounds 
(Bjarnsholt et al., 2008). Inflammation is also accelerated by the repeat ischaemic events in 
most of the ulcer conditions. In VLUs, venous insufficiency results in the retention of 
deoxygenated blood, resulting in a hypoxic environment. Reperfusion also increases the 
incidence of oedema, which increases the distance between capillaries and renders the 
environment even more hypoxic (J et al., 2010). In a hypoxic environment of under 40 mm 
Hg pO2, neutrophils have been shown to lose their bactericidal properties, further 
increasing the likelihood of developing infections (Hohn et al., 1976). The same hypoxic 
insults are experienced repeatedly in PUs, since extended pressure applied to regions of 
soft tissue reduces blood flow to the region. Readjustment of posture later on then results 
in blood reperfusion of the affected area. Diabetics are known to suffer from a number of 
microvascular diseases that also contribute to hypoxia, including reduction in capillary size, 
thickening of the basement membrane and arterial thickening (hyalinosis). 
The repeated occurrence of hypoxia followed by reperfusion events results in the 
continuous delivery of blood containing leukocytes that are activated in response to the 
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hypoxic environment to release ROS and pro-inflammatory cytokines (Woo et al., 2007). 
The generation of ROS also affects the availability of growth factors such as VEGF in the 
wound, inhibiting the level of angiogenesis occurring in chronic ulcers. In the hypoxic stage 
of an acute wound immediately following injury, the transcription factor hypoxia inducible 
factor (HIF)-1α is constitutively expressed which triggers fibroblasts to release VEGF. 
Excessive ROS have been shown to degrade HIF-1 α at the post-transcriptional level, 
resulting in reduced VEGF levels in the ulcer (Zou and Cowley, 2003). Following hypoxia, 
the reperfusion of oxygen to oxygen-starved cells can then also result in cell apoptosis, 
leading to further tissue damage within the chronic ulcer. Inflammation also drives the 
destruction of the underlying dermal integrity of skin. The upregulation of pro-
inflammatory cytokines IL-1, IL-6 and TNF-α in turn cause upregulation of MMPs, 
particularly MMP-2 and MMP-9 (Han et al., 2001, Raffetto and Marston, 2011). MMP-2 
was also reported to be increased 3-fold in DFUs (Lobmann et al., 2005). MMP activity is 
crucial in acute wound healing to degrade and remodel the newly deposited ECM. 
Normally MMP function is tightly regulated by Tissue Inhibitors of Metalloproteinases 
(TIMPs) within the wound. However, the rise of MMP activity and the reduction of TIMP 
levels in chronic ulcers results in considerable degradation of ECM proteins laid down in 
the wound, including collagen types I and III and fibronectin (Chen and Rogers, 2007, 
Muller et al., 2008). MMPs also act to degrade growth factors and their receptors, 
compromising wound regeneration (Ren et al., 2014). The loss of ECM is particularly 
detrimental to wound healing as it behaves as a substrate for migration and proliferation of 
tissue regenerative fibroblasts as well as restoring tensile strength and integrity to the skin. 
1.43 – Connexin expression in chronic ulcers and diabetic wounds 
In diabetics, wound healing is compromised, and hyperglycaemia appears to affect the level 
of connexin expression throughout numerous cells. In the endothelial cells of diabetics, 
some reports suggest that the expression levels of Cx37, Cx40 and Cx43 do not differ from 
normoglycaemic cells, while others argue that the levels are reduced. There is a general 
agreement that Cx43 expression and GJIC is decreased diabetic blood vessels, however, 
which occurs in conjunction with vessel breakdown and cell death (Zhang et al., 2006a, 
Muto et al., 2014, Makino et al., 2008, Inoguchi et al., 2001, Bobbie et al., 2010). Diabetic 
vascular endothelial cells as well as those cultured in vitro in hyperglycaemic conditions 
have also been found to have reduced gap junctional communication but an increase in 
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Cx43 phosphorylation (Kuroki et al., 1998, Inoguchi et al., 2001). Within the intact 
epidermis, studies of streptozotocin (STZ) diabetes-induced rats indicate that Cx43 and 
Cx26 protein expression as well as GJIC is significantly reduced (Wang et al., 2007). 
Hyperglycaemia does not appear to downregulate connexin levels across the board, 
however, since conflicting reports indicate Cx43 expression is both increased and 
decreased in diabetic kidney tubules (Zhang and Hill, 2005, Satriano et al., 2010, Poladia et 
al., 2005). Recent studies also suggest that Cx43 protein levels are instead increased in the 
hyperglycaemic dermis, with a positive linear relationship between blood glucose 
concentration and Cx43 expression in dermal fibroblasts identified (Mendoza-Naranjo et 
al., 2012b). Gap junction intercellular communication (GJIC) was also found to be 
increased in the diabetic dermis (Wang et al., 2007). Hyperglycaemia appears to affect cells 
differently and the reasons for these differences are not completely understood.  
During wound healing it is necessary for Cx43 downregulation to occur within 24 h in 
wound edge keratinocytes in order for cells to become migratory to reform the epithelial 
barrier (Wang et al., 2007, Qiu et al., 2003). The pre-established low levels of Cx43 in 
diabetic epidermis do not confer an advantage to wound healing, however, as studies of 
wounds in STZ rats have highlighted. Full-thickness wounds made to the dorsum of STZ 
rats form thickened non-migratory bulbs of keratinocytes at the wound edge which contain 
a high level of Cx43 protein (Wang et al., 2007). In those diabetic wounds Cx43 was only 
downregulated around 48 h after wounding, at which point keratinocytes began to migrate 
properly. Similar results have also been found in a human study of diabetic ulcers, in which 
ulcer wound edge keratinocytes were found not to downregulate Cx43 (Brandner et al., 
2004). These findings have been contested by a later study, however, which investigated 
human diabetic ulcer biopsies and found no significant change in Cx43 and Cx26 mRNA 
and protein levels (Brandner et al., 2008). Additionally, keratinocytes and fibroblasts 
cultured from diabetic ulcer biopsies showed similar localisation and levels of Cx43 
following immunostaining and western blotting (Pollok et al., 2011). The reason for these 
conflicting reports is unclear, but could be due to differences in chronic ulcer severity and 
subsequent cell culture conditions. 
Unlike Cx43, Cx26 expression in the STZ rats did not elevate above the high levels 
normally encountered in acute wound edge keratinocytes but expression was elevated 
further back from the wound edge, and over a larger area (Wang et al., 2007). Cx26 is 
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strongly associated with hyperproliferative skin conditions (Thomas et al., 2003). Cx26 has 
been found to be directly involved in regulating thickness of the epidermis, as mutations in 
the Cx26 gene GJB2 have resulted in a thicker epidermis both within the human population 
and using in vitro organotypic models (Man et al., 2007). These mutations can frequently go 
on to cause deafness. Cx26 upregulation has also been found to occur in hyperthickened 
psoriatic lesions (Labarthe et al., 1998). Experimentally, it has been shown that inducing 
Cx26 overexpression using an involucrin promoter in mouse keratinocytes increased ATP 
release which delayed re-epithelialisation, promoted hyperproliferation of the epidermis 
and caused invasion of inflammatory cells (Djalilian et al., 2006). 
 
1.5 – Chronic wound treatment 
1.51 – Conventional treatments 
Chronic ulcers have multiple underlying problems that existing therapeutic solutions 
attempt to address. Conventional approaches to treating ulcers often attempt to address the 
high levels of pressure that can cause ulcers to form as well as deal with oedema. 
Particularly in DFUs and VLUs, a common mode of treatment is to employ the method of 
offloading to reduce pressure. This includes bed rest, wheelchair use, wearing leg casts or 
elastic stockings and the wearing of therapeutic shoes (Wu et al., 2008). Elevation of the leg 
is also practiced in conjunction with compression therapy to improve the return flow of 
blood to the heart as well as reduce fluid buildup (Abu-Own et al., 1994). Compression 
therapy is a slow process, however, and although it can help reduce oedema, after 24 weeks 
of practice in one study it was found to be successful in only 30-60% of cases (Margolis et 
al., 2000). In contrast to applying pressure through compression, negative pressure 
treatments have also been practiced. Controlled negative pressure can be applied using a 
vacuum-assisted closure device to remove excess fluid released from open wounds. While 
there are indications that this practice may help reduce wound size and volume, it has been 
noted that there is not currently sufficient evidence or high quality data to support its use in 
ulcer management (Ubbink et al., 2008). 
Dressings are also typically applied to wounds in order to provide a temporary barrier 
against infection and also to keep the wound moist. Since the 1960s, it has generally been 
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accepted that wounds benefit from a moist environment as oppose to air drying, so a 
number of dressings have been developed to keep wounds moist (Hinman and Maibach, 
1963). Multilayer compression bandaging is routinely practiced in VLU treatment and 
dressings are usually placed on the ulcer before compression bandages and wrappings are 
applied (Fletcher et al., 1997). These wound dressings include foams, hydrocolloids, 
hydrogels, transparent films, gauzes and alginates (Fonder et al., 2008). The choice of 
dressing is often based on the level of exudate released from the ulcer, as well as based on 
the level of infection and necrotic tissue present in a wound. While dry gauzes have 
historically been a popular choice of dressing, evidence suggests that they can desiccate the 
wound base and that moist wound dressings may have a greater effect on wound healing 
(Callen et al., 2009, Bolton et al., 2004). Dry wounds are often the target of water-based 
hydrogel applications such as ActivHeal in order to create a moist wound environment, 
while wounds with heavy exudate may receive highly absorbent alginate or foam dressings 
(Jones and Milton, 2000, Fonder et al., 2008). Wounds that are particularly prone to 
infection may be treated with a transparent adhesive film, which provides a barrier against 
bacterial infection while also trapping internal moisture. Incorporation of silver have also 
been noted for their antimicrobial properties, but are not considered cost effective (Lo, 
2010). Transparent dressings can lead to discharge, however, and are not recommended for 
use in wounds with heavy exudate (Fonder et al., 2008). Hydrocolloids dressings such as 
Tagasorb are occlusive dressings that combine a gel-forming agent with an adhesive. They 
can be applied for a longer amount of time than regular dressings but are expensive relative 
to other dressing types (Singh et al., 2004). Despite the diverse number of dressings tailored 
to seemingly suit any type of ulcer, a comprehensive BMJ review of 254 dressing studies 
concluded that there was no convincing data that suggested the advanced dressings 
conferred any statistical improvement to ulcer healing (Palfreyman et al., 2007). This 
highlights the lack of scientific studies into the function of dressings and may also indicate 
that they are not actually that effective in promoting the healing of ulcers. 
1.52 – Surgery 
Conventional pressure therapy in conjunction with dressing application has a 71-80% 
chance of healing acute ulcers that are less than 3 months old. For ulcers that have been 
present for more than 3 months and are considered chronic, the chance of the wound 
healing falls to just 22% (Nelson et al., 2000). The prevalence of chronic ulcers highlights 
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the need for research into novel treatments as well surgical intervention. Chronic ulcers 
containing large amounts of necrotic tissue, bacteria and debris may be eligible for 
debridement in order to expose the receptive cells at the wound edge. This can be 
performed as sharp debridement using a scalpel or using biological methods such as the 
application of larvae (Dumville et al., 2009, Lebrun et al., 2010). While the rationale for 
debridement is logical, there is a need for convincing evaluations of undebrided versus 
debrided wounds. A review of five DFU studies of debrided wounds found that studies 
often lacked meaningful observations of wound healing following debridement and a lack 
of statistical significance testing (Lebrun et al., 2010). A second review of studies that 
employed debridement in VLU management concluded that, similarly, there was a need for 
accurate assessment of the effect of debridement on wound healing relative to undebrided 
wounds (Collins and Seraj, 2010). Despite this, debridement is commonly performed in 
DFU management alongside management of infection and offloading practices (Alexiadou 
and Doupis, 2012). 
A significant problem present in chronic ulcers is the overactivity of MMPs in the wound, 
resulting in proteolytic degradation of the epidermal basement membrane and dermal 
ECM. This results in a loss of wound integrity and can significantly reduce the potential for 
the ulcer to heal. In order to address large ulcers, another surgical approach is to perform 
autografting to cover the ulcer with healthy tissue. (An et al., 1995). This can be impractical 
in diabetic patients, however, since healing is often compromised in individuals such that it 
is unfeasible to create additional wounds in order to harvest tissue. This can also be true in 
the case of significant burns, where extensive damage to the body can leave too small an 
amount of viable tissue from which to derive grafts (Vacanti et al., 1998). One method to 
generate more tissue from a patient is to culture donor grafts in the laboratory. However, 
this method has significant drawbacks; it requires weeks of cell culture and the graft take 
success rate can be low. The chance of patient graft take can vary between 15-85%, with an 
average of just 53% for full-thickness wounds (Atiyeh and Costagliola, 2007, Paddle-
Ledinek et al., 1997). Skin grafting can also be ineffective when there is persistent oedema, 
which can often be the case in VLUs (Jones and Nelson, 2007). The practice of allografting 
in which donor tissue is derived from another person can also be employed, yet studies 
suggest that these may only act as temporary barriers within the host. DNA analysis of 
healed wounds in one study indicated that the healed tissue did not contain the DNA of 
the allograft donor (Roseeuw et al., 1990, Phillips and Gilchrest, 1991). 
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1.53 – Scaffolds as a chronic ulcer treatment 
The unsuitability of grafting in many ulcer patients has led to the production of epidermal 
and dermal mimicking devices termed 'scaffolds'. These are typically inserted into the full-
thickness ulcer or burn and are intended to function similar to the skin components they 
mimic (Shevchenko et al., 2010). Unlike dressings, which serve primarily as a means to 
control wound hydration and minimise infection, scaffolds are intended to be functional by 
either integrating with the wound or serving literally as a scaffold for cell adhesion and 
proliferation (Shevchenko et al., 2010). A range of commercial scaffolds have been made 
developed to treat full-thickness wounds (Figure 1. 6). Arguably the most complex types of 
scaffolds include Apligraf (Organogenesis website, 2011) and Orcel (Forticell Bioscience 
website, 2011). These are bilayer arrangements of human keratinocytes over an animal-
derived ECM containing human fibroblasts. Cell seeded scaffolds that comprise only 
epidermal (e.g. Epicel) or dermal (e.g. Dermagraft) layers are also commercially available. 
While improved wound closure rates using Apligraf have been reported, cellular scaffolds 
have several disadvantages: they are both expensive and time consuming to produce, and 
there is a potential risk of rejection of the incorporated allogenic cells (Schonfeld et al., 
2000). Apligraf in particular was estimated to cost about $30 per square cm in 2002 
(Bouchie, 2002). While reports detailing rejection of Apligraf are scarce, it was found that 
the scaffolds did not actually integrate with wounds as an autograft would, contrary to the 
original manufacturer claims made regarding the product. It was instead proposed that 
these this type of scaffold may instead promote wound healing by stimulating growth 
factor production (Ehrenreich and Ruszczak, 2006). Cellular scaffolds may therefore not be 
acting as substitutes for skin. 
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Figure 1. 6 – Examples of commercial cellular, acellular and extracellular matrix-
derived scaffolds. 
Scaffold information and diagram adapted from Shevchenko et al., 2010. 
 
Due to the drawbacks associated with cellular scaffolds, a number of scaffolds have been 
manufactured that are acellular, either as lyophilised extracellular matrix extracts (Oasis, 
Alloderm) or synthesised from scratch using synthetic components such as nylon (DRT, 
Integra) (Shevchenko et al., 2010). Dermal scaffolds have also been experimentally 
fabricated from ECM-derived polymers including collagen (Torres-Giner et al., 2009), 
fibrinogen (McManus et al., 2007) and hyaluronic acid (Ji et al., 2006), as well as from 
synthetic polymers such as polycaprolactone (PCL) (Garcia-Giralt et al., 2008) and 
polylactic-co-glycolic acid (PLGA) (Yang et al., 2009). These polymers have also been 
fabricated as solid microspheres and aqueous hydrogels in addition to large sheet structures 
(Ashton et al., 2007).  
The scope of current scaffold studies is limited, however, to the point that it is not clear 
whether most scaffolds actually improve wound healing. It appears that many wound 
healing studies involving scaffolds focus simply on whether wound closure occurs, with 
little exploration into the effect of scaffolds on cells at the wound (Gholipour Kanani and 
Hajir Bahrami, 2010, Rho et al., 2006, Sabolinski et al., 1996, Wainwright, 1995). Many 
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clinical studies also investigate the effect of scaffolds long after the wound has closed and 
the scaffold has degraded, often 30 days or more after the scaffold was initially applied. 
Additionally, studies using electrospun scaffolds are frequently performed by engineers 
who typically use cells as opposed to in vivo models to assess the function and 
biocompatibility of scaffolds, which does not accurately recapitulate the conditions of a 
wound (Chong et al., 2007, Zhang et al., 2005). The studies that assess wound healing at 
early time points often do not focus on the leading edge cells at the wound, and when 
images are captured they can often be at a low magnification where it is difficult to assess 
the reaction to scaffolds (Blackwood et al., 2008, Khil et al., 2003, Powell and Boyce, 2006). 
The efficacy of scaffolds has also been called into question following in-depth reviews of 
wound healing devices. A recent report investigated 60 studies that used venous leg ulcer 
advanced dressings, which included both ordinary dressings as well as cellular and acellular 
dermal scaffolds. They found the majority of scaffold studies to be flawed, concluding that 
that they could not prove that they significantly improved healing over controls (Zenilman 
et al., 2013). There is therefore a clear need to assess the effects of scaffolds on wound 
healing to determine whether they are suitable for use in healing chronic ulcers. 
1.54 – Antisense oligodeoxynucleotide therapy 
Due to the upregulation of Cx43 in chronic ulcers (Mendoza-Naranjo et al., 2012a, 
Mendoza-Naranjo et al., 2012b) and STZ diabetic rat wound edge keratinocytes (Wang et 
al., 2007), the concept of downregulating Cx43 as a potential chronic ulcer treatment has 
recently been explored. Antisense therapeutic approaches allow the targeting of individual 
components through the design of DNA and RNA molecules. These include ribozymes, 
which are engineered, catalytically active RNA molecules that can cleave the target mRNA 
sequence (Scherer and Rossi, 2003). Similar to RNAzymes are DNAzymes, which also 
target and directly cleave mRNA transcripts, but are instead engineered DNA molecules 
(Santoro and Joyce, 1997). RNA interference is another RNA-based approach that can 
result in effective gene silencing. In this method, the design of short interfering RNA 
sequences can result in the targeted degradation of specific mRNA transcripts (Soutschek 
et al., 2004). 
Research performed in the Becker lab, however, has led to the focus on single stranded 
antisense oligodexoynucleotides (asODN) as a method to downregulate Cx43, since it is 
typically overexpressed in chronic ulcers and models of perturbed wound healing 
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(Mendoza-Naranjo et al., 2012a, Mendoza-Naranjo et al., 2012b, Wang et al., 2007). The 
first successful use of ODN in gene therapy was by Zamecnik Stephenson in 1978, using a 
13-mer ODN complementary to the terminal sequences of the Rous sarcoma virus 35S 
RNA (Stephenson and Zamecnik, 1978). Using this approach, they demonstrated a 99% 
reduction in reverse transcriptase activity and a decrease in cellular transformation. The 
principle by which asODN silences protein expression is outlined in Figure 1. 7. In this 
method of silencing expression, a single stranded DNA sequence of typically no more than 
30 base pairs in length is designed that is complimentary to a length of the target mRNA 
sequence. Following gene transcription in the target cells to produce mRNA, the ODN 
sequence then binds to it (Akhtar, 1998). It has been suggested that asODN can prevent 
protein translation of the mRNA by two or more different ways. The first is that asODN 
prevents ribosome binding to the mRNA through steric interference, which has been 
supported by the finding that asODN directed against ribosome assembly regions had the 
greatest effect on translation (Boiziau et al., 1991, Goodchild, 1989). The second is through 
induction of RNaseH activity to degrade the mRNA. This occurs because RNaseH 
specifically recognises DNA-RNA duplexes such as those formed between mRNA and 
asODN. Silencing has also been found to take place following asODN entry into the 
nucleus to inhibit splicing, as well as prevent pre-mRNA processing or mRNA exit from 
the nucleus. 
The design of effective asODN sequences is critical in order to achieve effective silencing. 
There are two main methods employed to design ODN sequences. The first method is a 
more conventional approach, often referred to as a 'walk-the-gene' strategy (Akhtar, 1998). 
A series of ODN sequences that are complimentary to sites along the length of the mRNA 
sequence are immediately evaluated both in vitro and in vivo. This approach is particularly 
time consuming and not entirely exhaustive, leading to some dependence on chance 
(Akhtar, 1998). The second approach involves the use of RNaseH mapping (Ho et al., 
1996). In this method, a random or semi-random library of ODN sequences are hybridised 
to the mRNA sequence of interest, after which RNaseH is used to cleave only the duplexed 
structures. The resulting fragments are then analysed on a gel to identify accessible sites for 
designing asODN.  
Silencing protein expression using asODN has certain limitations, however. The most 
limiting factor regarding asODNs is their short duration of activity owing to their swift  
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Figure 1. 7 – Antisense oligodeoxynucleotide mode of action. 
Antisense oligodeoxynucleotide (asODN) sequences are designed complimentary to a 
section of the target mRNA sequence. These sequences bind to the mRNA and prevent 
protein translation, as well as inducing catalytic breakdown of the mRNA sequence via 
RNaseH activity (image derived and adapted from Robinson, 2004). 
degradation by exo- and endonucleases, both in the wound and within the cell cytoplasm 
(Agrawal, 1996). Specific 3' and 5' modifications, such as phosphorothioate modification, 
have been shown to increase the stability of asODN against nuclease damage (Shaw et al., 
1991). However, modifications have been shown to come at the cost of efficacy, and have 
also been demonstrated to increase both cell cytotoxicity and the chance of non-specific 
events occurring (Agrawal, 1996). High affinity is also particularly important in order to 
achieve effective silencing. Longer asODN sequences tend to result in greater affinity 
binding, as well as higher numbers of guanine-cytosine pairs (Hoke et al., 1991). 
Despite the short half-life of unmodified asODN sequences, application of asODN using a 
Pluronic hydrogel vector to prolong asODN longevity has been found to result Cx43 
knockdown for up to 2-3 days in the spinal cord, where Cx43 is not normally 
downregulated (Cronin et al., 2006). Cx43 protein has a short half-life of 1.5 h, such that 
the effects of preventing new protein production can be quickly observed (Leithe et al., 
2006). Using a 30-mer sequence directed against the rodent Cx43 mRNA, knockdown of 
Cx43 was accelerated in mouse wound edge keratinocytes. Within 2 h of wounding Cx43 
expression in wound edge keratinocytes had decreased, which is 4 h sooner than in 
untreated wounds (Goliger and Paul, 1995, Qiu et al., 2003). While Cx43 is normally 
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downregulated at the wound edge, the application of Cx43 asODN appeared to accelerate 
this downregulation, alongside increasing the rate of wound re-epithelialisation (Mori et al., 
2006, Qiu et al., 2003). Downregulation with Cx43 asODN also significantly reduced Cx43 
expression in diabetic rat wounds that expressed high levels of Cx43, similar to chronic 
wounds (Wang et al., 2007). The effects of the same Cx43 asODN sequence were also 
confirmed in another study which found that the inflammatory response was reduced, 
while fibroblast migration and wound closure was also significantly accelerated (Mori et al., 
2006). Given the positive results obtained in vivo, a human Cx43 asODN sequence is 
currently being tested as the drug Nexagon® to treat chronic ulcers and has passed stage 2 
clinical trials. In the trials it was found that there was a 69% reduction in VLU size 
following treatment with the drug (CoDa Therapeutics Inc. official webpage, 2011). 
Treatment of wounds with other asODN sequences to different targets has also been 
found to have an effect. In a different study, asODN against the glycoprotein osteopontin 
was found to significantly downregulate expression of the protein in wounds, as well as 
enhance the rate of wound re-epithelialisation, reduce fibrosis and dampen inflammation 
(Mori et al., 2008). The use of asODN sequences therefore appears to be a valid method to 
address the deregulated expression of specific proteins in perturbed healing. While asODN 
delivered using Pluronic gel is still degraded within hours, the incorporation of asODN 
into drug-eluting stents has indicated that alternative methods may afford a level of 
protection to DNA in a nuclease-rich environment (Zhang et al., 2004). 
 
1.6 – Aims of the study 
Dermal scaffolds are purported to promote wound healing by acting as a substitute 
extracellular matrix for cell adhesion and proliferation. Despite this, there is little conclusive 
evidence to support these claims, and particularly not at the cellular level or at the early 
stages of wound healing. Owing to a lack of supporting evidence, this led to the initial null 
hypothesis for the project, that: 'scaffolds do not promote healing of full-thickness wounds'. If 
this hypothesis were accepted, the next stage was to assess why this was the case and 
whether scaffolds could be optimised to promote wound healing.  
To test this hypothesis it required the fabrication of scaffolds similar to those used in 
wound healing studies, followed by application to full-thickness wounds using animal in 
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vivo models. Upon application, the reaction of wound edge keratinocytes could be assessed. 
Following the findings of the first results chapter (chapter 3), the hypothesis was 
considered to be correct. Scaffolds appeared to exert a negative effect on wound healing 
across a number of different observations. Attempts to optimise this scaffold using Cx43 
asODN to overturn the upregulation of Cx43 appeared only somewhat effective, yet it 
appeared that scaffolds may better function as a reservoir of Cx43 asODN through 
infusion of the structures with the drug. 
As such, a method of coating scaffolds in a similar way to sustained drug delivery stents 
was devised as a technique to deliver Cx43 asODN over time. Using this method, the aim 
was to improve the rate of wound re-epithelialisation and scaffold integration through 
delivery of Cx43 asODN to the wound. It also became apparent that Cx26 was also 
implicated in perturbed healing, and the availability of two new Cx26 asODN meant that 
Cx26 overexpression could be targeted as a second means to improve wound healing. 
Altogether, the aims of the project were to first investigate the effects of scaffolds on 
wound healing and then to design a scaffold capable of delivering asODN sequences 
beneficial to the healing of full-thickness wounds. 
 
The summarised aims for the project were therefore as follows: 
1. To produce a dermal scaffold for application to full-thickness wounds, to verify whether 
scaffolds promoted or inhibited the healing of full-thickness wounds at the cellular level. 
2. After scaffolds appeared to inhibit wound healing, the aim was to devise a novel coating 
method to coat scaffolds with Cx43 asODN, in order to assess whether scaffolds could 
function instead as a Cx43 asODN delivery device to promote wound healing. 
3. Following positive results using coated scaffolds, the final aim was to address whether 
scaffolds coated in the same manner but with novel asODN sequences to Cx26 mRNA 
could also improve in vivo wound healing, and whether combined Cx26 and Cx43 asODN 
coated scaffolds could further promote wound healing. 
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Introduction 
In this chapter, the techniques and materials used to carry out the experiments in chapters 
3-5 will be described. 
 
2.1 – Scaffold materials and design 
2.11 – Collagen scaffolds 
The method used to generate the scaffolds used throughout this study was electrospinning. 
This technique was chosen following a short review of the literature, in which it was found 
to be one of the most commonly used techniques to produce scaffolds (Huang et al., 2003). 
The primary aim of this study was to produce a scaffold comparable to those produced in 
other studies, such that the results and observations made throughout the first chapter of 
this thesis would be relevant to the engineers producing, but not thoroughly testing, their 
scaffolds. Electrospinning was also selected because it is relatively inexpensive and capable 
of producing micro-scale spun fibres similar to those found in commercial scaffolds 
(Shevchenko et al., 2010). Another significant factor governing the choice of scaffold 
fabrication method was our existing lab collaboration with Dr Suwan Jayasinghe, who had 
both the relevant experience and apparatus to produce scaffolds. Following a further 
search into the literature and the advice of Dr Jayasinghe, collagen was selected as the 
major scaffold fabrication material due to its abundance in the native matrix, routine use in 
biomaterials studies, biodegradability and ease at which it can be electrospun (Buttafoco et 
al., 2006, Huang et al., 2003). The method of electospinning used in a study by Torres-
Giner et al. (2009) was further modified over 6 months as this study thoroughly 
characterised the fibres produced with detailed methods, and was well cited by other 
sources (cited by 38 other publications). Collagen scaffolds were fabricated by 
electrospinning acid-soluble bovine collagen (>99% purity, Kensey Nash, PA, USA) 
blended with poly-ε-caprolactone (>99% purity, Sigma Aldrich, Poole, UK) at a 10:1 
weight ratio, respectively. The electrospinning work was carried out in Dr Jayasinghe’s 
laboratory in the Department of Mechanical Engineering at UCL. Blended polymers were 
dissolved in hexafluoropropan-2-ol (HFP, 99% purity, Apollo Scientific, UK) at 10% 
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(wt./v.). In this study, scaffolds were electrospun at a flow rate of 5 ml/hour, with a needle 
to collector distance of 130 mm and using an output voltage of 13 kV.  
In total, 30 ml of polymer solution was spun onto a 9 cm2 foil sheet to produce scaffolds 
with an average thickness of 0.8 mm. To generate thinner scaffolds with an average 
thickness 0.4 mm, 14 ml of polymer solution was electrospun (Figure 3. 4 only). Uncoated 
electrospun scaffolds in this study (but not coated scaffolds) were crosslinked by 
immersion in either a high (15% wt./v.) or a low (0.15% wt./v.) concentration of N-(3-
Dimethylaminopropyl)-N'-ethylcarbodiimide (EDC)  hydrochloride (99.5% purity, Apollo 
Scientific) in a 1:10 water to acetone solution. Scaffolds were washed for 20 min with sterile 
PBS, sterilised for 1 h using 70% ethanol, and washed 3 times with sterile PBS. Scaffold 
discs were then punched out using a 6 mm biopsy punch to match the size and shape of 
excisional wounds. 
2.12 – Alginate microspheres 
Alginate microspheres were produced in the same laboratory as the electrospun scaffolds. 
Microspheres were produced by electrospraying medium 2% (wt./v.) viscosity alginic acid 
powder Phosphtate buffered saline (PBS) solution (Sigma, A2033). The electrospraying 
process was carried out to a previously described specification (Klokk and Melvik, 2002). 
The polymer mixture was electrosprayed at a distance of 10 cm from the collector, using a 
voltage of 8 kV and a flow rate of 10 ml/hour. Microspheres were sprayed into a gelling 
bath containing a 200 µM concentration of calcium chloride dehydrate solution (≥98% 
purity, Sigma) to become crosslinked. The average sphere diameter generated using this 
method was measured as 685 µm using a phase contrast microscope at a 10 X objective. 
2.13 – Commercial scaffold materials 
Both alginate hydrogel and dressing materials under the brand name ActivHeal were kindly 
provided for use by Prof David Becker. This is produced by Advanced Medical Solutions 
(website: http://www.activheal.com).  
2.14 – Scanning electron microscopy assessment of scaffold structure 
Collagen scaffolds were air dried for 3 h at room temperature, snapped, and mounted onto 
aluminium stubs. Samples were sputter coated and subsequently imaged using a JEOL JSM 
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7401F electron microscope system set at 2.0 kV. Images were acquired at 800 X 
magnification.  
2.15 – Investigation of scaffold porosity 
Scaffold porosity was assayed by submerging scaffolds in a Pluronic gel solution 
comprising 30% (wt./v.) Pluronic® F-127 powder (Sigma Aldrich, UK) and 5% 
Fluorescein isothiocyanate (FITC) in water at 4 ºC overnight. The Pluronic F-127 structure 
is comprised of propylene oxide and ethylene oxide blocks that form a triblock structure 
resulting in a molecular weight of between 9,840–14,600. Pluronic gel is a liquid at 4 ºC and 
below, yet above this temperature it forms a gel with a toothpaste consistency. The gelling 
of Pluronic is thought to be due to the formation of micelles as a result of polypropylene 
oxide block dehydration. As temperature increases, micelles come into contact with each 
other and no longer have space to spread out. The restriction of micelle movement is 
believed to underlie the gelling of the solution (Machado et al., 2013). Scaffolds were then 
placed under a Leica MZ8 dissection microscope and excited using the FITC filter set to 
confirm the presence of FITC. The presence of fluorescence throughout the scaffold 
structure was confirmed and considered an indicator of scaffold permeability, such that the 
entirety of the scaffold was considered permeable to the vector. 
2.2 – Scaffold bioactivation 
2.21 – Infusion with Pluronic gel containing Cx43 asODN 
Rat Cx43 antisense oligodeoxynucleotides (Cx43 asODN), sequence 5’-GTA ATT GCG 
GCA GGA GGA ATT GTT TCT GTC-3’ (Sigma Genosis), were dissolved in molecular 
grade water to make a 1 mM stock.  They were then diluted into a 30% (wt./v.) Pluronic 
gel solution to a 30 μM concentration. Pluronic gel is liquid at 1-4ºC but sets to a 
toothpaste consistency when above about 4ºC. Collagen scaffolds of 6 mm diameter were 
immersed in 20 μl of either Pluronic gel containing Cx43 asODN or PBS at 4°C overnight. 
Alginate microspheres were soaked in a volume of Cx43 asODN Pluronic gel equal to the 
volume of polymer used in electrospraying at 4°C, which was 5 ml. 
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2.22 – Application of polymer coatings containing Cx43 asODN 
Unlike the Pluronic gel infusion method, both Cx43 and Cx26 asODN sequences were 
incorporated into polymer coatings using an emulsion technique. The same rat Cx43 
asODN sequence that was used in Pluronic gel delivery (section 2.21) was used for the 
purpose of coating scaffolds and had the sequence 5’-GTA ATT GCG GCA GGA GGA 
ATT GTT TCT GTC-3’. A non-functional sense (sODN) sequence to this Cx43 asODN 
was also incorporated to create one of the control scaffold treatments, and had the 
sequence: 5’- GAC AGA AAC AAT TCC TCC TGC CGC AAT TAC-3’. A modified 
version of this Cx43 asODN sequence was also separately obtained that had the 
fluorophores Cy3 and Cy5 conjugated at the 5’ and 3’ ends, respectively.  
In the case of Cx26 asODN, two different novel sequences had been developed by the 
laboratory at CoDa Therapeutics Inc in New Zealand and preliminary testing in the UCL 
laboratory suggested they were promising leads from previous in vivo data. These asODN 
sequences were both 20-mers, termed ‘AS3’ and ‘AS6’ (sequences currently undisclosed at 
the suggestion of CoDa Therapeutics Inc.). These sequences were entered into a multiple 
sequence analyser to confirm that the sequences did not bind each other or themselves 
(available at: www.thermoscientificbio.com/webtools/multipleprimer). Due to the limited 
time remaining in the PhD to examine each individually, both of these Cx26 sequences 
were instead combined into one coating mixture. The asODN sequences were first 
dissolved in nuclease-free water to a 10 mM concentration. Either PCL or Poly(D, L-
lactice-co-glycolide) (PLGA) was then dissolved in the solvent dimethyl carbonate (Sigma 
517127) at 10% wt./v. using gentle rocking. The PLGA selected had a lactide : glycolide 
content ratio of 65:35 ratio (Sigma, P2066). The aqueous asODN solutions were pipetted 
into the dissolved polymer solution to either a 100 μM final concentration (in the case of 
the initial coating experiments) or 300 μM, as used everywhere else. These two immiscible 
layers were then processed for 10 seconds using a handheld T8.01 Netzgerat IKA 
Labortechnik homogenizer (Janke and Kunkel, Staufen, Germany) on setting 4 (medium) 
at room temperature to produce an emulsion. After preparing the coating mixture, 
individual 6 mm collagen scaffolds were dipped for 1 second in the desired polymer-
asODN solutions and immediately placed in a tube of liquid nitrogen. Coated scaffolds 
were lyophilised in an Edwards (model name ‘Modulyo’) freeze-drier attached to an 
Edwards high vacuum pump (model EZM2) overnight to remove the solvent from the 
2. Materials and Methods 
57 
 
scaffolds in order to maintain the structure of the scaffold. In the later scaffold 
experiments, this coating process, from dipping to freeze drying, was repeated 3 times to 
produce 4 layers of polymer + asODN, or 7 times in the case of 8-layer ‘double coated’ 
scaffolds, which in total received 4 coating layers of PCL + asODN followed by 4 layers of 
PLGA + asODN.  
 
2.3 – In vitro analysis of coated scaffolds 
2.31 – Quantification of asODN elution 
Scaffolds coated in asODN using the emulsion method were assayed for asODN release 
rate in vitro. Three coated scaffolds were immersed in 40 μl of nuclease free water at 37°C. 
At daily intervals, 1.5 μl of liquid was removed and assayed using a NanoDrop 2000 UV 
spectrophotometer under the ‘ssDNA’ setting to determine DNA concentration. Scaffolds 
were placed in a fresh 40 μl of water to compensate for the reduction in volume following 
water removal for assays. Individual time point elution data was collected to produce both 
cumulative and daily asODN elution graphs.  
 
2.32 – Förster Resonance Energy Transfer (FRET) analysis 
The integrity of asODN incorporated into scaffolds was assessed using a Förster 
Resonance Energy Transfer (FRET) imaging technique (Hu et al., 2009). Scaffolds coated 
with Cx43 asODN conjugated at either end to fluorophores Cy3 and Cy5 using the 
previously detailed emulsion method was used in this technique. Scaffolds were either left 
untreated or submerged in 37°C sterile foetal bovine serum (FBS) for up to 7 days. 
Samples were removed every 24 h then snap frozen in Tissue-Tek® Optimal Cutting 
Temperature (OCT) medium (Sakura Finetek, UK), and sectioned to a thickness of 10 μm 
using a Leica cryostat. Scaffold sections were then washed briefly with PBS and mounted 
with a size 1 coverslip using Citifluor AF1 mountant (Citifluor Ltd, UK). Samples were 
imaged using a Leica SP8 confocal microscope using the FRET wizard package available 
within the Leica LAS AF software. Scaffolds were assessed using a FRET acceptor 
bleaching technique. Using this method, six randomly selected areas of FRET coated 
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scaffolds per time point were bleached for the Cy5 acceptor fluorophore using a 633 nm 
laser. After the Cy5 acceptor is bleached, an increase in donor Cy3 excitation can indicate 
that FRET was occurring since energy used to excite the Cy3 was previously resonating to 
the Cy5 fluorophore (Figure 2. 1). A marked increase in Cy3 signal emission at 570 nm 
post-bleaching was considered to be indicative of FRET activity, since energy was no 
longer transferring to the acceptor fluorophore via FRET. The detected change in donor 
emission intensity was acquired and interpreted by the software package to calculate a 
FRET efficiency percentage (FRETeff). The formula to calculate the FRETeff is stated in the 
software package and is as follows:  
FRETeff =(Dpost – Dpre) / Dpost 
In this formula, Dpost is the fluorescence intensity of the donor after photobleaching and 
Dpre is the donor fluorescence intensity prior to photobleaching. A minimum percentage of 
15-20% has been considered indicative of genuine FRET occurring in other studies (Lai et 
al., 2014)., and the average percentage obtained in this study was 21.4%. Images captured  
 
Figure 2. 1 – A simplified diagram illustrating the principles of FRET.  
(A): When an asODN sequence tagged with both Cy3 and Cy5 fluorophores at either end 
is intact, fluorophores are less than 10–100 Å apart (Sekar and Periasamy, 2003). When the 
donor fluorophore (Cy3) is excited using a 543 nm wavelength laser a portion of this 
energy may transfer resonate to the proximally located acceptor fluorophore (Cy5), 
resulting in light emissions at both 570 nm and 670 nm wavelengths. (B): When the 
asODN sequence is degraded, the fluorophores are no longer within range to permit 
FRET to occur, resulting in emission largely at 570 nm when excited with a 543 nm laser. 
10–100 Å 10–100 Å 
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were 8-bit single optical sections with a resolution of 1024 by 1024 pixels. To determine 
the potency of serum in degrading asODN the wavelength emission spectra of 6 asODN 
regions per time point were generated by performing xyλ-mode scans on FRET labelled 
asODN that had been incubated in FBS at 37°C. Individual λ-scans were performed using 
a 543 nm laser excitation, with 19 equally sized detection steps occurring between the 
wavelengths of 550 nm to 730 nm. Emission values were output using the LAS AF 
software. 
2.4 – Animal procedures 
All animal procedures and experiments were performed under the terms of a UK Home 
Office License and in accordance with the UK Animals (Scientific Procedures) Act, 1986. 
All animals were housed in individual cages at the Biological Service Unit at University 
College London. Animals obtained from suppliers were kept on site for 7 days to allow 
adjustment prior to experimentation. 
2.41 – Rodent strains 
ICR (CD-1) outbred mice were obtained from Harlan Laboratories and used in 
experiments at 6 weeks old. Sprague Dawley rats were reared on site at the BSU and also 
used at 6 weeks old. Animal weights were measured prior to surgery to calculate drug 
doses. 
2.42 – In vivo full-thickness wounding 
Anaesthesia was induced using 4% isoflurane, 20% oxygen and 10% nitrous oxide, and 
maintained using 1.5% isoflurane. Animals were injected subcutaneously with 0.03 mg/ml 
buprenorphine (Vetergesic®) before operation. The rodent dorsum was initially shaved 
then covered in a thin layer of Nair® hair removal cream (Church and Dwight, UK), after 
which both the cream and hair was removed using a warm moistened gauze pad. Animals 
were then placed on a heated mat for the duration of the procedure. Four full-thickness 
excisional biopsy punch wounds were made using a 6 mm medical biopsy punch to rodent 
backs, two on each side of the dorsal midline. Collagen scaffolds (coated or uncoated), 
alginate microspheres, commercial products (either an ActivHeal® brand alginate dressing 
or hydrogel; Advanced Medical Solutions, Winsford, UK) or 20 μl pluronic gel containing 
microspheres were applied directly to wounds, and covered with Tegaderm™ film (3M, 
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UK). Post-procedure, animals were kept in a heated chamber and monitored for recovery. 
Once recovered, animals were rehoused in individual cages and monitored regularly. 
 
2.5 – Histology procedures 
2.51 – Harvesting wounds 
Animals were culled by cervical dislocation at 1, 3, 5, 10 or 15 days post wounding. A large 
sheet of back skin containing the wounds was first excised to allow macroscopic imaging of 
individual wounds using a Leica MZ8 dissection microscope at 0.63 X magnification (D1-
5). Wounds were subsequently excised and fixed by immersion in a 4% paraformaldehyde 
(PFA)-PBS solution for 24 h at 4°C. Samples were washed 3 times for 1 h in PBS then 
transferred to 20% sucrose-PBS solution for 24 h at 4°C. Wounds were bisected and one 
half was snap frozen in OCT medium, then sectioned using a cryostat at a thickness of 
either 5 μm (mice) or 10 μm (both mice and rats). For mouse tissue, 5 μm thick tissue 
cryosections were stained with haematoxylin and eosin whilst 10 μm sections were used for 
immunostaining. 
2.52 – Haematoxylin and eosin staining 
Frozen tissue sections were thawed for 5 min then covered completely in tap water for 5 
min at room temperature. Slides were submerged in Harris’ haematoxylin solution (HHS16, 
Sigma) for 30 seconds followed by immersion in a container full of running tap water for 5 
min. Background staining was reduced by dipping the slides in a container full of 1% acid 
alcohol (1% glacial hydrochloric acid, 70% ethanol, 29% distilled water) for 3 seconds, after 
which slides were immersed in a container of running tap water for a further 5 min. 
Samples were then submerged for 15 seconds in a container full of eosin B solution (2853, 
Sigma), followed by immersion for 5 seconds in a container full of tap water to rinse away 
excess stain. Slides were then immersed in 70% ethanol for 2 min, 100% ethanol for 2 min 
and a second container of 100% ethanol for a further 2 min, to dehydrate the sections. 
Slides were then submerged in a container full of xylene for 5 min, then a second container 
of xylene for an additional 5 min. Slides were then individually removed and covered with 
approximately 1 ml of xylene based DPX mounting media (06522, Sigma), then sealed 
using a number 1 coverslip.  
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2.53 – Immunofluorescence staining 
Tissue sections were permeabilised in cold acetone for 5 min and then blocked against 
non-specific antigen binding for 30 min using a 0.1 M L-lysine (Sigma, L5501) PBS 
solution containing 0.1% Triton-X-100 (L5501, Sigma). This was known as the ‘blocking 
solution’, and all antibodies were made up in this solution. Sections were stained using 
polyclonal rabbit antibodies to Cx43 (Sigma C6219, 1:2000 dilution), Cx26 (for mouse 
tissue this was the anti-Cx26 antibody ‘GAP28’ used at 1:200 dilution, generated in a study 
by (Diez et al., 1999), and for rat tissue was Millipore AB8143 at 1:600) or mouse 
monoclonal alpha smooth muscle actin (α-SMA; Sigma A2547, 1:200) for 1 h, followed by 
3 x 5 min washes using blocking solution. Goat anti-rabbit Alexa 488 secondary antibody 
(Invitrogen UK, A11008) or goat anti-mouse Alexa 488 (Invitrogen UK, A11001) was 
applied at a 1:400 dilution for 1 h followed by a 5 min counterstain using Hoechst solution 
(Hoechst 33528 and Hoechst 33342 dyes each diluted to 1:50,000 in PBS, Sigma). Tissue 
sections were washed 2 x 5 min in PBS and then mounted with a size 1 coverslip using 
Citifluor AF1 mountant (Citifluor Ltd., UK). 
 
2.6 – Light microscopy 
2.61 – Epidermal measurements 
H&E stained tissue sections were examined using a Leica DMLB light microscope and 
images were captured at either 10 X or 20 X magnifications using the Leica IM50 software. 
The thickness of the epidermis at the wound edge was determined by measuring the 
thickest point along the axis from the basal to spinous layer within the end 100 µm (mice) 
or 150 µm (rats) of nascent epidermis using ImageJ. The length of nascent epidermis 
growing out from the wound edge was measured for rats at either side of the wound using 
ImageJ and averaged to return a re-epithelialisation distance measurement for each sample. 
 
2.62 – Polymorphonuclear cell quantification 
H&E stained tissue sections were examined using a Leica DMLB light microscope and 
polymorphonuclear leukocytes (PMNs) were identified and counted in a single field of view 
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700 µm from the wound edge in the lower dermis using a 40 X objective. For mice, high 
quality images of PMNs and scaffolds used in figures were captured using a Hamamatsu 
Nanozoomer 2.0 slide scanner using the 20 X objective using brightfield to generate 
automatically stitched montage images. For rats, high quality figure images were captured 
using a Zeiss Axio Scan.Z1 automated slide scanner using a 20 X objective and the 
brightfield image acquisition wizard settings. Images were automatically stitched together to 
form a montage. 
2.63 – Measurement of granulation tissue area 
Rat wounds harvested at D10 and D15 were H&E stained and loaded into a Zeiss Axio 
Scan.Z1 automated slide scanner. Brightfield images were captured using a 20 X objective 
using the image acquisition wizard settings, and were then automatically stitched together 
to form a montage. Montages were then exported to JPEG format and quantified for 
granulation tissue area using ImageJ. The granulation tissue (or wound area) was defined as 
the new area of tissue within the wound margins yet above the muscle and panniculus 
carnosus layers, and was measured using the freehand line tool within the program. 
 
2.64 – Assessment of smooth muscle actin area 
Rat wounds that had been harvested at D10 were loaded into the Zeiss Axio Scan.Z1 slide 
scanner and imaged using a 20 X objective using the built in image acquisition wizard. Both 
Hoechst and Alexa 488 fluorophores were excited using the image acquisition wizard 
settings and montages containing both channels were generated and overlaid. The Zeiss 
slide scanner proprietary ZEN 2012 Lite software was then used to open the montage 
images. The α-SMA staining in the green channel was then thresholded in the software to a 
level that allowed visualisation of both α-SMA positive blood vessels as well as a positive 
staining region in the wound gap, above the panniculus carnosus. This area was drawn 
around using a marker tool within the proprietary software and an area in square microns 
was displayed. This approach was applied in the same manner to each of the 8 samples in 
each treatment group.  
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2.7 – Confocal microscopy 
Single optical section images of Cx43 or Cx26 immunostained wound and tissue sections 
were acquired using a Leica SP2 confocal microscope using a 40 X oil objective. 
Fluorophores were excited sequentially (Hoechst using both 351 and 364 nm wavelength 
lasers, Alexa 488 using a 488 nm wavelength laser). 8-bit images were acquired using a 
frame average of 4 at a resolution of 1024 by 1024 pixels. Image acquisition settings 
remained identical between each treatment in order to allow comparisons to be made 
during image analysis. 
2.71 – Confocal image analysis 
Connexin protein expression was quantified by counting positive pixels on binary images 
of wound edges using ImageJ software using the method outlined in a study by (Wang et 
al., 2007). Images from each experiment were identically thresholded prior to analysis. Only 
the number of connexin positive pixels contained within the end 100 µm (for mouse) or 
150 µm (for rat) of nascent epidermis was assessed in order to gauge only protein 
expression at the wound edge. Connexin levels were also expressed per square micron of 
epidermis to compensate for variations in epidermal thickness between samples. In order 
to account for variations in connexin levels between individual animals, wound edge 
expression was normalised to connexin levels at a distal site away from the wound edge and 
expressed as a percentage change from distal levels. In the case of Cx26 stained tissue, 
distal levels were extremely low, to the extent that small fluctuations between samples 
could result in large differences between values. For this reason, Cx26 distal levels were 
averaged and these values were used to calculate the change in wound edge Cx26 
expression. 
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2.8 – Statistical analysis 
2.81 – Power analysis 
Sample size was determined using power analysis software G*Power. The effect size value 
used in the formula was derived from previous lab in vivo wound healing data obtained by 
a previous Masters student.  
2.82 – Normality tests 
All data amenable to statistical analysis was subjected to Kolmogorov-Smirnov tests using 
GraphPad Prism 5.0 software to ascertain normality. Data is classified as normal using this 
test when a significance value of over 0.05 is returned. All data was normally distributed 
and therefore subjected to parametric statistical tests. 
2.83 – Statistical tests 
After confirming normality, data was subjected to one-way ANOVA testing followed by a 
Tukey’s post-hoc test to investigate individual statistical significance differences. GraphPad 
Prism 5.0 software was used to perform all statistical analyses. A significance value of 0.05 
was used as the lowest threshold of significance.
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CHAPTER 3 
Design and application of a bioactive scaffold 
Associated publication: (Gilmartin et al., 2013) 
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3.1 – Introduction 
Chronic ulcers are hard-to-heal wounds that typically contain elevated numbers of 
inflammatory cells, reduced levels of growth factors, damage or loss of the dermal 
extracellular matrix (ECM) and the misexpression of specific proteins (Seah et al., 2005, 
Muller et al., 2008, Brandner et al., 2004). In particular, both chronic ulcers and diabetic rat 
wounds have been found to contain high levels of the gap junction protein connexin 43 
(Cx43) (Wang et al., 2007, Brandner et al., 2004). During acute wound healing Cx43 is 
normally downregulated in the first 6 h in keratinocytes at the wound edge and remains low 
until re-epithelialisation of the wound completes around days 5-7 (Coutinho et al., 2003). 
However, in chronic wounds Cx43 expression is reported to either fail to downregulate 
(Brandner et al., 2004) or may instead be upregulated (Mendoza-Naranjo et al., 2012a, 
Mendoza-Naranjo et al., 2012b) (Sutcliffe et al., submitted publication), a feature 
accompanied by a lack of epithelial migration to restore the epithelial barrier. The 
identification of Cx43 as a drug target has led to the development of an antisense 
oligodeoxynucleotide (asODN) sequence specific to Cx43 which, when applied to both 
diabetic and acute wounds, was found to downregulate Cx43 expression and accelerate re-
epithelialisation (Wang et al., 2007, Qiu et al., 2003). Cx43 asODN has also been 
demonstrated to promote fibroblast migration in vitro as well as reduce wound size. 
Additionally, Cx43 asODN has been noted to dampen the inflammatory response (Mori et 
al., 2006). 
While the use of Cx43 asODN addresses a number of problems pertinent to chronic 
ulcers, the frequently occurring damage to or loss of the underlying dermal ECM is not one 
of them. The loss of regular ECM is associated with over-activity of MMP enzymes, 
particularly MMP-2 and MMP-9. These normally function to degrade excess matrix 
proteins such as collagen and fibrinogen. A reduction in TIMPs, as well as MMP 
stimulation through inflammatory cytokines IL-1, IL-6 and TNF-alpha contribute to the 
degradative state of chronic ulcers (Raffetto and Marston, 2011, Han et al., 2001).  
Wounds that are significant in depth and result in the loss of both epidermal and dermal 
compartments are termed full-thickness wounds, and pose a difficult challenge in 
treatment. In terms of substituting significantly damaged tissue, autografts are considered 
to be the gold standard to heal large skin wounds (An et al., 1995). However, in the case of 
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chronic ulcer patients, healing is often compromised throughout the individual such that 
removal of donor skin from other parts of the body is not feasible due to the risk of 
generating additional non-healing wounds. This can also be true in the case of significant 
burns, where extensive damage to the body can leave too small an amount of viable tissue 
from which to derive donor grafts (Vacanti et al., 1998). One method to generate more 
tissue from a patient is to culture donor grafts. This method has its limitations, as it 
requires several weeks of cell culture and the success rate can be low. The chance of patient 
graft take is variable at 15-85%, while for full-thickness burns this has been estimated to be 
around 53% (Atiyeh and Costagliola, 2007, Paddle-Ledinek et al., 1997).  
The lack of suitability of grafts for many patients with significant full-thickness wounds has 
led to increased research into engineered scaffolds; substrates that are placed in the full-
thickness wound and are intended to mimic the native skin or dermal matrix (Shevchenko 
et al., 2010). The method to produce scaffolds varies considerably, from cell-cultured 
constructs to artificially synthesised polymer matrices. All types are intended to serve a 
similar purpose, which is to behave as scaffolds for cell attachment and proliferation in the 
missing wound bed (Rho et al., 2006). In an effort to most accurately recreate both the 
epidermal and dermal layers of normal skin, cellular scaffolds have been engineered such as 
the branded products Apligraf (Organogenesis webpage, 2012) and Orcel (Forticell 
Bioscience webpage, 2012). These comprise a bilayer arrangement of human keratinocytes 
over an animal-derived extracellular matrix. There are three major disadvantages to these 
scaffold types, however – they are expensive, time consuming to produce and there is a risk 
of patient rejection of allogenic cells (Schonfeld et al., 2000).  
As mentioned in chapter 1, these limitations have led to the development of a number of 
acellular scaffolds, including lyophilised extracellular matrix from animal skin, (Oasis, 
Alloderm) and synthetic nylon structures. (Integra) (Shevchenko et al., 2010). Recently, 
scaffolds have also been experimentally fabricated from matrix-derived polymers including 
collagen (Torres-Giner et al., 2009) and fibrinogen (McManus et al., 2007) as well as 
synthetic polymers such as polycaprolactone (PCL) (Garcia-Giralt et al., 2008) and 
polylactic-co-glycolic acid (PLGA) (Yang et al., 2009). In these studies, the scaffolds 
contain one layer and are intended to only substitute the extracellular matrix. It is 
anticipated that the wound is then encouraged to re-epithelialise over the artificial scaffold 
matrix to close the wound. As well as woven structures, various polymers have also been 
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used to synthesise solid microspheres and aqueous hydrogels in addition to large sheet 
structures (Ashton et al., 2007).  
While cell-based and freeze-dried dermal scaffolds may more closely mimic the existing 
skin architecture, the time and cost required to develop these devices, as well as the 
potential biocompatibility issues, make acellular options particularly more attractive from a 
commercial point of view. It is therefore the family of scaffolds fabricated using naturally 
derived polymers that appear to hold particular promise as a quick and affordable method 
to fill the damaged dermal layer in a full-thickness wound. A method commonly employed 
to fabricate fibrous acellular scaffolds is the technique of electrospinning. Using this 
method, a wide variety of polymers can be dissolved in a solvent and extruded through a 
syringe into an electric field to generate a mesh network of polymer fibres (Rho et al., 
2006). This technique is both affordable and highly customisable, with alterations to the 
applied voltage, volume of polymer used or the distance between the syringe and collector 
plate all resulting in differences in the output scaffold fibres. Importantly, this technique 
offers potential as an ‘off-the-shelf’ solution that could be ready for immediate application 
to a patient. 
However, although dermal scaffolds lack cells that could cause biocompatibility issues in 
vivo, there has been very little investigation into whether these types of devices actually 
promote healing of wounds. Much of the research into electrospun scaffolds has only been 
followed up with in vitro testing, commonly in the form of cell adhesion or migration 
assays. And while many studies have reported clinical outcomes using scaffolds, the vast 
majority pay little microscopic attention to the early stages of the healing process, and most 
observations at the macroscopic level (Gholipour Kanani and Hajir Bahrami, 2010, Rho et 
al., 2006, Sabolinski et al., 1996, Wainwright, 1995). When microscopic evaluation of 
wounds is performed, images taken have often been at a low magnification such that the 
behaviour of cells at the wound edge cannot be clearly characterised. Additionally, 
microscopic assessments are again typically performed at late time points after scaffolds 
have broken down or wounds have re-epithelialised (Rho et al., 2006). Furthermore, a 
recent report investigating 60 venous leg ulcer scaffold trials found the majority of studies 
to be flawed, concluding that the scaffolds in the studies were not proven to improve 
wound healing (Zenilman et al., 2013). Owing to the lack of clear evidence that acellular 
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polymer-based scaffolds adopted a supportive role in vivo, this led to an initial null 
hypothesis for the project, that: scaffolds do not promote healing of full-thickness wounds.  
In order to test the primary hypothesis, an electrospinning technique was used to generate 
a scaffold using collagen, one of the most commonly used natural polymers in biomaterials 
(Shevchenko et al., 2010). A source of purified acid-soluble bovine collagen had been 
identified that had been processed by the manufacturer in an effort to reduce the chance of 
potential adverse reactions (Kensey-Nash, 2014). Following fabrication and processing of 
scaffolds, they were then applied to full-thickness excision wounds made to the dorsum of 
mice. In this way, wounds could both be examined macroscopically and microscopically to 
assess the cellular response to scaffolds. In the latter case, wound re-epithelialisation and 
inflammatory cell association in response to scaffold application could be visualised 
following high power examination of haematoxylin and eosin staining tissue sections. Since 
Cx43 is found to be upregulated at the wound edge in more than one situation when 
wound healing is perturbed, it seemed possible that if scaffolds instead had a detrimental 
effect on healing that Cx43 expression analysis might be a useful tool to help detect such 
an occurrence. Cx26 expression has also been linked to hyperproliferative skin conditions 
and hard-to-heal wounds and its overexpression could also be indicative of poorly healing 
wounds. 
 
Aims 
The aims of this chapter were to: 
1. Produce a fibrous collagen scaffold that could be applied to a series of full-
thickness mouse wounds in vivo. 
2. Macroscopically characterise the wounds to determine whether the scaffolds 
inhibited or promoted wound healing. 
3. Microscopically assess wound re-epithelialisation, inflammatory cell response and 
Cx43 and Cx26 expression in cells at the wound edge, in order to characterise the 
effect of scaffolds on the wound the wound healing response. 
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3.2 – Materials and methods 
See Chapter 2 for a detailed description of the individual methods and materials employed. 
A condensed explanation of the methods used in this chapter is listed below. 
3.21 – Scaffold preparation 
Scaffold and microsphere fabrication 
Collagen scaffolds were fabricated by electrospinning a 20:1 ratio of acid-soluble bovine 
collagen with poly-ε-caprolactone (PCL) as described in Chapter 2. Scaffolds were 
electrospun to thicknesses of both 0.8 mm and 0.4 mm and crosslinked by immersion in 
either a high (15% wt./v.) or a low (0.15% wt./v.) concentration of N-(3-
Dimethylaminopropyl)-N'-ethylcarbodiimide (EDC)  hydrochloride in a 1:10 water to 
acetone solution. Scaffolds were washed as outlined in Chapter 2 and cut out of the 
scaffold sheet using a 6 mm biopsy punch to match the size and shape of excisional 
wounds. Alginate microspheres were produced by electrospraying medium 2% (wt./v.) 
viscosity alginic acid powder PBS solution using the method described in Chapter 2. 
Commercial scaffold materials 
Both alginate hydrogel and dressing materials under the brand name ActivHeal® were 
provided for use by Prof David Becker.  
Investigation of scaffold porosity 
Scaffold porosity was assayed by submerging scaffolds overnight in a solution of 30% 
(wt./v.) Pluronic® F-127 powder dissolved in water (herein referred to as 'Pluronic gel') 
that had been supplemented with 5% fluorescein isothiocyanate (FITC). Scaffolds were 
excited using blue light to confirm the presence of FITC under a dissection microscope. 
Scaffold infusion with Cx43 asODN 
Cx43 antisense oligodeoxynucleotides (Cx43 asODN), sequence 5’-GTA ATT GCG GCA 
GGA GGA ATT GTT TCT GTC-3’ were dissolved in nuclease free water and diluted 
Pluronic gel to a 30 μM concentration. Collagen scaffolds were immersed in 20 μl of either 
Cx43 asODN containing Pluronic gel or PBS at 4°C overnight. Alginate microspheres were 
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soaked in a volume of Cx43 asODN Pluronic gel equal to the volume of polymer used in 
electrospraying. 
3.22 – Surgery 
Six week old male imprinting control region (CD-1) outbred mice were anaesthetised via a 
nose cone using  4% isoflurane, 20% oxygen and 10% nitrous oxide, and maintained using 
1.5% isoflurane. Animals were injected subcutaneously with 0.03 mg/ml buprenorphine 
(Vetergesic) before operation. Mouse backs were shaved and covered in a thin layer of 
Nair® hair removal cream, after which both the cream and hair was removed using a warm 
moistened gauze pad. Animals were placed on heated mats for the operation. Four full-
thickness excisional biopsy punch wounds were made using a 6 mm medical biopsy punch 
to rodent backs, two on each side of the dorsal midline. Scaffold treatments were applied 
directly to wounds, after which the back was covered with a sheet of Tegaderm™ film. 
Post-procedure, animals were kept in a heated chamber and monitored for recovery. Once 
recovered, animals were re-housed in standard individual cages. 
3.23 – Processing and histology 
Tissue collection 
Animals were culled by cervical dislocation at 1, 3 or 5 days post wounding. Wounds were 
macroscopically imaged as outlined in chapter 2 then excised and fixed in 4% 
paraformaldehyde (PFA)-PBS solution for 24 h at 4°C. Tissue was immersed in 20% 
sucrose overnight then washed in PBS, after which wounds were bisected. Half of each 
wound was snap frozen in OCT medium, then sectioned using a cryostat at a thickness of 
either 5 μm (for H&E staining) or 10 μm (for immunofluorescence staining).  
Haematoxylin and eosin staining 
Frozen tissue sections were thawed for 5 min then covered completely in tap water for 5 
min at room temperature. Slides were submerged in Harris’ haematoxylin solution for 30 
seconds followed by immersion in a container full of running tap water for 5 min. 
Background staining was reduced by dipping the slides in a container full of 1% acid 
alcohol (1% glacial hydrochloric acid, 70% ethanol, 29% distilled water) for 3 seconds, after 
which slides were immersed in a container of running tap water for a further 5 min. 
3. Design and application of a bioactive scaffold 
72 
 
Samples were then submerged for 15 seconds in a container full of eosin B solution, 
followed by immersion for 5 seconds in a container full of tap water to rinse away excess 
stain. Slides were then immersed in 70% ethanol for 2 min, 100% ethanol for 2 min and a 
second container of 100% ethanol for a further 2 min, to dehydrate the sections. Slides 
were then submerged in a container full of xylene for 5 min, then a second container of 
xylene for an additional 5 min. Slides were then individually removed and covered with 
DPX mounting media, then sealed using a coverslip. 
Immunofluorescence staining 
Tissue sections were permeabilised in cold acetone for 5 min and then using a 0.1 M L-
lysine PBS solution containing 0.1% Triton-X-100. Sections were stained for 1 h using a 
rabbit polyclonal antibody to Cx43 (1:2000 dilution, C6219, Sigma Aldrich UK) or Cx26 
(1:200 dilution, (Diez et al., 1999). Sections were then stained using a goat anti-rabbit Alexa 
488 secondary antibody (A11008, Invitrogen UK) at a 1:400 dilution for 1 h. Tissue was 
counterstained using Hoechst solution (both Hoechst 33528 and Hoechst 33342 dyes at 
1:50,000 dilution, Sigma Aldrich UK). 
3.24 – Analysis 
Imaging 
Wounds were macroscopically and microscopically imaged as outlined in Chapter 2. 
Collagen scaffolds were sputter coated with tungsten and imaged using scanning electron 
microscopy (SEM) at 800 X magnification. Tissue sections immunostained for Cx26/43 
and Hoechst were imaged using confocal microscopy. Single optical section 8-bit images 
were acquired at the wound edge and at a distal region of skin at 1024 by 1024 pixels. 
Image settings were consistent between treatments. 
Epidermal thickening measurements 
Epidermal thickness was measured on H&E stained tissue and determined by measuring 
the thickest point along the basal to spinous layer axis within the end 100 µm (mice) or 150 
µm (rats) of nascent epidermis using ImageJ. The length of nascent epidermis outgrowing 
from the wound margin was measured in rats at either side of the wound using ImageJ and 
averaged to return a re-epithelialisation distance measurement for each sample. 
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Connexin 26 and 43 protein quantification 
Cx43 and Cx26 protein expression was quantified by counting positive pixels on binary 
images of wound edges using ImageJ software using the method outlined in a study by 
Wang et al. (2007). Images from each experiment were identically thresholded and the 
number of connexin positive pixels within the end 100 µm quantified. Connexin levels 
were expressed per square micron of epidermis and normalised to distal levels to reduce 
sample-to-sample variation. In the case of Cx26, distal levels were extremely low, to the 
extent that small variations in distal expression could strongly impact the calculated 
percentage change from distal to wound edge levels. For this reason, at each time point 
distal epidermal Cx26 levels for each sample were averaged to produce a single value. This 
averaged distal expression value was then used to calculate individual percentage increases 
in expression for each wound. 
Polymorphonuclear leukocyte quantification 
Polymorphonuclear leukocytes (PMNs) were identified 700 µm away from the wound edge 
in the lower dermis using a 63 X objective on a light microscope (see chapter 2 for full 
details). PMNs were counted in one field of view using a 40 X objective. Images displayed 
in figures were captured using a Hamamatsu Nanozoomer 2.0 slide scanner using the 20 X 
objective using brightfield to generate automatically stitched montage images. 
Statistical analyses 
Sample size was determined using power analysis software G*Power as described in 
Chapter 2. Data was subjected to Kolmogorov-Smirnov tests using GraphPad Prism 5.0 
software to ascertain normality, then to one-way ANOVA tests followed by Tukey’s post-
hoc tests to determine statistical significance. 
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3.3 – Development of a collagen scaffold for in vivo use 
Collagen scaffolds were fabricated using an electrospinning technique that had been 
employed by other groups to produce an uneven mesh network of fibres (Figure 3. 1A). 
Use of this method resulted in the generation of fibres with a diameter range of 0.03 - 4.12 
μm. SEM revealed a porous structure when viewed from above (Figure 3. 1B) and the side 
(Figure 3. 1C). This closely mirrored the scaffolds fabricated in other studies, which were 
designed to mimic the fibre diameter and porosity contained within native ECM (Torres-
Giner et al., 2009, Nishida et al., 1988). 
 
Scaffolds impede full-thickness wound repair 
3.31 – Scaffolds inhibit wound closure 
In order to assess the effect of scaffolds on wound healing, 6 mm diameter scaffold discs 
were biopsy punched out of the electrospun collagen mats and applied to same-size full-
thickness wounds made to the dorsum of mice (Figure 3. 2A-B). Cull time points of 3 and 
 
Figure 3. 1 – Electrospinning a collagen scaffold. 
Electrospun collagen scaffolds were fabricated by the method of electrospinning a blend of 
collagen and PCL to produce a mesh network of fibres Scaffolds were electrospun (A) and 
imaged using a scanning electron microscope (800 X magnification) from above (B) and 
side-on (C). Scale bar = 10 μm. Images shown are representative of triplicate observations 
of a minimum of n = 3 scaffolds. 
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5 days were selected to investigate re-epithelialisation and granulation tissue formation 
between treatments. 
Visual assessment of wounds at D3 and D5 (Figure 3. 2C) indicated scaffold application 
resulted in a clear decrease in the wound closure rate. It was also possible to occasionally 
observe re-epithelialisation over the wound site in control wounds (marked by a dotted 
line), but not over scaffolds. Wound contraction, a prominent feature in healing rodent 
wounds, was severely impeded by the presence of a solid scaffold. While scaffolds are 
intended to integrate with wounds, at D3 the applied scaffolds were typically disassociated 
from the wound edge and showing little or no integration. However, it was not clear 
whether wounds treated with scaffolds were re-epithelialising into the scaffolds or 
underneath them without further microscopic assessment. 
 
Figure 3. 2 – Scaffold application to wounds. 
(A-B): Collagen scaffolds were applied to full-thickness wounds and compared to wounds 
left untreated. (C): Macroscopic images of wounds were taken at D3 and D5 post 
wounding. The white dotted line outlines a visible leading edge of re-epithelialisation. 
Images are typical representations across all mice (n = 7), Scale bar = 1.5 mm. 
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3.32 - Scaffolds induce aberrant thickening of wound edge keratinocytes 
Following macroscopic assessment it seemed possible that scaffolds may actually delay 
healing, which is a feature more commonly associated with chronic wounds. In chronic 
ulcers and diabetic wounds, cells at the wound edge upregulate Cx43 (Mendoza-Naranjo et 
al., 2012a, Mendoza-Naranjo et al., 2012b, Wang et al., 2007). The epidermis at the chronic 
wound edge has also been found to thicken extensively and contain elevated levels of Cx26 
(Sutcliffe et al., submitted publication). In order to assess whether scaffolds were inducing 
features characteristic of chronic wounds, the excised tissue was histologically examined.  
At both D3 and D5 time points, scaffold application caused keratinocytes at the wound 
edge to form thickened, non-migratory bulbs compared to the thin tongues of cells formed 
in the rapidly healing untreated wounds (Figure 3. 3A-B). At D3 the average thickness of 
the nascent epidermis of scaffold-treated wounds was 106 ± 24 µm (mean +/- SEM); a 
significant 73% increase from the 33 ± 5 µm of untreated wounds (P < 0.01, Figure 3. 3C).  
At D5 there was a similar 57% increase in epidermal thickness in scaffold treated wounds 
(P < 0.05, Figure 3. 3D). Microscopically, there was no visual evidence of keratinocyte 
entry into or over the scaffolds. Keratinocyte and fibroblast migration instead appeared by 
D5 to occur down the side and underneath scaffolds, similar to how re-epithelialisation 
occurs under a scab (Figure 3. 3B). Scaffolds were also typically surrounded by 
polymorphonuclear cells with a morphology characteristic of neutrophils at both D3 and 
D5. By D5, in the majority of cases scaffolds had degraded considerably. This failure to 
develop a thinning epithelial tongue in scaffold treated wounds appeared to suggest that 
scaffolds were inducing a negative effect on healing. 
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Figure 3. 3 – Epithelial and Connexin response to scaffolds. 
H&E and Cx43 staining of D3 (A) and D5 (B) mouse full-thickness wounds following 
either no treatment or application of collagen scaffolds. Boxed areas of representative 
H&E stained wound edges are magnified below in high power confocal images of sister 
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sections. Expression of Cx26, Cx43 and epithelial thickness was quantified in keratinocytes 
at the wound edge at D3 (C) and D5 (D). Dotted white lines mark the epidermis. Scale bar 
= 100 µm, n = 7 samples per group, data is plotted as mean + SEM, WE = wound edge. 
For wound treatments CS = collagen scaffold, and NT = no treatment (* = P < 0.05, ** = 
P < 0.01). 
 
3.33 - Thickened epidermal bulbs contain elevated levels of connexins 43 and 26 
The thickening of the wound edge epidermis is characteristic of a chronic wound, which 
also contains elevated levels of Cx43 (Mendoza-Naranjo et al., 2012a). Cx26 
overexpression has also been found to be upregulated in chronic wounds in a recently 
submitted article (Sutcliffe et al.) as well as in hyperthickened skin conditions (Labarthe et 
al., 1998). In order to observe whether scaffolds were inducing a chronic wound-like state, 
wounds were stained for Cx43 and Cx26.  While connexin expression in fibroblasts in the 
wound did not appear markedly different between treatments, wound edge keratinocyte 
expression differed greatly between treatments (Figure 3. 3A-B). There was a 469% 
increase in Cx43 expression from distal epidermis levels at D3 (P < 0.01, Figure 3. 3C) in 
scaffold-treated wound edges, significantly higher than the 38% downregulation found in 
untreated leading edge keratinocytes (P < 0.01, Figure 3. 3C). Cx43 levels were also 
elevated over distal epidermal levels at D5 – a 457% increase in leading edge keratinocyte 
expression versus the 10% increase in control wounds (P < 0.05, Figure 3. 3).  
While a degree of Cx26 upregulation in wound edge keratinocytes is typical of healing 
wounds, Cx26 was upregulated by approximately 7,000% at D3, which was significantly 
greater than the 2,326% upregulation of non-treated wounds (P < 0.05, Figure 3. 3C). This 
feature was again observed at D5; scaffold-treated wounds had a 4,466% increase in wound 
edge keratinocyte Cx26 levels, which was significantly greater than the 167% detected in 
untreated wounds (P < 0.05, Figure 3. 3D).  
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Figure 3. 4 – Wound edge Connexin 43 expression is elevated across all different 
collagen scaffold applications. 
Cx43 staining of D1 full-thickness wound edges following treatment with varying physical 
properties of collagen scaffold. (A): Diagram illustrating site of confocal image capture. 
(B): High power single optical section confocal images of the boxed area in (A) of the 
leading edge epidermis. Scaffolds properties were varied (either 15 mM or 0.15 mM EDC 
used to cross-link, and scaffolds were spun to a thickness of either 0.4 mm – termed ‘thin’ 
or 0.8 mm – termed ‘thick’). Dotted white lines mark the outline of the epidermis. Scale bar 
= 100 µm, images are typical observations of n = 5 samples per group. Diagram legend: E 
= epidermis, D = dermis, PC = panniculus carnosus, WE= wound edge. 
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3.4 – Modification of scaffolds 
3.41 - Collagen scaffold design 
Due to differences in reported scaffold fabrication and cross-linking methods it raised the 
possibility that the negative effects encountered may have been due to how it was 
fabricated. In particular, the 0.8 mm thick scaffolds fabricated may have been too thick for 
the wounds to re-epithelialise over, or the use of a high concentration (15% wt./v.) and it 
was postulated that the crosslinker agent EDC could have resulted in residual crosslinker 
remaining on the scaffolds. However, following application of scaffolds prepared to a 
reduced thickness (0.4 mm) or using a lower crosslinker concentration (0.15%) to full-
thickness wounds, there appeared to be a strong upregulation of wound edge Cx43 in each 
case, even at D1 when Cx43 is typically downregulated (Figure 3. 4) (Coutinho et al., 2003). 
Wound edge keratinocytes also typically formed thickened bulbous areas, similar to that 
observed at D3 and D5 (Figure 3. 3). This suggested that the collagen scaffolds formulated 
in a variety of ways were all capable of retarding wound healing. The next point to address 
was whether other scaffold materials induced similar effects. 
3.42 – Investigation into the effect of alginate applications on wound healing 
In order to assess whether the negative effects observed were specific to collagen scaffolds 
or not, three additional polymer applications composed of alginate were applied to full-
thickness wounds (Figure 3. 5A). Wounds treated with solid alginate microsphere and spun 
alginate dressing applications typically developed bulbs of keratinocytes at the wound edge 
containing upregulated levels of Cx43 at D1 (Figure 3. 5B). However, this effect was not 
observed in wounds treated with the alginate hydrogel, as Cx43 was typically 
downregulated in wound edge keratinocytes relative to distal levels, and keratinocytes 
migrated as a thin process of cells. 
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Figure 3. 5 – Connexin 43 expression in alginate treated wounds. 
Alginate application to D1 full-thickness wounds. (A): Diagram to illustrate the application 
method of one of three alginate fabrications to wounds. One type of scaffold was applied 
to each wound. (B): Cx43 fluorescence staining of full-thickness wound edges (high power 
confocal single section images). Images focus on the boxed area of the wound edge 
illustrated in (A). Dotted white lines mark the outline of the epidermis. Scale bar = 100 µm, 
n = 5 samples per group. Diagram legend: E = epidermis, D = dermis, PC = panniculus 
carnosus, WE = wound edge. 
 
3.5 - Bioactivation of collagen scaffolds using Cx43 asODN 
3.51 – Bioactivated scaffolds macroscopically appear to integrate with wounds 
The upregulation of Cx43 and Cx26 as well as wound edge epidermal thickening appeared 
a consistent feature associated with both solid collagen and alginate scaffolds. The alginate 
hydrogel, which did not produce a negative reaction, was short-lived and did not function 
as a supportive matrix as intended. It remained to be determined whether an integrating 
solid scaffold could be achieved through optimising the existing scaffold. 
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Elevated levels of Cx43, as found in both scaffold treated and chronic wounds, have been 
successfully reduced through application of antisense oligodeoxynucleotides (asODN) to 
Cx43 (Wang et al., 2007, Qiu et al., 2003). In an effort to overturn the negative effects 
associated with scaffold use, collagen scaffolds were bioactivated using a previously 
validated rat Cx43 asODN sequence (Qiu et al., 2003). The spread of a FITC-labelled 30% 
Pluronic gel throughout the scaffold structure indicated scaffolds were permeable to the 
drug delivery vector, suggesting that the method would incorporate asODN into the whole 
of the scaffold (Figure 3. 6A). Following bioactivation, scaffolds were then applied to full-
thickness mouse back wounds (Figure 3. 6B). Macroscopic evaluation revealed that Cx43 
asODN bioactivated scaffolds at D3 and D5 appeared to be partially integrated with the 
wound edge, compared with untreated scaffolds (Figure 3. 6C).  
3.52 – Bioactivated scaffolds do not induce wound edge epidermal thickening 
Microscopic examination of wounds revealed significant differences in wound edge 
epithelial thickening between bioactivated and untreated scaffolds (Figure 3. 7A, Figure 3. 
8A). The wound edge epidermis following bioactive scaffold treatment was a significant 
60% thinner than untreated scaffolds at D3 (P < 0.01, Figure 3. 7D) and 52% thinner at 
D5 (P < 0.05, Figure 3. 8D), to a level insignificantly different from untreated wounds. 
Although macroscopic analysis indicated that bioactive scaffolds appeared to partially 
integrate with the wound edge, microscopic analysis revealed keratinocytes migrated down 
the side and underneath scaffolds as opposed to into or over them. 
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Figure 3. 6 – The in vivo effect of Cx43 asODN bioactivation of scaffolds. 
(A): Collagen scaffolds were infused with a FITC-labelled Pluronic gel to assess scaffold 
permeability to the drug delivery vector. (B-C): Cx43 asODN bioactivated scaffolds were 
applied to full-thickness wounds and compared to wounds with no treatment (NT) or 
control scaffolds infused with only Pluronic gel. Macroscopic images of wounds were taken 
at D3 and D5 post wounding. The dotted white line outlines a visible leading edge of re-
epithelialisation. Images are typical representations across all mice (n = 7), Scale bar = 1.5 
mm. 
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Figure 3. 7 – The microscopic effects 
of Cx43 asODN bioactivation of 
scaffolds 3 days after wounding. 
 
H&E and Cx43 staining of D3 mouse full-
thickness wounds following treatment 
with uncoated or Cx43 asODN infused 
collagen scaffolds. (A): Boxed areas of 
representative H&E stained wound edges 
are magnified below in high power 
confocal images of sister sections. 
Expression of Cx26 (B), Cx43 (C) and 
epithelial thickness (D) was quantified in 
keratinocytes at the wound edge. Dotted 
white lines mark the epidermis. Scale bar 
= 100 µm, n = 7 samples per group, data 
is plotted as mean + SEM. Diagram 
legend: S = scaffold, WE = wound edge. 
For wound treatments CS = collagen 
scaffold, as-CS = Cx43 asODN treated 
collagen scaffold and NT = no treatment 
(* = P < 0.05, ** = P < 0.01). 
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Figure 3. 8 – The microscopic effects of 
Cx43 asODN bioactivation of scaffolds 
5 days after wounding. 
 
H&E and Cx43 staining of D5 mouse full-
thickness wounds following treatment with 
uncoated or Cx43 asODN infused collagen 
scaffolds. (A): Boxed areas of representative 
H&E stained wound edges are magnified 
below in high power confocal images of 
sister sections. Expression of Cx26 (B), 
Cx43 (C) and epithelial thickness (D) was 
quantified in keratinocytes at the wound 
edge. Dotted white lines mark the outline of 
the epidermis. Scale bar = 100 µm, n = 7 
samples per group, data is plotted as mean 
+ SEM. Diagram legend: S = scaffold, WE 
= wound edge. For wound treatments CS = 
collagen scaffold, as-CS = Cx43 asODN 
treated collagen scaffold and NT = no 
treatment (* = P < 0.05). 
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3.53 – Cx43 and Cx26 expression is downregulated following application of Cx43 
asODN bioactivated scaffolds 
The significant reduction in wound edge epidermal thickening indicated bioactivation had a 
positive effect in reducing the effect of scaffolds. There were also significant differences in 
wound edge connexin expression shown by immunostaining for Cx43 and Cx26 (Figure 3. 
7A). Leading edge keratinocytes in bioactive scaffold treated wounds displayed a 91% 
significant reduction in Cx43 protein expression relative to control untreated scaffolds at 
D3 (P < 0.05, Figure 3. 7C). At D3, this level was also insignificantly different from 
untreated wounds. By D5, however, there was no significant difference in Cx43 expression 
between bioactivated and untreated scaffold treated wounds, indicating that the effect of 
the asODN had diminished (Figure 3. 8C). Cx26 levels were also reduced by 68% in 
wound edge keratinocytes at D3 (P < 0.05, Figure 3. 7B) and 87% at D5 (P < 0.05, Figure 
3. 8B) following bioactive scaffold application, to levels insignificantly different from 
untreated wounds. Despite this, Cx26 levels were still higher in Cx43 asODN bioactivated 
scaffold-treated wounds than untreated wounds at D5, and throughout all treatments Cx26 
expression at the wound edge was still upregulated from distal levels. 
 
3.6 – The effect of scaffold bioactivation on inflammation 
Chronic or impaired healing is typically associated with an elevated inflammatory response 
(Pierce, 2001), while the application of Cx43 asODN has been found to reduce 
inflammation (Mori et al., 2006). As such, the effect of untreated collagen and alginate 
scaffolds as well as Cx43 asODN bioactivated collagens scaffolds on inflammatory cell 
recruitment was investigated (Figure 3. 9). At 40 X magnification, the polymorphonuclear 
morphology of inflammatory cells could be characterised and the number of cells 
quantified. H&E staining of tissue sections revealed numerous polymorphonuclear 
leukocytes (PMNs) surrounding all solid structures including the collagen scaffold, alginate 
microspheres and the alginate dressing at D1 (Figure 3. 9). The effects were reduced in 
alginate hydrogel treated wounds, where PMNs were typically restricted to beneath the 
dermis in the panniculus carnosus.  
 
3. Design and application of a bioactive scaffold 
87 
 
 
Figure 3. 9 – The effect of scaffolds on polymorphonuclear cell recruitment. 
Histological assessment of cells infiltrating scaffolds and dressings. (A): D1 H&E images 
illustrating the clustering of round cells within and surrounding polymer applications. (B):  
High-power images focusing on a region of dermis 700 µm from the wound edge at the 
position indicated by the diagram at D1 following polymer application (top-left). 
Subsequent quantification of the number of leukocytes is also displayed (top-right). Cells 
were observed at high-power to identify polymorphonuclear leukocytes prior to counting 
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(example shown at top-left). (C): High-power images of the dermis of D3 and D5 treated 
wounds captured identically to those in (B). Leukocyte counts at both time points were also 
quantified (bottom-right). (A): Scale bar = 100 µm. (B): Polymorphonuclear leukocyte 
image scale bar = 10 µm, all other images = 50 µm. n=5 (D1) or n=6 (D3 & D5) samples 
were used, data is plotted as mean + SEM. Diagram legend: E = epidermis, D = dermis, 
PC = panniculus carnosus, WE = wound edge, PA = polymer application. For wound 
treatments NT = no treatment, CS = collagen scaffold, AD = alginate dressing, AM = 
alginate microspheres, AH = alginate hydrogel and as-CS = Cx43 asODN treated collagen 
scaffold (** = P < 0.01, *** = P < 0.001). 
 
In order to assess whether the inflammatory response induced by scaffolds extended into 
the tissue, the number of PMNs present in the dermis 3 fields of view from the wound 
edges was quantified (Figure 3. 9B). At D1 there was a significant 3.5-fold increase in 
numbers of invading PMNs in wounds treated with collagen scaffolds relative to untreated 
wounds (P < 0.01, Figure 3. 9B). Similarly, the alginate dressing induced a 3.8-fold increase 
(P < 0.01) and the alginate microspheres a 5.2-fold increase (P < 0.001) in the number of 
quantified PMNs. Unlike the solid structures, the number of PMNs present in this region 
for alginate hydrogel treated wounds was not significantly different from control wounds.  
Following assessment of collagen scaffolds, untreated applications induced a 10-fold 
increase in dermal PMNs at D3 (P < 0.001) and an 11.1-fold increase at D5 (P < 0.001, 
Figure 3. 9C). Bioactivated scaffolds, however, resulted in significantly reduced numbers of 
dermal PMNs at D3 (P < 0.001) and D5 (P < 0.001), and were comparable to that of 
untreated wounds. This finding indicates that Cx43 asODN could improve the host 
response to implanted biomaterials in vivo. 
 
3.7 – Discussion 
The initial aim of the study was to determine whether scaffolds served as a temporary 
matrix in a full-thickness wound that had lost the dermal layer. Following fabrication and 
application of fibrous collagen scaffolds to full-thickness mouse wounds, healing was 
severely perturbed. Macroscopically, wounds did not integrate with the scaffolds and 
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instead appeared much larger at D3 and D5 than untreated wounds (Figure 3. 2). Wound 
edges in contact with scaffolds were prone to forming non-migratory, thickened bulbs of 
keratinocytes in which the gap junction proteins Cx43 and Cx26 were significantly 
upregulated (Figure 3. 3). This response was comparable to that of rats with STZ-induced 
diabetes, which also formed thickened bulbs of non-migratory keratinocytes at the wound 
edge that expressed high levels of Cx43 (Wang et al., 2007). 
Cx43 is typically downregulated from moderate basal levels in wound edge keratinocytes 
and fibroblasts in the first 24 h of acute healing (Coutinho et al., 2003, Mendoza-Naranjo et 
al., 2012a, Goliger and Paul, 1995). The upregulation of Cx43 in the epidermis of scaffold-
treated wounds may be the cause of the evident perturbation to healing, as Cx43 
overexpression in diabetic rat wounds was found to prevent keratinocytes migration across 
the wound. Indeed, targeting Cx43 overexpression with Cx43 asODN restored healing to a 
standard rate (Wang et al., 2007, Mendoza-Naranjo et al., 2012b). It has also been shown 
that elevation of Cx43 expression in fibroblasts attenuates their migration by inhibiting 
their cytoskeletal dynamics (Mendoza-Naranjo et al., 2012a). Conversely, downregulation 
of Cx43 in fibroblasts reduces cell-cell adhesion and activates the small GTPases Rac1 and 
RhoA, enhancing cytoskeletal dynamics and promoting migration (Mendoza-Naranjo et al., 
2012b). This may be in part due to the interaction of the Cx43 cytoplasmic tail with the 
adhesion molecules zonular occludens 1 & 2, and components of the cytoskeleton 
(Giepmans et al., 2001b, Laird, 2006). 
While Cx43 is downregulated in wound edge keratinocytes, Cx26 is naturally upregulated 
and maintained at high levels during the process of cell migration (Coutinho et al., 2003). 
However, similar to Cx43, Cx26 expression was strongly upregulated in wound edge 
keratinocytes following scaffold application (Figure 3.3), to a significantly greater degree 
than wounds left untreated. Persistent Cx26 expression has been attributed to a 
hyperproliferative state in which wound healing is perturbed, and has also been strongly 
linked to a number of epidermal and barrier-related conditions (Djalilian et al., 2006, 
Labarthe et al., 1998, Lucke et al., 1999). It has also been suggested that high levels of Cx26 
can result in leakage of ATP, which in turn promotes inflammation (Djalilian et al., 2006). 
This is in agreement with the findings in this chapter, where scaffold treated wounds that 
expressed high levels of Cx26 in the epidermis at the wound edge also had significantly 
higher levels of neutrophils infiltrating into the tissue (Figure 3.9). 
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Since it was not immediately apparent as to why the fabricated collagen scaffolds caused a 
negative reaction, a number of different scaffolds were assessed for similar outcomes. The 
scaffolds applied appeared somewhat thick when viewed macroscopically, and there were 
concerns that the crosslinker used may have left residual chemical on the scaffolds. To test 
whether these properties were responsible for the observed negative reaction, thinner 
scaffolds were fabricated and using a 100-fold reduced concentration of the cross-linker 
(Figure 3.4). However, none of the different scaffold thickness or crosslinker permutations 
resulted in a visible improvement in healing; all scaffolds resulted in a similar thickening of 
the wound edge and upregulation of Cx43 at D1. Next, a number of different non-collagen 
based applications were assessed in vivo to determine whether a different material or form 
factor may result in a more biocompatible scaffold. This led to the selection of the naturally 
derived alginate, which is commercially available as a fibrous wound dressing or hydrogel, 
and can also be electrosprayed to form microspheres (Figure 3.5). Following application to 
full-thickness wounds, both the solid alginate dressing and microspheres induced a negative 
reaction, causing a significant elevation of inflammatory cell infiltration as well as wound 
edge epidermal thickening and Cx43 upregulation (Figure 3.5, Figure 3.9). However, this 
was not the case for the alginate hydrogel, which did not induce these effects.  
It appeared that the negative response observed in the presence of scaffolds might 
therefore be attributed to the presence of a foreign body in the wound bed rather than a 
specific substance inducing a reaction. Indeed, physical structures were surrounded by 
polymorphonuclear cells characteristic of leukocytes (Figure 3.9), typical of the early stages 
of a foreign body reaction (Anderson et al., 2008). Scaffolds appeared to degrade in the 
wound rapidly and inflammation spread beyond the wound bed into the surrounding 
dermis, where there is potential for PMNs to cause damage to uninjured tissue (Martin and 
Leibovich, 2005). Despite considerable degradation of scaffolds by D5 there were a 
significantly increased number of PMNs infiltrating the dermis, and continued repression 
of keratinocyte migration and overexpression of Cx43 and Cx26 within the thickened 
epidermal bulbs. The prolonged elevation of connexin expression has separately been 
linked to inflammation (Qiu et al., 2003). As a device to support the healing of full-
thickness wounds such as chronic ulcers, association of scaffolds with inflammation could 
be potentially harmful. Chronic ulcers typically contain high numbers of inflammatory cells 
prior to treatment, so it may be questioned whether placement of scaffolds that can 
promote further PMN invasion is most beneficial to healing (Pierce, 2001). 
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Since scaffolds are intended to function as a substitute dermal layer it would be reasonable 
to expect scaffolds to serve as a structure for cells to migrate into and over. However, 
macroscopically there appeared to be minimal integration of collagen scaffolds with the 
surrounding tissues at D3, with little improvement at D5 (Figure 3.2). Occasionally, re-
epithelialisation could be observed macroscopically in untreated wounds, yet this feature 
was absent in scaffold-treated wounds. Regardless of the effect of scaffolds on PMN 
infiltration, no fibroblast-like cells could be seen to associate with solid collagen or alginate 
scaffolds in this study, a finding that challenges the purported role of scaffolds as a 
supportive matrix for fibroblast attachment and proliferation (Zhong et al., 2010).  
The targeted downregulation of Cx43 protein expression in vivo has been shown on 
multiple occasions to accelerate wound healing whilst reducing the inflammatory response 
(Wang et al., 2007, Mori et al., 2006, Mendoza-Naranjo et al., 2012b, Qiu et al., 2003, 
Mendoza-Naranjo et al., 2012a). In the case of scaffolds, which appeared to be inducing 
features of chronic wound healing such as upregulation of Cx43, it was questioned whether 
simultaneous downregulation of Cx43 using asODN specific to Cx43 mRNA could 
optimise them in an in vivo setting. Following application of Cx43 asODN bioactivated 
collagen scaffolds to wounds, macroscopically there appeared to be a greater degree of 
scaffold integration with the wound edge relative to control scaffolds at both D3 and D5 
(Figure 3.6). Microscopic evaluation of H&E stained wounds revealed bioactivated 
scaffold-treated wounds induced fewer numbers of infiltrating polymorphonuclear cells in 
the dermis at both D3 and D5, which is consistent with the anti-inflammatory effects of 
Cx43 asODN on acute wound healing (Mori et al., 2006). Due to the observed reduction in 
inflammatory cell infiltration, the bioactivation of materials could be useful in both chronic 
ulcer and burn situations, where often dressing materials must be placed in contact with the 
wound as part of standard wound care procedures (Lyder, 2003). 
Bioactivation with asODN appeared to reduce the negative effects associated with scaffold 
application. At D3, Cx43 expression was significantly reduced in wound edge keratinocytes 
treated with bioactivated scaffolds compared to control scaffolds (Figure 3.7). Interestingly, 
Cx26 levels were also reduced by 69.6% following bioactivated scaffold application relative 
to control scaffolds at D3. This reduction is unlikely to be due to a direct effect of the 
antisense sequence, however, which was designed specifically to target the Cx43 mRNA. 
As an unmodified single stranded DNA sequence, it is also unlikely that there would be 
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asODN remaining after 24 h, as unmodified DNA is rapidly degraded within minutes in 
the presence of sera (Agrawal, 1996). Indeed, Cx43 expression in the wound edge was not 
significantly lower in bioactive scaffold-treated wounds than control scaffolds at D5, 
suggesting that the effect of the asODN had diminished. When Cx43 and Cx26 expression 
was reduced in the presence of asODN, however, it occurred in conjunction with a 
reduction in inflammatory cell infiltration. This correlation is supported in the literature, 
where conditions involving upregulation of these connexins often occur in conjunction 
with a heightened inflammatory response (Cronin et al., 2008, Djalilian et al., 2006, 
Labarthe et al., 1998). 
The bioactivation of scaffolds did not render them functional as a cell supportive matrix, 
however. By D5, bioactivated scaffold-treated wounds remained open, possibly due to the 
additional distance required for re-epithelialisation around scaffolds (Figure 3.6). While 
epithelial thickening and connexin downregulation was reduced at D5, where re-
epithelialisation could be observed it occurred underneath the scaffold similar to the 
situation of a scab (Figure 3.7). This suggested that even though bioactivation of scaffolds 
with Cx43 asODN could reduce epithelial thickening and connexin overexpression, 
scaffolds were still perceived as a foreign body and not a matrix to grow over and into. 
These findings challenge the role that scaffolds are typically thought to adopt. 
 
Conclusions 
Scaffolds are intended to promote healing of full-thickness wounds, yet in this chapter it 
was found that the application of multiple solid scaffolds retarded healing by inducing a 
severe thickening of the wound edge epidermis combined with connexin overexpression. 
In these acute wounds, the bioactivation of scaffolds using Cx43 asODN prevented many 
of these occurrences; yet healing was still disadvantaged through application of the devices. 
In a chronic wound setting, however, wounds typically do not heal efficiently to begin with, 
such that scaffolds may still be rendered suitable for application. In particular, the most 
promising outcome of these experiments was the efficacy of Cx43 asODN in reducing 
symptoms of a chronic-like wound. The role of scaffolds could therefore be altered from 
one of function to one of drug delivery, such that scaffolds could be bioactivated to deliver 
asODN over a longer period of time. In this chapter, infusion of scaffolds was performed 
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using Pluronic gel, a hydrogel that is degraded rapidly within the wound. Investigation into 
vascular stents highlighted the possibility of developing a coating application capable of 
eluting an incorporated drug over a specified period of time. This could be particularly 
useful in the bioactivation of biomaterials such as dressings, which must be placed in 
contact with wounds as part of standard full-thickness ulcer and burn treatment. With this 
in mind, focus was placed on developing a coated scaffold that could elute Cx43 asODN 
over a longer period of time, to determine whether this would have a beneficial effect on 
wound healing.
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CHAPTER 4 
Development of a Cx43 asODN sustained release scaffold 
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4.1 – Introduction 
In the previous chapter, following the fabrication of collagen scaffolds and subsequent in 
vivo application it became clear that scaffolds were in fact impairing acute full-thickness 
wound healing. The submersion of scaffolds into a Pluronic gel containing Cx43 asODN 
resulted in a transient bioactivation that alleviated some of the biocompatibility problems, 
but it still did not encourage non-inflammatory cells to associate with the scaffold matrix. 
This finding caused a change in direction to my research – while it may not be possible to 
make scaffolds function as a substitute dermal matrix, the ability of scaffolds to act as a 
reservoir for Cx43 asODN release appeared promising, particularly if they could be applied 
in a chronic or diabetic wound setting where Cx43 levels are typically highly over-expressed 
(Mendoza-Naranjo et al., 2012a, Mendoza-Naranjo et al., 2012b, Wang et al., 2007). This 
required investigation into a method to deliver asODN to the wound in a sustained manner 
over the time course of wound healing, since the asODN sequences used were unmodified 
and prone to degradation within minutes (Agrawal, 1996). While phosphorothioate 
modification can improve the half-life of asODN it comes at the cost of a decreased 
hybridisation with mRNA, as well as an increase in cell cytotoxicity and other non-specific 
effects (Stein, 1996). 
A number of vascular stents been developed to incorporate therapeutic drugs that elute 
from the devices over a pre-determined period of time (Krucoff et al., 2008, Mehilli et al., 
2006, Windecker et al., 2008). The first successful drug-eluting stents were developed to 
release the drug sirolimus to prevent restenosis. Following a clinical trial in 2002 they were 
approved for use in Europe, and soon after gained FDA approval for use in the US. Stents 
that eluted paclitaxel, another drug developed to treat restenosis, were approved soon after 
for clinical use in 2004. Drug-eluting stents typically comprise a polymer coating containing 
the drug that surrounds a traditional metal stent frame, which together provides both 
structural support to the blood vessel as well as a bioactive component. Many drug-eluting 
stents have been found to decrease the chance of restenosis occurring relative to traditional 
bare-metal stents (De Luca et al., 2012, Di Lorenzo et al., 2009). Since drug-eluting stents 
appear to be effective in the sustained and local delivery of drugs, it was hypothesised that 
a coating technique incorporating Cx43 asODN developed to deliver asODN to the 
wound may be beneficial to healing. In this way, asODN could be released over a longer 
period of time at the wound through diffusion as well as hydrolysis of the coating and 
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scaffold thus supplying the wound with asODN over the time course of healing. In the 
case of acute wound healing, this duration would need to be at least 5-7 days to cover the 
time course of re-epithelialisation (Coutinho et al., 2003).  
Designing a scaffold coating required investigation into the various properties of different 
polymers. The choice of polymer used to generate stent coatings varies, and is selected 
based on biocompatibility as well as the rate at which drugs elute from them. PLGA is a 
copolymer of poly lactic acid (PLA) and poly glycolic acid (PGA), and is one of the most 
commonly used synthetic coating polymers in the field of biomaterials. One of the main 
reasons for its popularity is its reported level of biocompatibility, illustrated by its FDA 
approval status (Makadia and Siegel, 2011). The approval status of PLGA is due to the 
breakdown of the polymer into lactic and glycolic acid, both of which are naturally 
metabolised to carbon dioxide and water through the Krebs cycle. As an additional 
advantage, the lactide to glycolide ratio of PLGA can also be adjusted to influence the rate 
of drug elution (Shive and Anderson, 1997). A ratio of 50:50 lactide to glycolide will elute 
incorporated drugs at a higher rate than when using a 75:25 ratio, for instance. It is also 
important to note that the use of over 75:25 lactide to glycolide ratios have been previously 
shown to prevent adequate drug release over several months, demonstrating the need to 
carefully select the polymer used to coat devices (Khan et al., 2004). The use of PCL in 
drug coatings is also well documented (Acharya et al., 2012, Drachman et al., 2000), and is 
reported to elute incorporated drugs at a slower rate than PLGA. The choice of molecular 
weight of the polymer is also important, as lower molecular weight polymers release 
incorporated drugs faster but are linked to heightened inflammatory responses (Billinger et 
al., 2006). 
While vascular stent coatings have been designed to release large drug molecules such as 
paclitaxel, the release of asODN from coatings is less common as a method to target 
restenosis, owing to the more common use of existing drugs used to treat patients. 
However, stent coatings have previously been developed to elute asODN targeting the 
DNA binding protein c-myb, platelet derived growth factor, and nonmuscle myosin heavy 
chain, and have led to positive results both in vitro and in vivo (Kipshidze et al., 2005). 
Results from other studies indicate that asODN may elute faster than traditional anti-
restenosis drugs, yet 32-mer sequences were found to elute at a slower rate from polymer 
microsphere preparations than smaller 7-mer or 15-mer sequences (Khan et al., 2004). 
4. Development of a Cx43 asODN sustained release scaffold 
97 
 
Since the Cx43 asODN sequence is a 30-mer, this finding suggested that the selected 
coating polymer must not have too slow a release profile. In order to measure the rate of 
asODN release from scaffolds, UV spectrophotometry can be employed, which is a 
popular method used to determine single stranded DNA concentration. Using this 
technique asODN elution can be quantified at specified time points over a specified period 
of time (Zhang et al., 2006b). 
Following a literature search into scaffold coating polymers, PLGA appeared to be a 
suitable choice (Makadia and Siegel, 2011). A PLGA formulation manufactured with a high 
molecular weight of 40,000-75,000 and a low to medium glycolide to lactide ratio (65:35) 
was sourced from Sigma Aldrich, UK (P2066). After focusing on the choice of polymers, a 
method to coat scaffolds with using the polymer as well as asODN was required. This 
required investigation into previously used methods employed to produce drug-eluting 
coatings. Complex methods specific to commercial stents have been developed to coat 
scaffolds such as a cobalt chromimum stent with laser-etched reservoirs that are filled using 
PLGA (Serruys et al., 2005). In terms of a less complex coating that could be translated to 
coat scaffolds, a study performed by (Kim et al., 2005) illustrated that a simple technique 
could also be successful. The team successfully prepared a simple polymer coating solution, 
and used it cover porous hydroxyapatite scaffolds. In this method, they dissolved the 
coating polymer in an organic solvent along with the antibiotic vancomycin then dipped 
the scaffolds into the crude solution. Scaffolds were then vacuum dried. However, unlike 
the vancomycin used in that study, asODN sequences that have been dissolved in water are 
not miscible with organic solvents. While this technique demonstrated the validity of a 
simplified coating method, a different method of preparation would be required to 
incorporate asODN. One technique commonly practiced in the case of immiscible liquids 
is to prepare an emulsion. In this approach, a water-oil emulsion is prepared whereby 
asODN that has been dissolved in water can be dispersed as droplets throughout the 
solvent. The emulsion is generated through homogenisation of the two immiscible layers 
and the droplets typically range in size from 10 nm - 100 µm. (Tamilvanan, 2004). With this 
in mind, an emulsion technique was selected for use in coating scaffolds. 
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Aims 
After developing a protocol to coat scaffolds with PLGA and Cx43 asODN, the initial 
aims of this chapter were as follows: 
1. To produce a polymer coating that results in asODN elution for at least the 5-7 days; the 
time required for re-epithelialisation to complete. 
2. To establish whether the polymer coating method employed altered the incorporated 
asODN or the wound nuclease activity.  
3. To apply coated scaffolds in vivo to validate the function of the devices, and to 
determine what effects coated scaffolds had on wound healing.  
 
4.2 – Materials and Methods 
See Chapter 2 for a detailed description of the individual methods, reagents and equipment 
employed. A condensed explanation of the methods used in this chapter is listed below. 
4.21 – Scaffold fabrication 
Collagen scaffolds were fabricated through use of the same electrospinning technique and 
reagents as described and used in chapter 3.  
4.22 – Application of polymer coatings containing Cx43 asODN to scaffolds 
Unlike the Pluronic gel infusion method used in the previous chapter, the same Cx43 
asODN sequence was incorporated into polymer coatings using an emulsion technique. 
The rat Cx43 asODN sequence used had the sequence 5’-GTA ATT GCG GCA GGA 
GGA ATT GTT TCT GTC-3’. A non-functional sense (sODN) sequence to this Cx43 
asODN was also incorporated to create one of the control scaffold treatments, and had the 
sequence: 5’- GAC AGA AAC AAT TCC TCC TGC CGC AAT TAC-3’. A modified 
version of this Cx43 asODN sequence was also separately obtained that had the 
fluorophores Cy3 and Cy5 conjugated at the 5’ and 3’ ends, respectively.  
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Either PCL or Poly(D, L-lactice-co-glycolide) (PLGA) was dissolved in the solvent 
dimethyl carbonate at 10% wt./v. using gentle rocking. The asODN sequences were 
dissolved in water and mixed with the polymer solutions to either a 100 μM or 300 μM 
final DNA concentration. The two immiscible layers were processed for 10 seconds using a 
handheld homogenizer on a medium setting at room temperature to produce an emulsion. 
After preparing the coating mixture, individual 6 mm collagen scaffolds were dipped for 1 
second in the desired polymer-asODN solutions and immediately placed in a tube of liquid 
nitrogen and lyophilised overnight to remove the solvent from the scaffolds in order to 
maintain the structure of the scaffold. In the later scaffold experiments, this coating 
process, from dipping to freeze drying, was repeated 3 times to produce 4 layers of 
polymer + asODN, or 7 times in the case of 8-layered ‘double coated’ scaffolds, which in 
total received 4 coating layers of PCL + asODN followed by 4 layers of PLGA + asODN. 
4.23 – Surgery 
Six week old Sprague Dawley rats were anaesthetised using 4% isoflurane, 20% oxygen and 
10% nitrous oxide, and maintained using 1.5% isoflurane by nose cone. Animals were 
injected subcutaneously with 0.03 mg/ml buprenorphine (Vetergesic) before operation. Rat 
backs were shaved and covered in a thin layer of Nair® hair removal cream, after which 
both the cream and hair was removed using a warm moistened gauze pad. Animals were 
placed on heated mats for the operation. Four full-thickness excisional biopsy punch 
wounds were made using a 6 mm medical biopsy punch to rodent backs, two on each side 
of the dorsal midline. Scaffold treatments were applied directly to wounds, after which the 
back was covered with a sheet of Tegaderm™ film. Post-procedure, animals were kept in a 
heated chamber and monitored for recovery. Once recovered, animals were re-housed in 
individual cages. 
4.24 – Processing and histology 
Harvesting wounds 
Animals were culled by cervical dislocation at 1, 3, or 5 days post wounding. Wounds were 
macroscopically imaged as outlined in Chapter 2. Wounds were then excised and fixed in 
4% paraformaldehyde (PFA)-PBS solution for 24 h at 4°C. Tissue was immersed in 20% 
sucrose overnight then washed in PBS, after which wounds were bisected. Half of each 
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wound was snap frozen in OCT medium, then sectioned using a cryostat at a thickness of 
either 5 μm (for H&E staining) or 10 μm (for immunofluorescence staining).  
Haematoxylin and eosin staining 
Frozen tissue sections were thawed for 5 min then covered completely in tap water for 5 
min at room temperature. Slides were submerged in Harris’ haematoxylin solution for 30 
seconds followed by immersion in a container full of running tap water for 5 min. 
Background staining was reduced by dipping the slides in a container full of 1% acid 
alcohol (1% glacial hydrochloric acid, 70% ethanol, 29% distilled water) for 3 seconds, after 
which slides were immersed in a container of running tap water for a further 5 min. 
Samples were then submerged for 15 seconds in a container full of eosin B solution, 
followed by immersion for 5 seconds in a container full of tap water to rinse away excess 
stain. Slides were then immersed in 70% ethanol for 2 min, 100% ethanol for 2 min and a 
second container of 100% ethanol for a further 2 min, to dehydrate the sections. Slides 
were then submerged in a container full of xylene for 5 min, then a second container of 
xylene for an additional 5 min. Slides were then individually removed and covered with 
xylene-based DPX mountant solution, then sealed using a coverslip. 
Immunofluorescence staining 
Tissue sections were permeabilised in cold acetone for 5 min and then using a 0.1 M L-
lysine PBS solution containing 0.1% Triton-X-100. Sections were stained for 1 h using a 
rabbit polyclonal antibody to Cx43 (1:2000 dilution, C6219, Sigma Aldrich UK) or Cx26 
(1:200 dilution, (Diez et al., 1999). Sections were then stained using a goat anti-rabbit Alexa 
488 secondary antibody (A11008, Invitrogen UK) at a 1:400 dilution for 1 h. Tissue was 
counterstained using Hoechst solution (both Hoechst 33528 and Hoechst 33342 dyes at 
1:50,000 dilution, Sigma Aldrich UK). 
4.25 – In vitro assays 
Quantification of asODN elution 
Scaffolds coated in asODN using the emulsion method were assayed for asODN release 
rate in vitro. Three coated scaffolds were immersed in 40 μl of nuclease free water at 37°C. 
At daily intervals, 1.5 μl of liquid was removed and assayed using a NanoDrop 2000 UV 
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spectrophotometer under the ‘ssDNA’ setting to determine DNA concentration. Scaffolds 
were placed in a fresh 40 μl of water to compensate for the reduction in volume following 
water removal for assays. Individual time point elution data was collected to produce both 
cumulative and daily asODN elution graphs.  
Förster Resonance Energy Transfer analysis 
A more detailed explanation of the Förster Resonance Energy Transfer (FRET) acceptor 
photobleaching technique is provided in the materials and methods chapter. Scaffolds 
coated with Cx43 asODN conjugated at either end to fluorophores Cy3 and Cy5 using the 
previously detailed emulsion method was used in this technique. Scaffolds were either left 
untreated or submerged in 37°C sterile foetal bovine serum (FBS) for up to 7 days. 
Samples were removed every 24 h then snap frozen in OCT medium, and sectioned to a 
thickness of 10 μm using a Leica cryostat. Samples were imaged using a confocal 
microscope and analysed using the incorporated Leica LAS AF software FRET wizard. 
Scaffolds were assessed using a FRET acceptor bleaching technique. Six randomly selected 
areas for each scaffold were bleached for the Cy5 acceptor fluorophore using a 633 nm 
laser. Using this method, Cy3 emission intensity at 570 nm is expected to increase, since 
energy transfer to the acceptor fluorophore was no longer occurring. The detected change 
in donor emission intensity was acquired and interpreted by the software package to 
calculate a FRET efficiency percentage (FRETeff). The formula to calculate the FRETeff is 
stated in the software package and is as follows:  
FRETeff =(Dpost – Dpre) / Dpost 
In this formula, Dpost is the fluorescence intensity of the donor after photobleaching and 
Dpre is the donor fluorescence intensity prior to photobleaching. A minimum percentage of 
15-20% has been considered indicative of genuine FRET occurring in other studies (Lai et 
al., 2014)., and the average percentage obtained in this study was around 25%. Images 
captured were 8-bit single optical sections with a resolution of 1024 by 1024 pixels. To 
determine the potency of serum in degrading asODN the wavelength emission spectra of 6 
asODN regions per time point were generated by performing xyλ-mode scans on FRET 
labelled asODN that had been incubated in FBS at 37°C. Individual λ-scans were 
performed using a 543 nm laser excitation, with 19 equally sized detection steps occurring 
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between the wavelengths of 550 nm to 730 nm. Emission intensity values were output 
using the LAS AF software.  
4.26 – Analysis 
Imaging 
Wounds were macroscopically and microscopically imaged as outlined in Chapter 2. Tissue 
sections immunostained for Cx26/43 and Hoechst were imaged using confocal 
microscopy. Single optical section 8-bit images were acquired at the wound edge and at a 
distal region of skin at 1024 by 1024 pixels. Image settings were consistent between 
treatments. 
Epidermal thickening measurements 
Epidermal thickness was measured on H&E stained tissue and determined by measuring 
the thickest point along the basal to spinous layer axis within the end 150 µm of nascent 
epidermis using ImageJ. The length of nascent epidermis outgrowing from the wound 
margin was measured at either side of the wound using ImageJ and averaged to return a re-
epithelialisation distance measurement for each sample. 
Connexin 26 and 43 protein quantification 
Cx43 and Cx26 protein expression was quantified by counting positive pixels on binary 
images of wound edges using ImageJ software using the method outlined in a study by 
(Wang et al., 2007). Images from each experiment were identically thresholded and the 
number of connexin positive pixels within the end 100 µm quantified. Connexin levels 
were expressed per square micron of epidermis and normalised to distal levels to reduce 
sample variation. In the case of Cx26, distal levels were extremely low, to the extent that 
small fluctuations between samples could result in large differences between values. For 
this reason, Cx26 distal levels were averaged and these values were used to calculate the 
change in wound edge Cx26 expression. 
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Polymorphonuclear cell quantification 
H&E stained D1, D3 and D5 rat full-thickness wounds were identified microscopically 
using a 63 X objective. At 700 µm from the wound edge in the lower dermis, rounded cells 
with a polymorphonuclear morphology (PMNs) were identified and counted in a single 
field of view using a 40 X objective were counted, a method to quantify probable 
inflammatory leukocytes infiltrating the uninjured tissue. Images used in figures were 
captured using a Zeiss Axio Scan.Z1 automated slide scanner using a 20 X objective and 
the brightfield image acquisition wizard settings. Images were automatically stitched 
together to form a montage (see chapter 2 for full details). A total of n=5 wounds were 
assessed per time point and treatment and values were averaged. 
Measurement of granulation tissue area 
Rat wounds harvested at D10 and D15 were H&E stained and loaded into an automated 
Zeiss Axio Scan.Z1 slide scanner. Brightfield images were captured using a 20 X objective, 
then automatically stitched together to form a montage. Montages were then imported into 
ImageJ. The granulation tissue (or wound region) was defined as the new area of tissue 
within the wound margins yet above the muscle and panniculus carnosus layers, and was 
measured using the freehand line tool within the program. 
Assessment of smooth muscle actin area 
Rat wounds harvested at D10 were loaded into the same Zeiss slide scanner and imaged 
using a 20 X objective using the built in image acquisition wizard. Hoechst and Alexa 488 
fluorophores were excited to produce a montage image of the tissue. α-SMA staining in the 
green channel was thresholded in the software to a level that allowed visualisation of both 
α-SMA positive blood vessels as well as a positive staining region in the wound gap, above 
the panniculus carnosus. This area was drawn around using a marker tool within the 
proprietary ZEN 2012 software and an area in square microns was displayed. This 
approach was applied in the same manner to each of the 8 samples in each treatment 
group. 
Statistical analyses 
Sample size was determined using power analysis software G*Power as described in 
Chapter 2. Data was subjected to Kolmogorov-Smirnov tests using GraphPad Prism 5.0 
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software to ascertain normality, then to one-way ANOVA tests followed by Tukey’s post-
hoc tests to determine statistical significance. 
4.3 – Design of a drug eluting polymer coating 
4.31 – Investigation into coating properties 
In order to design a scaffold coating to elute asODN, the literature was first assessed. It 
was not immediately clear what the rate of elution of Cx43 asODN would be, nor whether 
it would be preferable to use a higher or lower percentage of PLGA in a coating. For these 
reasons, scaffolds were coated using either a 10% or 15% (wt./v.) solution of PLGA 
(wt./v.) and Cx43 asODN dissolved in water to a final volume concentration of 100 µm 
(Figure 4. 1A). UV spectrophotometry revealed that over 95% of DNA had eluted by the 
D2 time point for both 10% and 15% PLGA coated scaffolds. Approximately 10 µg of 
DNA eluted over the time course studied. Both the low quantity and short duration of 
asODN elution using single PLGA coatings led to the requirement for an improved 
coating technique. 
 
 
Figure 4. 1 – Coating of collagen scaffolds with a Cx43 asODN and PLGA 
emulsion.  
(A): Collagen scaffolds were coated in an emulsion of 100 μM Cx43 asODN and either 
10% or 15% PLGA and subsequently lyophilised.  
(B): Cumulative Cx43 asODN elution from scaffolds was quantified in water at 37 degrees 
over 4 days. The average of 3 samples was recorded for all elution measurements and error 
bars represent SEM. 
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Figure 4. 2. – Cx43 asODN elution from differing combinations of scaffold 
coatings.  
(A): Scaffolds were coated to three different specifications (labelled 1-3). Scaffolds were 
either coated in a single layer of PLGA mixed with 300 µM Cx43 asODN (1), a single layer 
of PCL mixed with 300 µM Cx43 asODN (2) or a single layer of PLGA mixed with 300 
μM Cx43 asODN followed by a single layer of PCL mixed with 300 µM (‘Double Coating’; 
3). The coating process was performed once: ‘1 coating layer’ (as in B) or repeated a further 
three times: ‘4 coating layers’ (as in C). (B): Single layer scaffolds were quantified for 
asODN elution for 7 days. Data is plotted as a cumulative elution. (C): 4-layer scaffolds 
were quantified for asODN elution in water for 7 days. In the case of ‘double coated’ 
scaffolds, scaffolds received 4 coatings of each polymer (8 layers total). Data is plotted as 
cumulative elution (bottom left and centre) or new asODN eluted at each time point 
(bottom right). The average of 3 samples was recorded for all elution measurements and 
error bars represent SEM. 
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In an effort to prolong the duration and quantity of asODN release, the concentration of 
asODN in the coating solution used to immerse scaffolds into was increased from 100 µM 
to 300 µM. The literature also highlighted PCL as a polymer with a slower release profile 
than PLGA when used in coating (Acharya et al., 2012). Scaffolds were therefore coated in 
one of three ways: 1 - with 15% PLGA and Cx43 asODN, as before, 2 - with just 10% 
PCL and Cx43 asODN, or 3 - with both layers (PCL + asODN followed by PLGA + 
asODN) (Figure 4. 2A). Elution recordings ceased at D7 when new asODN release had 
mostly ceased. 
Only 19 µg of DNA eluted from the PCL only coating within 7 days, but the release profile 
was more gradual than from the PLGA only coating (Figure 4. 2B). The halfway point of 
total release was approximately 1 day for the PCL coating, relative to nearly 15 h for the 
PLGA coating. Scaffolds receiving both coatings eluted approximately 48 µg in total, of 
which half eluted within 15 h. While the use of two coatings increased the total amount of 
asODN eluted, the majority still eluted within the first 24 h. It was therefore proposed that 
further increasing the number of coating layers may improve on the duration of release.  
In order to improve the elution duration the number of individual coatings was increased 
from 1 to 4 (or in the case of the combined PCL and PLGA scaffold, from 2 layers to 8) 
(Figure 4. 2A). Further layer additions made the scaffolds too brittle and hard, which was 
infeasible for in vivo use. Individual scaffolds were then subjected to in vitro assays (Figure 
4. 2C, left). The halfway point of release for PCL only coatings was 2.5 days, relative to just 
1 day for the PLGA only coating. This represents an improvement of approximately 1.5 
days for the 4-layered PCL coating relative to the single layer (Figure 4. 1). The greatest 
improvement was found using the PCL and PLGA double-coated scaffolds. Double coated 
scaffolds resulted in a total release of 265 µg, which was considerably greater than the 
individual PCL or PLGA coatings. Furthermore, when asODN elution from double-coated 
scaffolds was assessed on a day-by-day basis as opposed to cumulative release, there were 
two clear peaks of asODN elution - a burst release between 0 h and D1 and a later peak 
between D3 and D4 (Figure 4. 2C, right).  
4.32 – Analysis of asODN degradation in scaffold coatings 
While elution assays identified the 8-layered PCL + PLGA coating as the most suitable for 
in vivo use, it was not clear if the coating method damaged the incorporated asODN. In 
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order to evaluate the coating asODN integrity a series of fluorescence resonance energy 
transfer (FRET) experiments were carried out on sections of coated scaffolds containing 
Cx43 asODN labelled with Cy3 and Cy5 dyes. Using confocal microscopy, the FRET 
efficiency calculated by the Leica software was 25% for the coated scaffold (Figure 4. 3B, 
‘Day 0’). This was above the 15-20% often considered to be indicative of genuine FRET 
occurring (Lai et al., 2014).  
Although FRET analysis of coated asODN scaffolds indicated that that the coating process 
did not damage the integrity of the asODN, it was unclear if the coating could also confer a 
level of nuclease protection to asODN within the wound. This would be necessary to 
ensure asODN remained intact and functional throughout the duration of wound healing. 
The same Cy3-Cy5 Cx43 asODN coated scaffolds were therefore submerged in foetal 
bovine serum (FBS) for up to 7 days and FRET efficiencies were recorded every 24 h 
(Figure 4. 3B). The average FRET efficiencies calculated between D1 and D7 ranged from 
17.5 - 26.7%, in each case remaining above 15%, indicating the presence of intact asODN. 
In order to confirm the nuclease activity of the FBS used, Cy3-Cy5 labelled Cx43 asODN 
was dissolved in water and mixed with FBS for 6 h. A lambda scan was then performed on 
the solution using a 533 nm wavelength laser as well as on a control solution containing 
nuclease-free water in place of FBS. The lambda scans showed a second peak of emission 
between 650-680 nm in the control asODN solution, yet this peak was absent in the 
solution treated with FBS (Figure 4. 3C). The second peak of correlated with the emission 
range of Cy5, which indicated that FRET was occurring due to resonance. 
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Figure 4. 3 – Cx43 asODN elution from differing combinations of scaffold coatings. 
PCL & PLGA double coated scaffolds containing [Cy3] [Cy5] tagged Cx43 asODN were 
submerged in FBS for up to 7 days. Scaffolds were then cryosectioned and subjected to 
FRET confocal analysis. (A): A simplified diagram of a FRET-asODN coated scaffold to 
illustrate the stochastic dispersion of asODN clusters across the scaffold as well as the site 
at which images were captured in (D). (B): Scaffolds were submerged in FBS for up to 7 
days, after which they were sectioned and acceptor (Cy5) bleached using a confocal 633 nm 
wavelength laser. FRET efficiency was calculated as a percentage increase in donor 
fluorescence intensity after acceptor bleaching relative to before acceptor bleaching. A total 
of 6 regions were quantified per time point, graph data = means + SEM error bars. 
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(C): xyλ scans were performed on a 300 μM asODN solution either treated or untreated 
with FBS for 8 h to test the potency of the FBS as a nuclease effective against asODN. The 
mean fluorescence intensity values detected at 19 steps between 550 nm and 730 nm 
following excitation with a 533 nm laser were plotted. Six regions were assessed to generate 
averages. (D): A typical confocal image of a scaffold section following immersion in FBS 
used to generate the FRET efficiencies plotted in (B). Images show labelled asODN 
clusters both before and after Cy5 bleaching. Scale bar = 20 μm. 
 
4.4 – Using coated scaffolds to deliver Cx43 asODN to wounds 
Elution and FRET assays indicated that the PCL and PLGA coated scaffolds eluted Cx43 
asODN over 7 days, and that the coating protected asODN against nuclease damage. In 
order to test whether the scaffolds had an effect on wound healing, coated scaffolds were 
applied to wounds in vivo. Unlike the previous uncoated scaffold experiments in mice, 
Sprague Dawley rats were instead chosen for scaffold application. This was due to previous 
issues regarding epidermal fragility following Tegaderm removal from mice, owing to 
limited D1 data, as well as the benefits of validating scaffold findings in a second species.  
4.41 – Macroscopic analysis of wounds 
In order to ensure the in vivo effects of incorporated asODN in the polymer coated 
scaffolds were assessed accurately, a series of control scaffolds were devised to allow 
comparisons (Figure 4. 4A). These consisted of an uncoated scaffold, as used in the 
previous chapter, as well as two additional polymer coated scaffolds, in which one lacked 
any asODN (‘coated scaffold’) and the other contained the complementary ‘sense’ version 
of the sequence to Cx43 asODN (‘coated scaffold & Cx43 sODN’). Full-thickness 6 mm 
wounds were made to the backs of rats and approximately 0.8 mm thick, same size 
individual scaffolds were applied (n=8 per treatment).  
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Figure 4. 4 – Macroscopic wound evaluation following coated scaffold placement. 
(A): Full thickness rat wounds were treated with one of a number of different collagen 
scaffolds or left untreated. (B): Animals were culled at either 1, 3 or 5 days after wounding 
and the wounds macroscopically imaged. Scale bar = 1 mm. 
 
Wounds were harvested at D1 to look at the early stages of wound healing, as well as D3 
and D5 to examine re-epithelialisation, as in the previous chapter. Upon examination, 
wounds at D1, 3 and 5 that received uncoated scaffolds were again typically larger than any 
of the other treatments, including those left untreated (Figure 4. 4B) At D1, all scaffold 
applications appeared to prevent wound contraction to some degree, following visual 
comparisons to untreated wounds. From macroscopic observations during processing and 
handling, it appeared that coating scaffolds also appeared to make them more dense and 
brittle. However, by D3, wounds treated with Cx43 asODN coated scaffolds appeared 
markedly reduced in size compared to those treated with one of the control scaffolds, to a 
level similar to untreated wounds. Wounds treated with uncoated scaffolds at D3 remained 
similar in size to the initial wounds. The coated scaffolds themselves had reduced in size by 
varying degrees at both D3 and D5, and wound edges did not appear to integrate with the 
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structures. By D5, wounds treated with the Cx43 asODN coated scaffolds had reduced in 
size considerably, to either the same level of untreated wounds or slightly greater.  
4.42 – Re-epithelialisation analysis following scaffold placement 
Coated scaffolds appeared macroscopically to be poorly integrated with the wound edge 
although at this level it was not clear whether the Cx43 asODN coated scaffolds improved 
wound healing. Wounds were therefore sectioned using a cryostat to permit histological 
assessment. The polymers used in coating sectioned poorly and coated scaffolds often 
detached from the wound during processing on account of the loose association with the 
tissue to begin with. For this reason, coated scaffolds were typically not present throughout 
the microscopic analyses. Despite this, the effect of scaffold placement on wound re-
epithelialisation could still be measured. 
At D1, untreated wounds had re-epithelialised on average a distance of 274 μm ± 27 μm 
(all re-epithelialisation data is reported as mean ± SEM, Figure 4. 5). This was greater than 
control scaffold-treated wounds (uncoated, coating only, and coated + Cx43 sODN), 
which had re-epithelialised on average a distance of 202 μm ± 25 μm, although the 
difference was not significant. Wounds treated with bioactivated scaffolds coated in Cx43 
asODN, however, had re-epithelialised significantly further than any of the other 
treatments. At an average distance of 407 μm ± 32 μm, this was 67% greater than untreated 
wounds (P < 0.05) and 101% greater than the combined averages of the control scaffold-
treated wounds (P < 0.01 and P < 0.001). While the actual scaffolds coated with PCL and 
PLGA could not be visualised due to processing, wound edge keratinocytes typically 
appeared to migrate down the side of the wound margins and out towards the wound bed.  
Following assessment at D1, wound re-epithelialisation was also measured at D3 and D5. 
At D3, untreated wounds had re-epithelialised an average of 522 μm ± 52 μm, which was 
again higher than the average of 389 μm ± 42 μm for the combined average distances of 
control scaffold-treated wounds by 34%, yet this difference was not statistically significant 
(Figure 4. 6). Wounds treated with the Cx43 asODN bioactivated scaffolds had again re-
epithelialised further than every other treatment. The average re-epithelialisation distance of 
859 μm was 65% greater than untreated wounds (P < 0.05) and 121% greater than the 
averaged distance for all control treated wounds (P < 0.01 and P < 0.001). At this time 
point, while wound edges treated with uncoated scaffolds tended to re-epithelialise down 
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the side of the wound margin, some of the polymer coated scaffolds re-epithelialised 
outwards, across the wound bed. 
Similar measurements were also recorded at D5 (Figure 4. 7). At this time point some of 
the wounds were close to fully re-epithelialising. Untreated wounds had re-epithelialised an 
average distance of 882 μm ± 47 μm, which was only 12% higher than the combined 
averaged distance of 779 μm ± 87 μm for the three control scaffold-treated wounds. Cx43 
asODN bioactivated scaffold-treated wounds had re-epithelialised on average 1345 μm ± 
98 μm, which was a 65% increase over untreated wounds (P < 0.05). The increase was 
again more pronounced over the control scaffold treatments – Cx43 asODN scaffold-
treated wound re-epithelialisation was 70% increased over the average of the three control 
scaffold treatments (P < 0.05 and P < 0.01). Scaffolds coated with polymers containing 
Cx43 asODN resulted in significantly increased levels of wound re-epithelialisation across 
all the studied time points.  
The assessment of thickening of the leading edge epidermis was also measured, since it was 
unknown whether coated scaffolds induced epithelial thickening similar to perturbed 
healing in diabetic wounds and chronic ulcers (Wang et al., 2007), (Sutcliffe et al., 
submitted article). All epithelial thickening measurements are reported as means of 8 
animals ± SEM. At D1, the thickness of wounds treated with uncoated scaffolds (107.5 
µm, ± 9.1 µm), coating only scaffolds (79.5 µm, ± 17.0 µm) and Cx43 sODN coated 
scaffolds (61.7 µm, ± 11 µm), which were all higher than untreated wounds (50 µm, ± 4.2 
µm), although only uncoated scaffolds were deemed significantly different (Figure 4. 8). 
Cx43 asODN coated scaffolds resulted in the thinnest measured leading edges, at 27.8 µm, 
± 6.2 µm. This was 74.1% reduced from wounds treated with uncoated scaffolds, 65% 
reduced from coated scaffolds, 54.9% reduced from Cx43 sODN coated scaffolds and 
44.4% lower than untreated wounds. Despite this, only differences to untreated wounds (P 
< 0.001) and coating only scaffolds (P < 0.01) were deemed significant. This trend 
continued at D3; the average thickness of the leading edge following Cx43 asODN coated 
scaffold application was 39.7 µm, ± 3.7 µm, which was 60.5% lower than wounds left 
untreated (70.3 µm, ± 11.3 µm), 79.5% reduced from uncoated scaffolds (135.3 µm, ± 11.3 
µm), 59.9% lower than coating only scaffolds (69.4 µm, ± 6.4 µm) and 61.8% lower than 
Cx43 sODN scaffolds (72.7 ± 11.3 µm). This difference was only significant against 
uncoated scaffolds, however (P < 0.001). Similar findings were evident at D5 – epithelial 
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thickening following Cx43 asODN coated scaffold application was 29.3 ± 3.8 µm; 41.2% 
lower than wounds left untreated (49.8 ± 4.7 µm), 79.3% reduced from uncoated scaffolds 
(141.7 ± 15.2 µm), 49.5% lower than coating only scaffolds (57.9 ± 7.2 µm) and 60.4% 
lower than Cx43 sODN scaffolds (74.0 ± 11.2 µm). Despite this, significance was only 
reported against uncoated scaffolds (P < 0.001) and Cx43 sODN scaffolds (P < 0.05). 
 
Figure 4. 5 – D1 full-thickness wound healing following application of Cx43 asODN 
polymer coated scaffolds. 
(A): A simplified wound diagram to illustrate the site at which images were captured. 
(B): Wounds were either left untreated or treated with a control scaffold (red bars) or a 
coated scaffold containing asODN (green bars). Wound re-epithelialisation distances 
outlined by dotted yellow lines were measured for each type of scaffold applied and plotted 
as a graph (top left). Eight rat wounds were assessed for re-epithelialisation, data is plotted 
as mean values + SEM error bars (* = P < 0.05, ** = P < 0.01, *** = P < 0.001). Scale bar 
= 100 μm. 
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Figure 4. 6 – D3 full-thickness wound healing following application of Cx43 asODN 
polymer coated scaffolds 
(A): A simplified wound diagram to illustrate the site at which images were captured. 
(B): Wounds were either left untreated or treated with a control scaffold (red bars) or a 
coated scaffold containing asODN (green bars). Wound re-epithelialisation distances 
outlined by dotted yellow lines were measured for each type of scaffold applied and plotted 
as a graph (top left). Eight rat wounds were assessed for re-epithelialisation, data is plotted 
as mean values + SEM error bars (* = P < 0.05, ** = P < 0.01, *** = P < 0.001). Scale bar 
= 100 μm. 
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Figure 4. 7 – D5 full-thickness wound healing following application of Cx43 asODN 
polymer coated scaffolds 
(A): A simplified wound diagram to illustrate the site at which images were captured. 
(B): Wounds were either left untreated or treated with a control scaffold (red bars) or a 
coated scaffold containing asODN (green bar). Wound re-epithelialisation distances 
outlined by dotted yellow lines were measured for each type of scaffold applied and plotted 
as a graph (top left). Eight rat wounds were assessed for re-epithelialisation, data is plotted 
as mean values + SEM error bars (* = P < 0.05, ** = P < 0.01, *** = P < 0.001). Scale bar 
= 100 μm. 
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Figure 4. 8 – Leading edge epidermal thickening following Cx43 asODN scaffold 
application. 
Full-thickness rat wounds treated with different types of scaffolds were measured for 
thickening of the leading edge epithelium within the end 150 µm of the nascent tip. 
Measurements were recorded across n=8 samples at D1, D3 and D5, and values plotted 
are means of 8 animals + SEM error bars (* = P<0.05, ** = P < 0.01, *** = P < 0.001). 
Significance stars are coloured to match the treatment that is significantly different (e.g. 
light pink star = significantly different to uncoated scaffold-treated wounds) 
 
4.43 – Local inflammatory response following Cx43 asODN scaffold application 
Since Cx43 knockdown has previously been shown to dampen the inflammatory response 
following acute wounding (Mori et al., 2006), it was questioned whether the Cx43 asODN 
sustained release scaffold had a similar effect over an extended period of time. 
Polymorphonuclear leukocytes (PMNs) were thus identified and counted in the intact 
dermis distal to the wound edge in order to investigate whether coated Cx43 asODN 
scaffolds had an effect on inflammatory cell infiltration (Figure 4. 9). All PMN counts are 
reported as means ± SEM. Analysis at D1 revealed that the Cx43 asODN coated scaffolds 
reduced PMN infiltration relative to control scaffolds. Only 15.6 ± 1.3 PMNs were 
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quantified for Cx43 asODN scaffolds, which was 37.1% less than untreated wounds (24.8 
± 7.4), 76.5% lower than uncoated scaffolds (66.4 ± 9.9), 60% lower than coating only 
scaffolds (39 ± 2.9) and 71% lower than Cx43 sODN scaffolds (53.8 ± 5.9). Significant 
differences were only returned against uncoated scaffolds (P < 0.001) and Cx43 sODN 
coated scaffolds (P < 0.001), however. 
At D3, the assessed dermal regions distal to wounds had slightly elevated numbers of 
PMNs compared to D1 for all treatments (Figure 4. 9A-B). Cx43 asODN coated scaffolds 
resulted in a count of 18.8 ± 4.1 PMNs in the dermis. This was only 6.9% lower than 
untreated wounds (20.2 ± 2.7), 73.6% lower than uncoated scaffolds (71.2 ± 12.5), 61.3% 
decreased from control coated scaffolds (48.6 ± 4.3) and 69.2% reduced from Cx43 sODN 
scaffolds (61 ± 5.3). Differences were significant against each type of control scaffold (P < 
0.001 = uncoated scaffold, P < 0.001 = Cx43 sODN scaffold, P < 0.05 = control coated 
scaffold). By D5, PMN infiltration of the distal dermis had decreased considerably across 
all treatments, including uncoated scaffolds. Cx43 asODN coated scaffolds still resulted in 
the lowest recorded PMN counts, however, with an average count of 9.4 ± 2.5 PMNs. 
PMNs in the dermis distal to wounds containing Cx43 asODN scaffolds were 38.16% 
reduced compared to untreated wounds (15.2 ± 4.3), 73.1% lower than uncoated scaffolds 
(35 ± 7.3), 60.5% lower than control uncoated scaffolds (23.8 ± 2.1) and 69.9% reduced 
from Cx43 sODN scaffolds (31.2 ± 5.4). Of these differences, Cx43 asODN treated 
wounds only resulted in significant differences in PMN counts between uncoated scaffolds 
(P < 0.01) and Cx43 sODN coated scaffolds (P < 0.05). 
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Figure 4. 9 – The effect of Cx43 asODN scaffold application on the dermal 
infiltration of polymorphonuclear cells 
(A): Full-thickness wounds that received a scaffold treatment were assessed for 
polymorphonuclear cell invasion into the lower dermis 700 µm away from the wound edge 
as indicated in the topleft of diagram. High-power typical images of the dermal region are 
also shown for each scaffold treatment. The typical images shown are of the unwounded 
dermis distal to D3 wounds. Scale bar = 50 μm. (B): Quantification of polymorphonuclear 
cells for each treatment across time points of D1, D3 and D5 were plotted as average 
values of n=5 samples. Error bars represent SEM. Diagram legend: E = epidermis, D = 
dermis, PC = panniculus carnosus, WE = wound edge (* = P<0.05, ** = P < 0.01, *** = P 
< 0.001). 
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4.44 – Cx26 and 43 expression in wound edge keratinocytes following scaffold 
application 
Following H&E assessment, it was questioned whether the Cx43 asODN coating resulted 
in a knockdown of Cx43, and for how long, in full-thickness wound edges. Wounds were 
therefore immunostained for Cx43, as well as for Cx26, as in the previous chapter. 
At D1, staining for Cx26 revealed a strong upregulation of protein in wound edge 
keratinocytes across all conditions, including wounds left untreated, with no significant 
differences observed between groups (Figure 4. 10). Cx26 was not significantly elevated in 
uncoated scaffold-treated wounds relative to untreated wounds. Despite the lack of 
significant differences, Cx26 levels in Cx43 asODN bioactivated scaffold-treated wound 
edge epidermis was 38% lower than untreated wounds and 57% less than the average of all 
three control scaffold-treated wounds. Staining for Cx43 revealed a different outcome, 
however. At D1, application of each of the control scaffolds resulted in an increase in Cx43 
expression in the wound edge epidermis, with an average increase of 141% over distal 
levels (Figure 4. 11). Cx43 in untreated wound edges was 35% reduced, while bioactivated 
scaffold-treated wound edge expression decreased by an even greater degree (85%). Cx43 
expression was significantly reduced in the bioactive scaffold-treated wounds relative to all 
three control scaffold treatments (P < 0.05 and P < 0.01).  
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Figure 4. 10 – D1 Cx26 expression in the epidermal wound edge of scaffold-treated 
wounds. 
Full-thickness wounds treated either left untreated or treated with a scaffold were harvested 
at D1. Below: tissue was immunostained for Cx26 (green) or Hoechst (blue) and confocal 
images of the nascent epidermis were captured. Above: positive Cx26 pixels were 
quantified in the end 150 μm of the wound edge epidermis as pixels per µm2. Values were 
then normalised to a region of distal epidermis to calculate the percentage change (increase 
or decrease) from distal levels. Data plotted are means + SEM error bars. Significance stars 
are coloured to match the treatment that is significantly different (e.g. dark red star = 
significantly different to Cx43 sODN scaffold-treated wounds). Scalebar = 50 μm, n=8 rats 
assessed (no differences were significant in this graph). 
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Figure 4. 11 – D1 Cx43 expression in the epidermal wound edge of scaffold-treated 
wounds. 
Full-thickness wounds treated either left untreated or treated with a scaffold were harvested 
at D1. Below: tissue was immunostained for Cx43 (green) or Hoechst (blue) and confocal 
images of the nascent epidermis were captured. Above: positive Cx43 pixels were 
quantified in the end 150 μm of the wound edge epidermis as pixels per µm2. Values were 
then normalised to a region of distal epidermis to calculate the percentage change (increase 
or decrease) from distal levels.. Data plotted are means + SEM error bars. Significance 
stars are coloured to match the treatment that is significantly different (e.g. dark red star = 
significantly different to Cx43 sODN scaffold-treated wounds). Scalebar = 50 μm, n=8 rats 
assessed (* = P<0.05, ** = P < 0.01). 
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As scaffold coatings appeared to elute asODN in vitro for several days, it was hypothesised 
that Cx43 asODN coated scaffolds might reduce Cx43 expression in vivo at later time 
points. At D3, wound edge keratinocyte Cx26 expression was increased from distal levels 
for all treatments (Figure 4. 12). Uncoated scaffolds produced the highest increase in 
wound edge Cx26 expression, at an increase of 6370%. Staining also revealed differences 
between species - the percentage upregulation of Cx26 in untreated rat wound edges was 
approximately double that found in mice (Figure 3. 3), yet was still lower than the uncoated 
scaffold-treated mouse wounds. In rat wounds, the uncoated scaffold did not appear to 
induce greater upregulation of Cx26 than the control coated scaffolds (Figure 4. 12). As 
with the mouse wounds, application of Cx43 asODN bioactivated scaffolds resulted in 
significantly lower Cx26 expression at wound edges relative to control coated and uncoated 
scaffolds at D3 (P < 0.05 and P < 0.01). Cx43 asODN coated scaffold-treated wound 
edges featured a Cx26 upregulation of only 375%.  
In the case of Cx43 expression at D3, a 65% downregulation was observed in wound edges 
treated with bioactivated scaffolds, which was comparable to untreated wounds (Figure 4. 
13). This was a significantly lower level of expression than wounds treated with uncoated 
scaffolds (335% increase, P < 0.05) and Cx43 sODN coated scaffolds (283% increase, P < 
0.05), but not coated scaffolds, although coated scaffolds still induced Cx43 upregulation. 
Cx43 upregulation in uncoated scaffold-treated wound edges occurred, similar to that 
observed chapter 3 using mice at D3 (see Figure 3. 3). 
At D5, wound edge Cx26 was markedly reduced from the levels at D3 for all treatments, 
while only the Cx43 asODN scaffold resulted in Cx26 downregulation from distal levels 
(Figure 4. 14). All three control scaffolds resulted in an increase in wound edge Cx26 
expression, with an average rise of 147%. Both coated and uncoated control scaffolds 
resulted in significantly higher wound edge keratinocyte Cx26 levels than the Cx43 asODN 
bioactivated scaffold-treated wounds (P < 0.05), although the Cx43 sODN scaffolds did 
not produce a significant difference. In contrast to when Cx43 asODN was applied in 
Pluronic gel to mouse wounds, rat wound edges in contact with Cx43 asODN coated 
scaffolds still maintained a 91% downregulation of Cx43 at D5 (Figure 3. 8) & (Figure 4. 
15). This was a greater downregulation than that of untreated wound edges (57%). Cx43 
expression was again upregulated from distal levels at D5 across all control scaffold 
treatments. Wounds treated with both uncoated and coated control scaffolds resulted in 
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higher levels of Cx43 expression relative to the bioactive scaffold-treated wounds (P < 0.01 
and P < 0.001), although significance was not achieved against the sODN coated scaffold 
treatment group, which had high variability.  
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Figure 4. 12 – D3 Cx26 expression in the epidermal wound edge of scaffold-treated 
wounds. 
Full-thickness wounds treated either left untreated or treated with a scaffold were harvested 
at D3. Below: tissue was immunostained for Cx26 (green) or Hoechst (blue) and confocal 
images of the nascent epidermis were captured. Above: positive Cx26 pixels were 
quantified in the end 150 μm of the wound edge epidermis as pixels per µm2. Values were 
then normalised to a region of distal epidermis to calculate the percentage change (increase 
or decrease) from distal levels.. Data plotted are means + SEM error bars. Significance 
stars are coloured to match the treatment that is significantly different (e.g. dark red star = 
significantly different to Cx43 sODN scaffold-treated wounds). Scalebar = 50 μm, n=8 rats 
assessed (* = P<0.05, *** = P < 0.001). 
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Figure 4. 13 – D3 Cx43 expression in the epidermal wound edge of scaffold-treated 
wounds. 
Full-thickness wounds treated either left untreated or treated with a scaffold were harvested 
at D3. Below: tissue was immunostained for Cx43 (green) or Hoechst (blue) and confocal 
images of the nascent epidermis were captured. Above: positive Cx43 pixels were 
quantified in the end 150 μm of the wound edge epidermis as pixels per µm2. Values were 
then normalised to a region of distal epidermis to calculate the percentage change (increase 
or decrease) from distal levels.. Data plotted are means + SEM error bars. Significance 
stars are coloured to match the treatment that is significantly different (e.g. dark red star = 
significantly different to Cx43 sODN scaffold-treated wounds). Scalebar = 50 μm, n=8 rats 
assessed (** = P < 0.01, *** = P < 0.001). 
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Figure 4. 14 – D5 Cx26 expression in the epidermal wound edge of scaffold-treated 
wounds. 
Full-thickness wounds treated either left untreated or treated with a scaffold were harvested 
at D5. Below: tissue was immunostained for Cx26 (green) or Hoechst (blue) and confocal 
images of the nascent epidermis were captured. Above: positive Cx26 pixels were 
quantified in the end 150 μm of the wound edge epidermis as pixels per µm2. Values were 
then normalised to a region of distal epidermis to calculate the percentage change (increase 
or decrease) from distal levels. Data plotted are means + SEM error bars. Significance stars 
are coloured to match the treatment that is significantly different (e.g. light pink star = 
significantly different to uncoated scaffold-treated wounds). Scalebar = 50 μm, n=8 rats 
assessed (* = P<0.05). 
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Figure 4. 15 – D5 Cx43 expression in the epidermal wound edge of scaffold-treated 
wounds. 
Full-thickness wounds treated either left untreated or treated with a scaffold were harvested 
at D5. Below: tissue was immunostained for Cx43 (green) or Hoechst (blue) and confocal 
images of the nascent epidermis were captured. Above: positive Cx43 pixels were 
quantified in the end 150 μm of the wound edge epidermis as pixels per µm2. Values were 
then normalised to a region of distal epidermis to calculate the percentage change (increase 
or decrease) from distal levels.. Data plotted are means + SEM error bars. Significance 
stars are coloured to match the treatment that is significantly different (e.g. light pink star = 
significantly different to uncoated scaffold-treated wounds). Scalebar = 50 μm, n=8 rats 
assessed (** = P < 0.01, *** = P < 0.001). 
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4.5 – The effect of Cx43 asODN coated scaffolds on the late stages of 
wound healing 
4.51 – Granulation tissue formation following scaffold application 
Because Cx43 asODN coated scaffolds appeared to affect Cx43 expression over at least 5 
days, it was questioned whether their application also had an effect on the later stages of 
wound healing such as granulation tissue formation. Scaffolds applied to rat wounds were 
thus harvested at D10 and D15 (Figure 4. 16 & Figure 4. 17). Granulation tissue was then 
measured between the wound margins, above the panniculus carnosus layer (Figure 4. 
16A).  
Analysis of the now re-epithelialised wounds at D10 revealed significant differences in the 
region of granulation tissue formation between the scaffold treatments (Figure 4. 16B). 
Data for granulation tissue area measurements are reported as mean values of 8 (D10) or 7 
(D15) rats ± SEM. At D10, treatment of wounds with Cx43 asODN coated scaffolds 
resulted in an average granulation tissue area of 2.30 ± 0.21 mm2 , which was significantly 
smaller than uncoated scaffold-treated wounds that measured an average of 4.47 ± 0.34 
mm2 (P < 0.001). The measured area for bioactive scaffold-treated wounds was also 
significantly smaller than wounds treated with sODN coated scaffolds (3.41 ± 0.11 mm2, P 
< 0.05), coated scaffolds (3.47 ± 0.22 mm2, P < 0.05) and untreated wounds (3.61 ± 0.18 
mm2, P < 0.01). Similar results were also observed at the later time point of D15. At D15, 
wounds that received Cx43 asODN coated scaffolds had a measured granulation tissue 
region of 1.391 ± 0.07 mm2 (Figure 4. 17B), significantly lower than the 2.29 ± 0.34 mm2 
of untreated wounds (P < 0.05). The bioactive scaffold-treated wounds also measured 
significantly lower than uncoated scaffold (2.70 ± 0.31 mm2, P < 0.001), coated scaffold 
(2.33 ± 0.20 mm2, P < 0.05) and coated scaffold + Cx43 sODN-treated wounds (2.39 ± 
0.23 mm2, P < 0.05). Application of bioactivated scaffolds appeared to consistently reduce 
the area of granulation tissue present within wounds at D10 and D15. 
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Figure 4. 16 – Full-thickness wounds treated with scaffolds at D10 
Full-thickness wounds were either left untreated or treated with a scaffold. Wounds were 
harvested at D10.  
(A): A simplified wound diagram to illustrate the granulation tissue region which was 
measured in (B). 
(B): Wounds either left untreated or treated with a control scaffold (red bars) or a coated 
scaffold containing asODN (green bars) were measured for granulation tissue/wound area. 
Eight rat wounds were assessed, data is plotted as mean + SEM error bars (* = P < 0.05, 
** = P < 0.01, *** = P < 0.001), scale bar = 100 μm. 
(C): Typical H&E stained images illustrating the quantified granulation tissue area of the 
individual wounds in (white dots).  
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Figure 4. 17 – Full-thickness wounds treated with scaffolds at D15 
Full-thickness wounds were either left untreated or treated with a scaffold. Wounds were 
harvested at D15. 
(A): A simplified wound diagram to illustrate the granulation tissue region which was 
measured in (B). 
(B): Wounds either left untreated or treated with a control scaffold (red bars) or a coated 
scaffold containing asODN (green bars) were measured for granulation tissue/wound area. 
Seven rat wounds were assessed, data is plotted as mean + SEM error bars (* = P < 0.05, 
** = P < 0.01, *** = P < 0.001), scale bar = 100 μm. 
(C): Typical H&E stained images illustrating the quantified granulation tissue area of the 
individual wounds in (white dots).  
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4.52 – Application of Cx43 asODN coated scaffolds reduces the region of wound 
alpha smooth muscle actin (α-SMA) at D10 
It was postulated that the reduction in granulation tissue area following Cx43 asODN 
coated scaffold application could have been due to the activity of contractile 
myofibroblasts. This was because the use of Cx43 asODN has been shown to advance the 
appearance of α-SMA positive myofibroblasts in the wound by 2-3 days (Mori et al., 2006). 
Full-thickness rat wounds were therefore harvested at D10, when myofibroblasts are 
typically still contracting down the wound, and stained for the myofibroblast marker α-
SMA (Figure 4. 18). Staining revealed a large α-SMA positive region in the coating only 
scaffold-treated wounds, relative to the Cx43 asODN scaffold-treated wounds (Figure 4. 
18B). Measurement of this area (as illustrated by the dotted yellow outlines) revealed a 
significant 60.6% decrease in the area of positive α-SMA staining following Cx43 asODN 
scaffold placement, relative to the control scaffold (P < 0.001). Staining in the Cx43 
asODN scaffold-treated wounds was more centrally localised within the wounds, 
compared to the extensive staining in control-scaffold treated wounds which was also 
found close to the wound margins. 
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Figure 4. 18 – α-SMA expression in D10 scaffold-treated wounds 
Rat full-thickness wounds treated with either control coated scaffolds (no asODN) or Cx43 
asODN coated scaffolds were harvested at D10 and stained for both α-SMA (green) and 
Hoechst (blue). (A): The α-SMA+ region outlined in (B) was quantified for two different 
treatments on the same animals; a coated collagen scaffold without asODN and a coated 
scaffold coated with Cx43 asODN. This region was defined as positive stain in the wound 
gap above the blood vessel dense panniculus carnosus. A total of n=8 animals were 
assessed, values plotted are means + SEM error bars (*** = P < 0.001, scale bar = 500 
μm). (B): Typical immunofluorescence montage images illustrating the measured region of 
α-SMA in the wound (yellow dots) as well as the initial wound margins (red dots).  
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4.7 – Discussion 
It became apparent that the initial method of coating scaffolds with a single layer of PLGA 
containing 100 μM Cx43 asODN was insufficient for sustained antisense delivery since 
acute wound re-epithelialisation can take between 5-7 days. Single-layer coated scaffolds 
released over 95% of the total eluted asODN within just the first 48 h (Figure 4. 1). The 
shortcomings of this method demanded further investigation into the literature. Research 
into other studies highlighted the possibility of utilising multiple coating layers. In one 
study, coating stents with three thin polymer films containing the drug S-
Nitrosoglutathione was found to markedly increase the overall amount of drug eluted, 
although most of the additionally incorporated drug was still eluted within the first 24 h 
(Acharya et al., 2012). The use of multiple polymer layers containing asODN therefore 
appeared to be a valid method to increase the amount of asODN eluted, and it was 
proposed that increasing the number of layers above 3 might improve the timescale of 
elution relative to the other study. Indeed, when collagen scaffolds were coated with 4 
layers of PLGA containing Cx43 asODN, the amount of asODN eluted within the first 3 
days approximately tripled, indicating that this approach was more successful than the 
previous method (Figure 4. 2). Despite the improved dose delivery, over 95% of asODN 
that eluted in total from PLGA still eluted within the first 72 h, indicating that the PLGA 
used in the study may not be sufficient to achieve sustained release of Cx43 asODN. This 
was not the case with scaffolds coated in four layers of PCL, which resulted in a more 
sustained release profile in which asODN elution only began to plateau at around 6-7 days. 
This outcome is in agreement with the results of a study performed by (Acharya et al., 
2012), where it was found that the use of PCL resulted in a more sustained release profile 
than PLGA or polyethylene glycol. This can be explained through differences in the 
molecular composition of each polymer - the chemical bonds between repeating glycolic 
acid units in PLGA are more sensitive to hydrolysis than those between the caproic acid 
monomers in PCL. In addition, PLGA breakdown occurs more rapidly since it produces 
acidic by-products when degraded, which promote auto-catalysis (Eglin and Alini, 2008). 
While coating scaffolds with 4 layers of PCL resulted in a sustained release of asODN, 
coating scaffolds with 4 layers of PCL followed by an additional 4 layers of PLGA achieved 
the greatest overall release of Cx43 asODN across the 7-day assessment (Figure 4.2 C). 
Additionally, the elution profile for double coated scaffolds appeared to adopt the 
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characteristics of both the individual PLGA and PCL coatings. There was a large burst 
release of asODN in the first 24 h characteristic of the individual PLGA release profile as 
well as the more sustained release profile of PCL. This included a small second peak of 
elution around 3-4 days, which was also present in the PCL-only coated scaffold, and may 
have occurred due to hydrolysis of the coating layers. Second peaks of elution have also 
been found using other multi-layered approaches, such as with two-layered scaffold fibres 
containing an inner layer of PLGA mixed with gentamicin, lidocaine and vancomycin, and 
a blank outer layer (Chen et al., 2012). The occurrence of a second peak appears to be 
linked to the use of multiple layers, and could be the result of sufficient exposure of the 
inner coating layers occurring by this time. This can occur both through hydrolysis of 
chemical bonds within the outer layer polymer, as well as through enzymatic degradation of 
polymers within the wound. Indeed, polymer breakdown occurs more rapidly in vivo than 
in vitro (Eglin and Alini, 2008). The initial burst release of asODN observed could be 
useful in a wound setting, as Cx43 must be downregulated in the first 24 h in order for the 
re-epithelialisation process to initiate (Mori et al., 2006).  
The finding that multiple coating layers improved the overall duration of asODN elution is 
also in agreement with the results of a clinical trial study that used multi-layered stent 
coatings. In this study, stents were coated with an inside polymer layer containing Sirolimus 
as well as an outer layer containing no drug (Schofer et al., 2003). The group found that the 
use of an outer coating provided a barrier to slow the elution of drug from the inner layer, 
such that up to 80% of the drug eluted over a 30-day period. The application of multiple 
outer layers to scaffolds may have conferred a similar effect on the elution properties of the 
coatings developed in this study. It is important to note, however, that the in vitro 
assessment of elution dynamics serves only as a guideline to estimate in vivo asODN 
elution. In the in vivo experiments performed in the previous chapter using mice it was 
clear that collagen scaffolds are enzymatically degraded in wounds, with significant 
degradation having typically occurred by D5. The wound environment may result in a 
greater rate of elution than that observed when performing in vitro assays. On the other 
hand, coating layers containing drugs have been widely reported to incompletely release all 
drug contents, with one study finding that as much as 25% of the incorporated drug 
tacrolimus remained in a single layered coating (Wieneke et al., 2003). In the case of 
scaffolds coated multiple times within this study, this could mean that an even greater 
proportion of asODN may have remained trapped in the coatings in vitro, while in vivo the 
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breakdown of scaffolds could result in a greater release due to the exposure of trapped 
asODN. 
While spectrophotometry-based elution profiling showed that a considerable quantity of 
asODN eluted from PCL-PLGA double-coated scaffolds over 7 days, it did not reveal 
whether the homogenisation and solvent processing steps performed in the coating process 
damaged the structure of the incorporated DNA. FRET acceptor photobleaching was 
performed on sectioned scaffolds coated using a Cy3 and Cy5 dual labelled Cx43 asODN 
sequence (Figure 4. 3). This technique has been successfully used to study asODN integrity 
and is favoured for both its accuracy and simplicity (Rupenthal et al., 2012). Bleaching the 
Cy5 acceptor fluorophore on scaffolds sectioned immediately after coating (0 h) revealed a 
FRET efficiency of 25.9% (Figure 4. 3B). The fact this was above the 15-20% considered 
to signify that genuine FRET is occurring (Lai et al., 2014) suggested that the asODN was 
intact, and that the coating process did not destroy the asODN. FRET acceptor 
photobleaching following several days of serum immersion also resulted in high FRET 
efficiencies, indicating that there was intact asODN still contained within the scaffold 
structure (Figure 4. 3B). This indicated that that the coating conferred a degree of nuclease 
protection. Protection against nuclease activity is particularly important, since the wound 
environment is rich in DNAses; the most active of which is DNAse I (von Kockritz-
Blickwede et al., 2009). The performance of a lambda scan on a solution serum-treated 
asODN attenuated the second peak of light emission around 640 - 700 nm following 
excitation, indicating that the serum was indeed effective at breaking down asODN when 
not contained within a coating. 
In order to test whether scaffolds had an effect in vivo they were applied to 6 mm full-
thickness wounds, this time made to the dorsum of rats. Macroscopic assessment of the 
scaffolds suggested that coating scaffolds with the artificial polymers appeared to reduce 
wound integration even further (Figure 4. 4). Coating scaffolds appeared to make scaffolds 
more brittle, and could perhaps explain the ease with which scaffolds disassociated from 
wound edges. The poor level of coated scaffold integration was also reflected by how easily 
scaffolds detached from wounds during processing. Despite this, coated scaffolds appeared 
to shrink in size in the wound, at a rate faster than the uncoated scaffolds. This was 
possibly through dissolution of the scaffold fibres and hydrolysis of the polymer coatings. 
Unlike the bioactivated scaffolds in the previous chapter, the Cx43 asODN coated scaffold 
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did not appear to prevent wound contraction, while the control coated scaffolds had only a 
mild negative effect on wound size. This could have been due to the fact that the coating 
method used within this chapter prevented prior cross-linking of scaffolds, allowing the 
collagen fibres within the scaffold to break down more rapidly in conjunction with wound 
contraction. The finding that Cx43 asODN bioactivated scaffolds resulted in the smallest 
wounds is in agreement with previous direct wound applications of Cx43 asODN in 
Pluronic gel, where treated wounds were found to contract to a greater degree than 
untreated wounds (Qiu et al., 2003). This observation could be due to enhancement of 
fibroblast migration into the wound due to Cx43 knockdown, which can be responsible for 
wound contraction following differentiation into myofibroblasts (Mori et al., 2006). Cx43 
knockdown in fibroblasts, as previously discussed, can result in cytoskeletal changes to 
promote lamellipodia formation (Machacek et al., 2009). However, despite the possibility 
that Cx43 asODN may have had an effect on fibroblast migration, differences in Cx43 
expression within the dermis was not visually apparent in this study. This may be due to the 
time points investigated or even due to additional unknown mechanisms by which Cx43 
knockdown may act. 
The presence of hair regrowth, scab formation and the ability of scaffolds to mask the 
wound prevented accurate measurements being made from macroscopic evaluations, but 
microscopic assessment revealed significant differences between the scaffold treatments. 
Because of the ease at which scaffolds separated from the wound edge, it appeared that 
coated scaffolds may be behaving purely as a drug delivery reservoir; acting in a different 
capacity to a matrix supporting cell growth and wound regeneration. The biological effect 
of applying Cx43 asODN coated scaffolds to wounds resulted in a clear and significant 
effect on wound re-epithelialisation (Figure 4. 5, Figure 4. 6 & Figure 4. 7). This finding, 
along with the observations that wound size reduction was slightly enhanced, suggested 
that coating scaffolds with Cx43 asODN in layers of PLGA and PCL may actually improve 
wound healing, in stark contrast to the previous chapter where bioactivation appeared to 
only reduce the side effects of using collagen scaffolds. The positive results obtained in this 
chapter are in agreement with other Cx43 asODN studies, where wound re-epithelialisation 
was found to be accelerated following Cx43 asODN application (Qiu et al., 2003, Wang et 
al., 2007). In this case, it appears to be the first time a similar result has been achieved using 
a sustained asODN delivery approach. The enhancement to re-epithelialisation following 
Cx43 asODN scaffold application was accompanied by the reduction in thickness of the 
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leading edge epidermis at the wound (Figure 4. 8). This mirrors the findings of the previous 
chapter in mice, where transient scaffold bioactivation with Cx43 asODN reduced 
epithelial thickening relative to unocated scaffolds. This outcome also agrees with findings 
in STZ diabetic rats, where diabetic wound edge epidermis thickened and re-
epithelialisation was retarded, yet Cx43 asODN was found to overturn these effects (Wang 
et al., 2007). The control coated scaffolds also resulted in a lower degree of leading edge 
thickening than the uncoated scaffolds, and in some cases was not significantly different to 
Cx43 asODN coated scaffold-treated wounds. This could imply that the coating confers a 
greater degree of biocompatibility to the scaffold, or it could alternatively be the result of 
the reduced association and integration of coated scaffolds with the wound edge compared 
to uncoated scaffolds. 
The application of Cx43 asODN coated scaffolds reduced the number of 
polymorphonuclear leukocytes (PMNs) infiltrating the dermis distal to the wound edge 
relative to control scaffolds (Figure 4. 9). Unlike in the previous chapter, where transiently 
bioactivated scaffolds still resulted in higher numbers of PMNs than untreated wounds in 
mice, the application of the coated bioactive scafolds to rats resulted in the lowest PMN 
counts across all treatments at all time points. PMN counts for bioactive scaffold-treated 
wounds was also lower than untreated wounds, although significance between was not 
obtained. In a chronic ulcer where the inflammatory phase is protracted, this could be a 
useful feature of an applied scaffold (Pierce, 2001). 
The effects of enhanced re-epithelialisation occurred in conjunction with Cx43 
downregulation at D1, D3 and D5, relative to the control-treated scaffolds where Cx43 
expression was again conversely upregulated (Figure 4. 11, 13, and 15). It is reported that 
within 6 h after wounding Cx43 is normally downregulated in keratinocytes at the wound 
edge and this is a necessary step for cells to undergo migration (Coutinho et al., 2003). The 
enhanced knockdown of Cx43 using Cx43 asODN may help speed up this process to 
cause keratinocytes to initiate re-epithelialisation sooner and at an enhanced rate. The effect 
of Cx43 downregulation on the adoption of a migratory phenotype in keratinocytes has, 
similar to in fibroblasts, been linked to a reduced level of protein-protein interactions with 
cytoskeletal components (Hunter et al., 2005). However, Cx43 may also behave as a master 
regulator with the ability to influence expression of over 300 other genes (Iacobas et al., 
2007). Knockdown of Cx43 may therefore also have an effect on other proteins at the 
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transcriptional level, which could result in acceleration of wound healing. Unlike in mouse 
wounds in chapter 3, Cx43 in the Cx43 asODN-treated rat wounds remained 
downregulated, even at the later time point of D5. This could be due to the continued 
effect of asODN, which would likely have been present in the wound for a considerably 
greater period of time than when applied using Pluronic gel. However, sODN coated 
scaffolds resulted in variable levels of wound edge Cx43 expression and although they 
caused wound edge upregulation of Cx43 relative to distal levels unlike bioactivated 
scaffolds, the difference was not significant. While untreated wound edges downregulated 
Cx43 as typical of acute wound healing, the Cx43 asODN coated scaffold appeared to 
downregulate Cx43 expression to a greater degree. 
It was interesting to again observe that scaffolds bioactivated with Cx43 asODN influenced 
wound edge keratinocyte Cx26 expression, similar to in the mouse study (Figure 4. 10, 
Figure 4. 12 & Figure 4. 14). While Cx43 asODN coated scaffolds had no significant effect 
on Cx26 expression at D1, at D3 and D5 the bioactivated scaffolds resulted in significantly 
lower levels of expression than the other scaffold treatments. While it is not clear how 
Cx43 and Cx26 are linked, the two proteins have both been found to be upregulated in 
situations of perturbed wound healing (Labarthe et al., 1998, Mendoza-Naranjo et al., 
2012a, Mendoza-Naranjo et al., 2012b, Wang et al., 2007). Immunostaining has revealed 
both connexin proteins to be strongly upregulated within the same non-migratory wound 
edge keratinocytes in the ulcer tissue. Another explanation could again be that Cx43 adopts 
the role of a master regulator capable of influencing Cx26 expression through downstream 
effects, although further investigation to support this theory is required (Iacobas et al., 
2007). 
While in vitro assays had highlighted the ability of scaffold coatings to elute asODN in a 
sustained manner, evaluation of treated wounds at D10 and D15 gave a clearer indication 
of the effects of long-term Cx43 asODN delivery on the later stages of wound healing. At 
the selected late stage time points scaffolds were no longer visible within wounds when 
they were harvested. This could be due to considerable degradation of the coating layers 
and scaffold fibres by this time, but may also be due to the loss of the shrunken scaffolds 
from the heavily contracted wounds, which had never integrated considerably with the 
coated scaffolds to begin with (Ishaug et al., 1994). The gradual detachment of Tegaderm 
film securing scaffolds to wounds before these time points also adds to this possibility. 
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Nevertheless, wounds that received a Cx43 asODN bioactivated coated scaffold had 
significantly smaller defined regions of granulation tissue, the tissue rich in cigar-shaped 
fibroblasts and blood vessels, than all the other treatments (Figure 4. 16 & 17).  
Cx43 asODN coated scaffold-treated wounds appeared to be further ahead in the wound 
contraction process than the other treatments, including scaffolds that were coated 
identically except using sODN instead of asODN. One possible explanation for this is that 
Cx43 knockdown can promote fibroblast migration, which could have resulted in the 
appearance of myofibroblasts in the wound sooner (Mori et al., 2006). Myofibroblasts 
normally contract intracellular bundles of α-SMA to help pull the margins of a wound 
together (Hinz et al., 2001). Initially appearing at the wound margins, myofibroblasts 
eventually migrate towards the centre of the wound around 7-14 days and are then lost, 
possibly through apoptosis (Mori et al., 2006). Staining control coated scaffold wounds 
with an anti-α-SMA antibody revealed large regions of positive staining throughout the 
entirety of the wound, including close to the wound margins (Figure 4. 18). In contrast, 
Cx43 asODN coated scaffolds resulted in a significantly smaller area of α-SMA staining 
and the stained region was highly localised to the centre of the wound. The possibility that 
Cx43 knockdown enhances myofibroblast activity to promote wound contraction is 
supported by this observation; Cx43 asODN-treated wounds had both the smallest staining 
regions of α-SMA and myofibroblasts were centrally located, which is normally associated 
with myofibroblasts that are soon to be lost (Mori et al., 2006). By D15 there was no 
convincing staining of α-SMA to image across the two different treatments, which 
appeared to suggest that myofibroblasts were no longer present in the majority of wounds 
by this stage. 
 
Conclusions 
Using an emulsion technique a multi-layered Cx43 asODN eluting scaffold can be 
fabricated that released asODN over 7 days. Following application in vivo, the coated 
scaffolds appeared to offer multiple advantages over transient bioactivation with Cx43 
asODN in the previous chapter. Coated scaffolds did not appear to inhibit wound 
contraction between D1-D5, while also maintaining Cx43 down-regulation throughout at 
least the first 5 days of wound healing. In both this and the previous chapter, it became 
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increasingly apparent that Cx26 was linked to wounds in which healing was perturbed. 
Cx26 up-regulation has also been linked to hyperproliferative skin conditions (Labarthe et 
al., 1998), and ectopic Cx26 has also been found to delay restoration of the epidermal 
barrier and promote the formation of an inflammatory response (Djalilian et al., 2006). By 
some mechanism, Cx43 asODN treated scaffolds resulted in significant decreases in 
wound edge keratinocyte Cx26 expression at D3-D5, although not at the onset of wound 
healing. 
As devices intended to ultimately promote healing of full-thickness wounds such as chronic 
ulcers, it would also be useful to develop the coating to deliver drugs that can target other 
deregulated proteins such as, potentially, Cx26. However, it remained to be seen whether a 
potential Cx26 asODN sequence alone could also improve wound healing, especially since 
Cx26 is normally strongly upregulated at the wound edge of healing acute wounds 
(Coutinho et al., 2003).
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5.1 – Introduction 
Following the redesign of my polymer coating for scaffolds outlined in the previous 
chapter, Cx43 asODN was found to elute over 7 days following a series of in vitro elution 
assays. This extended release profile had a positive effect on wound healing in vivo. As a 
means of potentially further improving scaffolds as therapeutic devices, attention was 
focused on Cx26.   
There is currently a greater understanding of the role of Cx43 in wound healing than Cx26 
– Cx43 is naturally downregulated in wound edge cells within the first 6-24 h and coincides 
with the adoption of a migratory phenotype both in keratinocytes and fibroblasts 
(Coutinho et al., 2003). In situations when Cx43 is not downregulated, such as in diabetic 
and chronic wounds, cell migration is significantly perturbed and wound healing is severely 
retarded (Mendoza-Naranjo et al., 2012a, Mendoza-Naranjo et al., 2012b, Wang et al., 
2007). Throughout both chapters 3 and 4, it was clear that Cx26, as well as Cx43, was 
strongly upregulated in thickened bulbs of keratinocytes when wound healing was 
perturbed. 
The role of Cx26 in wound healing is less clear. While it is known that Cx26 and Cx30 are 
strongly upregulated in wound edge keratinocytes within 24 h, it is not fully understood 
how this affects wound healing (Coutinho et al., 2003). As previously discussed, one 
possible explanation is that wound edge keratinocytes form a communication compartment 
separate to the keratinocytes further away in the uninjured epidermis. While Cx43 is 
downregulated in the basal layer, Cx26 and Cx30 are instead upregulated in the spinous 
layers of keratinocytes following injury (Coutinho et al., 2003). Since Cx26 and Cx30 can 
interact with each other, but not Cx43, it is possible that two connexins could establish a 
unique compartment with properties distinct to the rest of the epidermis (Marziano et al., 
2003). In this way, it is possible that wound edge keratinocytes cannot interact with the rest 
of the epidermis through connexins, possibly resulting in reduced cell adhesion and the 
transition to a migratory cell phenotype. 
It is unclear whether the Cx26 that is expressed in migratory keratinocytes during re-
epithelialisation is beneficial to wound healing. In the previous chapter it was found that 
Cx43 asODN appeared to reduce wound edge keratinocyte Cx26 expression at D3 and D5, 
and this occurred alongside an improvement to re-epithelialisation (Figures 4. 10 & 4. 12). 
5. Targeting Cx26 expression using scaffolds 
143 
 
This observation could have been due to Cx43 asODN effectively appearing to advance 
wound re-epithelialisation by 1-2 days, potentially to a stage where Cx26 levels begin to 
reduce naturally. While it is unclear what effect Cx26 downregulation may have, the ectopic 
overexpression of Cx26, similar to that observed following the application of uncoated 
scaffolds, has been shown to delay the restoration of the epithelial barrier (Djalilian et al., 
2006). Cx26 up-regulation has also been linked to hyperproliferative skin conditions 
(Labarthe et al., 1998) and more recently, Sutcliffe et al. reported that Cx26 was strongly 
upregulated in chronic ulcers similar to Cx43 (journal article submitted). Because of this, it 
was proposed that Cx26 upregulation could be involved in the formation of thickened 
bulbs of keratinocytes, a possibility strengthened by the fact the bulbs express high levels 
of Cx26 following application of scaffolds (Figures 3. 3 & 4. 10). It has been previously 
postulated that Cx26 expression may be necessary in wound edge keratinocytes in order for 
migration to occur (Coutinho et al., 2003). However, it has separately been shown using in 
vitro scratch wound healing migration assays that mutant cells expressing nonfunctional 
Cx26 did not migrate slower, but nor did they migrate faster (Thomas et al., 2007). Our 
current understanding is insufficient to make definitive statements, but Cx26 expression in 
migrating keratinocytes may not actually be necessary to promote wound healing. 
Despite investigations into the effects of Cx26 mutations, the role of Cx26 downregulation 
in wound healing has not been sufficiently analysed. Since Cx26 upregulation appears to be 
associated with perturbed healing and hyperproliferative skin conditions, it seemed possible 
that downregulation of Cx26 could actually be beneficial to healing. Targeted Cx26 
downregulation could perhaps be even more effective in situations where Cx26 would be 
upregulated to extreme levels, such as in the epidermis of scaffold-treated wound or in a 
chronic ulcer (Sutcliffe et al., submitted journal article). Furthermore, if Cx26 asODN was 
found to have a positive effect on wound healing, it is possible that its combination with 
the previously tested Cx43 asODN sequence may even yield a synergistic effect. In the 
CoDa laboratory in New Zealand, a series of Cx26 asODN sequences have recently been 
designed. Following a pilot screening of a number of sequences in an in vivo mouse 
experiment performed in the laboratory, two sequences (termed ‘AS3’ and ‘AS6’) that 
appeared to have a mild positive effect on wound closure were previously identified. Using 
these two sequences, it was proposed that the scaffold coating method devised in the 
previous chapter could also be used to incorporate and deliver Cx26 asODN to wounds. If 
this resulted in Cx26 knockdown in migrating wound edge keratinocytes it could validate 
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the efficacy of the sequences and may also reveal what effect the knockdown of Cx26 had 
on wound re-epithelialisation and inflammation. Success using other asODN sequences 
could also highlight the potential of the developed coating method as an off-the-shelf 
method of delivering multiple different sequences. Since Cx43 asODN had a positive effect 
on wound healing, it was also proposed that if Cx26 asODN improved wound healing, the 
combined application of both Cx26 and Cx43 asODN in a coating might result in a 
synergistic effect. With this in mind, the efficacy of the new Cx26 asODN sequences on 
the healing of rat full-thickness wounds relative to control and Cx43 asODN scaffold 
treatments was investigated. 
 
The aims of this chapter were as follows: 
To adapt the scaffold coating approach to incorporate the novel Cx26 asODN sequences 
into a scaffold coating. 
To confirm the efficacy of the asODN sequences in vivo, through application of coated 
Cx26 asODN scaffolds to rat full-thickness wounds followed by immunostaining, re-
epithelialisation and inflammatory cell analysis. 
 To investigate whether combined Cx26 and Cx43 asODN scaffold applications had a 
synergistic effect on wound healing. 
 
5.2 – Materials and Methods 
See Chapter 2 for a detailed description of the individual methods, reagents and equipment 
employed. A condensed explanation of the methods used in this chapter is listed below. 
5.21 – Scaffold fabrication 
Collagen scaffolds were fabricated through use of the same electrospinning technique used 
throughout the previous 2 chapters, a detailed explanation of which is provided in chapter 
2. 
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5.22 – Application of polymer coatings containing Cx26 or Cx43 asODN to 
scaffolds 
Both Cx43 and Cx26 asODN sequences were incorporated into polymer coatings using the 
emulsion technique employed in chapter 4. The same rodent Cx43 asODN sequence used 
in both chapters 3 and 4 was used in for the purpose of coating scaffolds and had the 
sequence 5’-GTA ATT GCG GCA GGA GGA ATT GTT TCT GTC-3’. A non-
functional sense (sODN) sequence to this Cx43 asODN was also incorporated to create 
one of the control scaffold treatments, and had the sequence: 5’- GAC AGA AAC AAT 
TCC TCC TGC CGC AAT TAC-3’.  
In the case of Cx26 asODN, two different novel sequences (termed ‘AS3’ and ‘AS6’) that 
have been previously developed by CoDa Therapeutics Inc. in New Zealand had been 
identified to be potentially effective following pilot in vivo screening of multiple sequences. 
Both sequences are 20-mers (sequences currently undisclosed at the instruction of CoDa). 
Due to the limited time remaining in the PhD to examine each individually, both Cx26 
sequences were instead combined into one coating. Cross-annealing between the two 
asODN sequences was first ruled out before opting to combine the sequences. Either PCL 
or Poly(D, L-lactice-co-glycolide) (PLGA) was dissolved in the solvent dimethyl carbonate 
at 10% wt./v. using gentle rocking. The individual asODN sequences were dissolved in 
nuclease-free water and mixed with the polymer solutions at a 300 μM final DNA 
concentration. In the case of Cx26 asODN, both AS3 and AS6 sequences were each 
dissolved at a final concentration of 300 μM, and for the combined Cx43 + Cx26 asODN 
scaffolds the three asODN sequences were each incorporated at a 300 μM concentration. 
The two immiscible layers were processed for 10 seconds using a handheld homogeniser 
on a medium setting at room temperature to produce an emulsion. After preparing the 
coating mixture, individual 6 mm collagen scaffolds were dipped for 1 second in the 
desired polymer-asODN solutions and immediately placed in a tube of liquid nitrogen and 
lyophilised overnight to remove the solvent from the scaffolds in order to maintain the 
structure of the scaffold. This coating process, from dipping to freeze drying, was repeated 
7 times, such that each scaffold received 4 coating layers of PCL + asODN followed by 4 
layers of PLGA + asODN (8 layers in total). 
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5.23 – Surgery 
Six week old Sprague Dawley rats were anaesthetised using 4% isoflurane, 20% oxygen and 
10% nitrous oxide, and maintained using 1.5% isoflurane. Animals were injected 
subcutaneously with 0.03 mg/ml buprenorphine (Vetergesic®) before operation. Rat backs 
were shaved and covered in a thin layer of Nair® hair removal cream, after which both the 
cream and hair was removed using a warm moistened gauze pad. Animals were placed on 
heated mats for the operation. Four full-thickness excisional biopsy punch wounds were 
made using a 6 mm medical biopsy punch to rodent backs, two on each side of the dorsal 
midline. Scaffold treatments were applied directly to wounds, after which the back was 
covered with a sheet of Tegaderm™ film. Post-procedure, animals were kept in a heated 
chamber and monitored for recovery. Once recovered, animals were rehoused in standard 
individual cages. 
5.24 – Processing and histology 
Harvesting wounds 
Animals were culled by cervical dislocation at 1, 3, 5, 10 & 15 days post wounding. Wounds 
were macroscopically imaged at D1 - 5 as outlined in Chapter 2. Wounds were then excised 
and fixed in 4% paraformaldehyde (PFA)-PBS solution for 24 h at 4°C. Tissue was 
immersed in 20% sucrose overnight then washed in PBS, after which wounds were 
bisected. Half of each wound was snap frozen in O.C.T. medium, then sectioned using a 
cryostat at a thickness of either 5 μm (for H&E staining) or 10 μm (for 
immunofluorescence staining).  
Haematoxylin and eosin staining 
Frozen tissue sections were thawed for 5 min then covered completely in tap water for 5 
min at room temperature. Slides were submerged in Harris’ haematoxylin solution for 30 
seconds followed by immersion in a container full of running tap water for 5 min. 
Background staining was reduced by dipping the slides in a container full of 1% acid 
alcohol (1% glacial hydrochloric acid, 70% ethanol, 29% distilled water) for 3 seconds, after 
which slides were immersed in a container of running tap water for a further 5 min. 
Samples were then submerged for 15 seconds in a container full of eosin B solution, 
followed by immersion for 5 seconds in a container full of tap water to rinse away excess 
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stain. Slides were then immersed in 70% ethanol for 2 min, 100% ethanol for 2 min and a 
second container of 100% ethanol for a further 2 min, to dehydrate the sections. Slides 
were then submerged in a container full of xylene for 5 min, then a second container of 
xylene for an additional 5 min. Slides were then individually removed and mounted using 
DPX mounting media. 
Immunofluorescence staining 
Tissue sections were permeabilised in cold acetone for 5 min and then using a 0.1 M L-
lysine PBS solution containing 0.1% Triton-X-100. Sections were stained for 1 h using a 
rabbit polyclonal antibody to Cx43 (1:2000 dilution, C6219, Sigma Aldrich UK) or Cx26 
(1:200 dilution, (Diez et al., 1999). Sections were then stained using a goat anti-rabbit Alexa 
488 secondary antibody (A11008, Invitrogen UK) at a 1:400 dilution for 1 h. Tissue was 
counterstained using Hoechst solution (both Hoechst 33528 and Hoechst 33342 dyes at 
1:50,000 dilution, Sigma Aldrich UK). 
 
5.25 – Analysis 
Imaging 
Wounds were macroscopically and microscopically imaged as outlined in Chapter 2. Tissue 
sections immunostained for Cx26 or Cx43 and Hoechst were imaged using confocal 
microscopy. Single optical section 8-bit images were acquired at the wound edge and at a 
distal region of skin at 1024 by 1024 pixels. Image settings were consistent between 
treatments. 
Epidermal thickening and re-epithelialisation measurements 
Epidermal thickness was measured on H&E stained tissue and determined by measuring 
the thickest point along the basal to spinous layer axis within the end 150 µm of nascent 
epidermis using ImageJ. The length of nascent epidermis outgrowing from the wound 
margin was measured at either side of the wound using ImageJ and averaged to return a re-
epithelialisation distance measurement for each sample. 
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Connexin 26 and 43 protein quantification 
Cx43 and Cx26 protein expression was quantified on D1, D3 and D5 wounds by counting 
positive pixels on binary images of wound edges using ImageJ software using the method 
outlined in a study by (Wang et al., 2007). Images from each experiment were identically 
thresholded and the number of connexin positive pixels within the end 100 µm quantified. 
Connexin levels were expressed per square micron of epidermis and normalised to distal 
levels to reduce sample variation. In the case of Cx26, distal levels were extremely low, to 
the extent that small fluctuations between samples could result in large differences between 
values. For this reason, Cx26 distal levels were averaged for the group, and this averaged 
value was used to calculate changes in wound edge keratinocyte Cx26 expression for each 
animal. 
Polymorphonuclear cell quantification 
H&E stained D1, D3 and D5 rat full-thickness wounds were microscopically assessed at 63 
X. At 700 µm from the wound edge in the lower dermis, rounded cells with a 
polymorphonuclear morphology (PMNs) were identified and counted in a single field of 
view as a means to quantify inflammatory leukocytes infiltrating the uninjured tissue. A 
total of n=5 wounds were assessed per time point and treatment and values were averaged. 
Measurement of granulation tissue area 
Rat wounds harvested at D10 and D15 were H&E stained and loaded into an automated 
Zeiss Axio Scan.Z1 slide scanner. Brightfield images were captured using a 20 X objective, 
then automatically stitched together to form a montage. Montages were then imported into 
ImageJ. The granulation tissue (or wound region) was defined as the new area of tissue 
within the wound margins yet above the muscle and panniculus carnosus layers, and was 
measured using the freehand line tool within the program. 
Assessment of smooth muscle actin area 
Rat wounds harvested at D10 were loaded into the same Zeiss slide scanner and imaged 
using a 20 X objective using the built in image acquisition wizard. Hoechst and Alexa 488 
fluorophores were excited to produce a montage image of the tissue. SMA staining in the 
green channel was thresholded in the software to a level that allowed visualisation of both 
SMA positive blood vessels as well as a positive staining region in the wound gap, above 
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the panniculus carnosus. This area was drawn around using a marker tool within the 
proprietary ZEN 2012 software and an area in square microns was displayed. This 
approach was applied in the same manner to each of the 8 samples in each treatment 
group.  
Statistical analyses 
Sample size was determined using power analysis software G*Power as described in 
Chapter 2. Data was subjected to Kolmogorov-Smirnov tests using GraphPad Prism 5.0 
software to ascertain normality, then to one-way ANOVA tests followed by Tukey’s post-
hoc tests to determine statistical significance. 
 
5.3 – Wound healing response to a Cx26 asODN coated scaffold 
In order to assess the efficacy of the Cx26 asODN sequences on Cx26 knockdown in vivo, 
collagen scaffolds that had been coated in two Cx26 asODN sequences were applied to 6 
mm diameter full thickness wounds made to the dorsum of rats. In addition to this, some 
scaffolds were coated with both the Cx26 asODN sequences as well as the Cx43 asODN 
sequence resulting in a combined 'Cx26/43 asODN' coated scaffold. Rats treated with 
both scaffold types were culled at D1, 3 and 5, after which the wounds were 
macroscopically assessed and compared to the control and Cx43 asODN treatments 
(Figure 5. 1). 
5.31 – Evaluation of macroscopic wound closure 
At D1, wounds across all treatments appeared macroscopically similar in size to the initial 6 
mm wounds made at 0 h (Figure 5. 1). At D3, both the Cx26 asODN and Cx26/43 
asODN coated scaffold-treated wounds had reduced in size to a level comparable to that 
of untreated wounds, which was slightly smaller than control coated scaffold-treated 
wounds. Wounds treated with both scaffold types containing Cx26 asODN appeared 
markedly reduced in size relative to the uncoated scaffold, similar to the Cx43 asODN 
coated scaffolds. By D5, wounds treated with the Cx26 and Cx26/43 asODN coated 
scaffolds had considerably reduced in size, to the extent of untreated wounds or greater, 
although hair regrowth and the presence of scaffolds could obscure the wound margins. 
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Similar to the Cx43 asODN coated scaffolds, both of the Cx26 asODN containing 
scaffolds reduced in size over the duration of wound healing at a greater rate than the 
uncoated scaffolds, while also exhibiting minimal integration with the wound edge. The 
combined Cx26/43 asODN scaffold treated wounds did not, on average, appear markedly 
reduced in size relative to the Cx26 only asODN or Cx43 asODN only scaffold treatments.  
 
 
 
Figure 5. 1 – Effect of scaffold application on macroscopic wound appearance 
(A): Full thickness rat wounds were treated with Cx26 asODN only coated scaffolds or 
scaffolds coated in both Cx26 asODN and Cx43 asODN. These treatments were 
compared to existing scaffold treatments as well as untreated wounds. (B): Animals (n=8) 
were culled at either 1, 3 or 5 days (D1, D3 & D5) after wounding and the wounds 
macroscopically imaged. Scale bar = 1 mm. 
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5.32 – Cx26 asODN coated scaffolds significantly improve wound re-
epithelialisation 
Similar to in the previous chapter, the PLGA and PCL coated scaffolds containing Cx26 
asODN sectioned poorly relative to the uncoated scaffolds, and exhibited a considerable 
lack of integration with the wound edge. Coated scaffolds often curled up following 
sectioning or became easily detached during wound processing. All re-epithelialisation 
values are reported as the means of n=8 animals ± SEM. Following microscopic evaluation 
of wound re-epithelialisation at D1, wounds treated with the Cx26 asODN only scaffold 
had re-epithelialised a distance of 404 ± 29 μm μm, which was a significant 47.5% increase 
over the 274 μm  ± 27.1 μm of untreated wounds (Figure 5. 2, P < 0.05). This was similar 
to the average distance for Cx43 asODN scaffold treated wounds (407 μm ± 32 μm). 
Furthermore, the combined Cx26/43 asODN coated scaffolds resulted in a moderately 
higher re-epithelialisation distance (494 ± 40.8 μm) over scaffolds containing asODN 
against only one type of connexin. Combining both Cx26 and 43 asODNs in a coating 
increased re-epithelialisation by 22.3% over Cx43 asODN only scaffolds. 
In order to assess whether Cx26 asODN and Cx26/43 asODN coated scaffolds had a 
similar effect on healing at later time points, wound re-epithelialisation was also measured 
at D3 (Figure 5. 3). The Cx26 asODN only coated scaffolds had re-epithelialised on 
average 791 ± 53.1 μm. This was significantly improved over the three control scaffold 
treatments, which had on average re-epithelialised only 50.8% as far (P < 0.05, P < 0.01 
and P < 0.001). This distance was not significantly different from Cx43 asODN only 
treated wounds, however. Additionally, re-epithelialisation of the Cx26 asODN only 
scaffold-treated was insignificantly different from untreated wounds, in contrast to the 
Cx43 asODN only scaffolds. Similar to D1, wounds treated with scaffolds containing the 
combined Cx26 and Cx43 asODN sequences had re-epithelialised the furthest distance. At 
an average of 972 ± 118.3 μm, combined asODN scaffold-treated wounds had re-
epithelialised significantly further than every non-asODN treatment. Wounds treated with 
the combined asODN scaffold had re-epithelialised 12% further than those treated with 
the Cx43 asODN scaffold, and 18.6% further than those treated with the Cx26 asODN 
only scaffold. 
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Figure 5. 2 – D1 full-thickness wound healing following application of scaffolds 
coated with Cx26 asODN 
(A): A simplified wound diagram to illustrate the site at which images were captured. 
(B): Wounds were either left untreated or treated with a control scaffold (white/red bars) 
or coated scaffolds containing asODN (green bars). Wound re-epithelialisation distances 
outlined by dotted yellow lines were measured for each type of scaffold applied and plotted 
as a graph (top left). Eight rat wounds were assessed for re-epithelialisation, data plotted 
are means + SEM error bars (* = P < 0.05, ** = P < 0.01, ** = P < 0.001). Scale bar = 100 
μm. 
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Figure 5. 3 – D3 full-thickness wound healing following application of scaffolds 
coated with Cx26 asODN 
(A): A simplified wound diagram to illustrate the site at which images were captured. 
(B): Wounds were either left untreated or treated with a control scaffold (white/red bars) 
or coated scaffolds containing asODN (green bars). Wound re-epithelialisation distances 
outlined by dotted yellow lines were measured for each type of scaffold applied and plotted 
as a graph (top left). Eight rat wounds were assessed for re-epithelialisation, data plotted 
are means + SEM error bars (* = P < 0.05, ** = P < 0.01, *** = P < 0.001). Scale bar = 
100 μm. 
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Re-epithelialistion distance at D5 was also measured (Figure 5. 4). Cx26 asODN coated 
scaffold-treated wounds had re-epithelialised a distance of 1325 ± 43.4 μm, which was 
significantly further than untreated wounds (882 ± 47.3 μm, P < 0.05) and wounds treated 
with control coated scaffolds. Wounds treated with Cx26 asODN coated scaffolds had re-
epithelialised significantly further than control coated scaffolds (806 ± 65.1 μm, P < 0.01), 
uncoated scaffolds (713 ± 132.1 μm, P < 0.01) and Cx43 sODN coated scaffolds (819 ± 
62.5 μm, P < 0.05). The effect of Cx26 asODN on wound re-epithelialisation at D5 was 
similar to that of Cx43 asODN (1325 ± 43.4 μm vs. 1345 ± 97.7 μm, respectively). The 
combined Cx26 and Cx43 asODN scaffold again resulted in the greatest effect on re-
epithelialisation, at 1695 ± 173.9 μm. This was 26% higher than wounds treated with Cx43 
asODN only scaffolds and 27.9% greater than those treated with just the Cx26 asODN 
coated scaffolds. Across all wounds at D5, those receiving a scaffold that contained Cx43 
asODN (either Cx43 asODN only scaffolds or both Cx43 and Cx26 asODN) had on 5 
occasions fully re-epithelialised. Only 1 wound treated with the Cx26 asODN only scaffold 
had re-epithelialised, however, and only one of the control wounds had re-epithelialised. 
Thickening of the nascent epidermis following Cx26 asODN scaffold application was also 
measured, since Cx26 expression is commonly linked to epithelial thickening disorders 
(Labarthe et al., 1998, Lucke et al., 1999) (Figure 5. 5). All thickening measurements are 
reported as means ± SEM. It was observed that at D1 (P < 0.01), D3 (P < 0.001) and D5 
(P < 0.001) wounds treated with Cx26 asODN coated scaffolds had significantly lower 
epithelial thickening values than the uncoated scaffolds. Coating scaffolds with Cx26 
asODN reduced epithelial thickening to a similar level of Cx43 asODN coated scaffolds at 
each time point. Cx26 asODN coated scaffolds resulted in measured epithelial thicknesses 
of 49.4 ± 7.9 μm (D1), 36.9 ± 5.5 µm (D3) and 33 ± 5 µm (D5), which were significantly 
thinner than the measured epithelia of most control scaffold treatments (Figure 5. 5). Cx26 
asODN coated scaffold-treated wound edge epidermis was not significantly thinner than 
measurements for uncoated scaffold-tread wounds at D1 and D3 or Cx43 sODN scaffold-
treated wounds at D1 and D5, however. The combined Cx26/43 asODN scaffold did not 
appear to have a synergistic effect in reducing epithelial thickening, as thickness 
measurements for the combined asODN scaffold were similar to the other bioactivated 
scaffolds. The combined Cx26 /43 asODN scaffold did, however, result in a significantly 
thinner measured epidermal leading edge than untreated wounds at D3 (P <0.05). 
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Figure 5. 4 – D5 full-thickness wound healing following application of scaffolds 
coated with Cx26 asODN 
(A): A simplified wound diagram to illustrate the site at which images were captured. 
(B): Wounds were either left untreated or treated with a control scaffold (white/red bars) 
or coated scaffolds containing asODN (green bars). Wound re-epithelialisation distances 
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outlined by dotted yellow lines were measured for each type of scaffold applied and plotted 
as a graph (top left). (C): Each of the D1, D3 and D5 re-epithelialisation averages was 
individually plotted (see individual time points for significant differences). Eight rat wounds 
were assessed for re-epithelialisation, data plotted are means + SEM error bars (* = P < 
0.05, ** = P < 0.01, *** = P < 0.001). Scalebar = 100 μm. 
 
 
 
Figure 5. 5 – Thickening of the nascent epidermis following Cx26 asODN scaffold 
application. 
The same full-thickness wounds treated with different types of scaffolds were also 
measured for epithelial thickness within the end 150 µm of the nascent tip of epidermis. 
Measurements were recorded across n=8 samples at D1, D3 and D5 (* = P <0.05, ** = P 
< 0.01, *** = P < 0.001). Data values plotted are means + SEM error bars. Significance 
stars are coloured to match the treatment that is significantly different (e.g. white star = 
significantly different to untreated wounds).  
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5.33 - The effect of Cx26 asODN coated scaffolds on the local inflammatory cell 
response 
In order to assess the effect of Cx26 asODN coated scaffolds on the infiltration of 
inflammatory cells, the number of individual cells with a rounded polymorphonuclear 
morphology characteristic of polymorphonuclear leukocytes (PMNs) were identified and 
measured in a region of dermis distal to the wound edge similar to the previous chapter 
(see chapter 2 for full method). This was performed in order to determine whether 
scaffolds caused extensive inflammatory cell invasion of the native tissue, and cell counts 
for each treatment are reported as means ± SEM (Figure 5. 6A). At D1, Cx26 asODN 
coated scaffolds resulted in the lowest PMN counts of any treatment, with an average of 
11.6 ± 2.4 cells recorded in the region of dermis analysed (Figure 5. 6C). This was lower 
than that found using both Cx43 asODN coated scaffolds (15.6 ± 1.3) and the combined 
Cx26 + Cx43 asODN scaffolds (16 ± 4), although the differences were insignificant. Cx26 
asODN scaffolds resulted in a significantly lower number of infiltrating PMNs than all 
control scaffold treatments at D1. The quantified number of PMNs for Cx26 asODN 
treated tissue were 82.5% lower than uncoated scaffolds (P <0.001), 70% lower than 
coating only scaffolds (P <0.05), and 78.4% lower than Cx43 sODN scaffolds (P <0.001).  
At D3, the dermis distal to wounds treated with Cx26 asODN scaffolds contained a 
slightly higher number of PMNs relative to Cx43 asODN scaffold-treated wounds (27.4  ± 
7.2 vs. 18.80 ± 14.1 cells) but this difference was insignificant (Figure 5. 6B-C). The dermis 
distal to Cx26 asODN scaffold treated wounds contained significantly reduced numbers of 
PMNs compared to uncoated scaffolds (71.2 ± 12.5, P <0.001) and coating + Cx43 sODN 
scaffolds (61 ± 5.3, P <0.01), but was not significantly lower than coating only scaffolds, 
although there was a marked difference (27.4 ± 7.2 vs. 48.6 ± 4.3 PMNs). Despite this, the 
combined Cx26 + Cx43 asODN scaffolds resulted in a count of 17 ± 2.6 PMNs, which 
was significantly lower than all three control scaffold types at D3. 
Following on with measurements at D5, PMNs were greatly reduced across all treatments 
(Figure 5. 6C). Cx26 asODN coated scaffolds resulted in an average count of 8.2 ± 1.8 
PMNs in the dermis, while the combined Cx26 + 43 asODN scaffold resulted in 9.8 ± 1.4. 
This was similar to the cell counts recorded for Cx43 asODN only scaffolds (9.4 ± 2.5 
PMNs). Both the Cx26 and Cx26 + 43 coated scaffolds resulted in significantly lower 
numbers of quantified PMNs relative to control coating only scaffolds (P < 0.01) and Cx43 
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sODN scaffolds (P < 0.05), but not the control uncoated scaffolds, although the number 
was still lower. Cx26 asODN scaffold treated tissue PMNs were 76.6% reduced in the 
dermis from uncoated scaffold dermal measurements, and 73.7% reduced from the 
number quantified for Cx43 sODN scaffolds. These differences were similar to that of 
combined Cx26 + 43 asODN scaffolds. Although Cx26 asODN only, Cx43 asODN only 
and Cx26 + 43 asODN scaffolds did not significantly reduce PMN infiltration relative to 
untreated wounds, PMN counts were in a number of cases lower than wounds treated 
scaffolds not coated in Cx26 or Cx43 asODN. 
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Figure 5. 6 – The effect of Cx26 asODN scaffold application on the number of 
polymorphonuclear cells (PMNs) infiltrating the unwound dermis. 
Full-thickness wounds that received a scaffold treatment were assessed for 
polymorphonuclear cell invasion into the lower dermis 700 µm away from the wound edge 
as indicated in the diagram (A). (B):  High-power typical images of the dermal region 
indicated in (A) for each scaffold treatment. The typical images shown are of the 
unwounded dermis distal to D3 wounds. Scale bar = 50 μm. (C): Quantification of 
individual PMNs for each treatment across time points of D1, D3 and D5 were plotted as 
means + SEM error bars of n=5 samples. Diagram legend: E = epidermis, D = dermis, PC 
= panniculus carnosus, WE = wound edge (* = P <0.05, ** = P < 0.01, *** = P < 0.001). 
Significance stars are coloured to match the treatment that is significantly different (e.g. 
dark red star = significantly different to Cx43 sODN scaffold-treated wounds). 
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5.5 – Cx26 asODN promotes wound edge Cx26 downregulation 
In order to examine whether the two Cx26 asODN sequences directly resulted in Cx26 
knockdown at the wound, wound tissue sections were immunostained for Cx26. At D1, 
Cx26 was upregulated from distal levels in wound edge keratinocytes in both Cx26 asODN 
scaffold treated wounds (141.4% upregulation) and the combined Cx26/43 scaffold-treated 
wounds (225.6% upregulation) (Figure 5. 7). Despite this, the level of Cx26 upregulation 
was significantly lower than that measured in control treated wound edges, which were 
several thousand percent higher. Cx26 asODN only scaffolds did not result in a significant 
decrease in wound edge Cx26 expression relative to the Cx43 asODN only scaffold-treated 
wounds, although levels were decreased. Additionally, wound edge keratinocyte Cx26 levels 
were similar between both Cx26 asODN and combined Cx26/43 asODN scaffold 
treatments. The application of Cx26 asODN coated scaffolds did not result in a reduced 
level of wound edge Cx43 expression at D1 compared to untreated wounds, however; 
wounds exhibited a 121.9% upregulation of Cx43 similar to that found using control 
scaffolds (Figure 5. 8). Scaffolds containing both Cx26 and Cx43 asODN sequences 
however, resulted in an 85.9% downregulation of Cx43. 
Wounds harvested at D3 that had been treated with a Cx26 asODN coated scaffold again 
featured reduced levels of Cx26 expression at the wound edge (Figure 5. 9). Wounds 
treated with scaffolds containing only Cx26 asODN featured a 48% downregulation of 
Cx26 at the wound edge, while for the combined Cx26/43 asODN scaffold this 
downregulation was 49.8%. For both types of scaffold this was significantly lower than 
untreated wounds as well as wounds treated with control scaffolds. Although Cx43 asODN 
coated scaffold-treated wound edges expressed significantly lower levels of Cx26 than the 
control treatments, expression was still upregulated and considerably higher than wound 
edges that had a scaffold applied containing Cx26 asODN. At D3, wounds that received 
Cx26 asODN scaffolds featured a 209.6% increase in Cx43 levels at the wound edge from 
distal levels (Figure 5. 10). Again, this was not found using scaffolds coated in both Cx26 
and Cx43 asODN, which resulted in an 89% downregulation in Cx43 expression at the 
wound edge. 
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At the later time point of D5, wound edge keratinocyte Cx26 levels had considerably 
reduced from the levels at D3 across all treatments. Despite this, Cx26 asODN scaffolds 
resulted in significantly lower levels of Cx26 expression at the wound edge than other 
treatments (Figure 5. 11). Cx26 asODN scaffold-treated wound edge epidermis had 
downregulated Cx26 levels by 68.4% from distal levels, which was significantly lower than 
untreated wounds (199.2% upregulation), uncoated scaffolds (419.1% upregulation), 
control coated scaffolds (431.4% upregulation) and Cx43 sODN scaffolds (417.5% 
upregulation). Combined Cx26/43 asODN scaffolds resulted in a slightly greater 
downregulation of Cx26 asODN at the wound edge (an 87.4% downregulation) relative to 
the Cx26 asODN only scaffold. Although both types of scaffold containing Cx26 asODN 
reduced Cx26 levels compared to Cx43 asODN only scaffolds, the difference was not 
significant. In contrast to D1 and D3, at D5 the Cx26 asODN only scaffold resulted in a 
significant downregulation of Cx43 relative to the control scaffold treatments (Figure 5. 
12). While control scaffolds all resulted in an upregulation of Cx43 at the wound edge 
epidermis, Cx26 asODN scaffolds resulted in a 62.3% downregulation of Cx43, similar to 
the 56.8% downregulation observed in untreated wounds. Scaffolds containing Cx43 
asODN however, resulted in a greater downregulation of Cx43, although the difference 
was insignificant. 
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Figure 5. 7 – D1 Cx26 expression in the epidermal wound edge of scaffold-treated 
wounds. 
Full-thickness wounds treated either left untreated or treated with a scaffold were harvested 
at D1. Below: tissue was immunostained for Cx26 (green) or Hoechst (blue) and confocal 
images of the nascent epidermis were captured. Above: positive Cx26 pixels were 
quantified in the end 150 μm of the wound edge epidermis as pixels per µm2, and then 
normalised to a region of distal epidermis to calculate the percentage change (increase or 
decrease) from distal levels. Data plotted are means + SEM error bars. Significance stars 
are coloured to match the treatment that is significantly different (e.g. dark red star = 
significantly different to Cx43 sODN scaffold-treated wounds). Scalebar = 50 μm, n=8 rats 
assessed (* = P <0.05, ** = P < 0.01, *** = P < 0.001). 
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Figure 5. 8 – D1 Cx43 expression in the epidermal wound edge of scaffold-treated 
wounds. 
Full-thickness wounds treated either left untreated or treated with a scaffold were harvested 
at D1. Below: tissue was immunostained for Cx43 (green) or Hoechst (blue) and confocal 
images of the nascent epidermis were captured. Above: positive Cx43 pixels were 
quantified in the end 150 μm of the wound edge epidermis as pixels per µm2, and then 
normalised to a region of distal epidermis to calculate the percentage change (increase or 
decrease) from distal levels. Data plotted are means + SEM error bars. Significance stars 
are coloured to match the treatment that is significantly different (e.g. dark red star = 
significantly different to Cx43 sODN scaffold-treated wounds). Scalebar = 50 μm, n=8 rats 
assessed (* = P <0.05, ** = P < 0.01). 
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Figure 5. 9 – D3 Cx26 expression in the epidermal wound edge of scaffold-treated 
wounds. 
Full-thickness wounds treated either left untreated or treated with a scaffold were harvested 
at D3. Below: tissue was immunostained for Cx26 (green) or Hoechst (blue) and confocal 
images of the nascent epidermis were captured. Above: positive Cx26 pixels were 
quantified in the end 150 μm of the wound edge epidermis as pixels per µm2, and then 
normalised to a region of distal epidermis to calculate the percentage change (increase or 
decrease) from distal levels. Data plotted are means + SEM error bars of 8 rats. 
Significance stars are coloured to match the treatment that is significantly different (e.g. 
dark red star = significantly different to Cx43 sODN scaffold-treated wounds). Scalebar = 
50 μm (* = P <0.05, ** = P < 0.01, *** = P < 0.001). 
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Figure 5. 10 – D3 Cx43 expression in the epidermal wound edge of scaffold-treated 
wounds. 
Full-thickness wounds treated either left untreated or treated with a scaffold were harvested 
at D3. Below: tissue was immunostained for Cx43 (green) or Hoechst (blue) and confocal 
images of the nascent epidermis were captured. Above: positive Cx43 pixels were 
quantified in the end 150 μm of the wound edge epidermis as pixels per µm2, and then 
normalised to a region of distal epidermis to calculate the percentage change (increase or 
decrease) from distal levels. Data plotted are means + SEM error bars. Significance stars 
are coloured to match the treatment that is significantly different (e.g. dark red star = 
significantly different to Cx43 sODN scaffold-treated wounds). Scalebar = 50 μm, n=8 rats 
assessed (* = P <0.05, ** = P < 0.01, *** = P < 0.001). 
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Figure 5. 11 – D5 Cx26 expression in the epidermal wound edge of scaffold-treated 
wounds. 
Full-thickness wounds treated either left untreated or treated with a scaffold were harvested 
at D5. Below: tissue was immunostained for Cx26 (green) or Hoechst (blue) and confocal 
images of the nascent epidermis were captured. Above: positive Cx26 pixels were 
quantified in the end 150 μm of the wound edge epidermis as pixels per µm2, and then 
normalised to a region of distal epidermis to calculate the percentage change (increase or 
decrease) from distal levels. Data plotted are means + SEM error bars. Significance stars 
are coloured to match the treatment that is significantly different (e.g. dark red star = 
significantly different to Cx43 sODN scaffold-treated wounds). Scalebar = 50 μm, n=8 rats 
assessed (* = P <0.05). 
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Figure 5. 12 – D5 Cx43 expression in the epidermal wound edge of scaffold-treated 
wounds. 
Full-thickness wounds treated either left untreated or treated with a scaffold were harvested 
at D5. Below: tissue was immunostained for Cx43 (green) or Hoechst (blue) and confocal 
images of the nascent epidermis were captured. Above: positive Cx43 pixels were 
quantified in the end 150 μm of the wound edge epidermis as pixels per µm2, and then 
normalised to a region of distal epidermis to calculate the percentage change (increase or 
decrease) from distal levels. Data plotted are means + SEM error bars. Significance stars 
are coloured to match the treatment that is significantly different (e.g. light pink star = 
significantly different to uncoated scaffold-treated wounds). Scalebar = 50 μm, n=8 rats 
assessed (* = P <0.05, ** = P < 0.01, *** = P < 0.001). 
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5.6 – The effect of Cx26 asODN coated scaffolds on the late stages of 
wound healing. 
5.61 – Granulation tissue area measurements at D10 and 15. 
Since the application of scaffolds coated with Cx26 asODN accelerated wound re-
epithelialisation as Cx43 did, it was questioned whether, similar to Cx43, Cx26 asODN also 
had the effect of advancing wound healing at the later stages, including the reduction in 
area of wound granulation tissue. The area of granulation tissue formed in the wound was 
measured (for method, see Chapter 2; Materials and Methods) and is here reported as 
means ± SEM. H&E staining of Cx26 asODN scaffold-treated wounds at D10 had an 
average granulation tissue area of 2.65 ± 0.19 mm2, which was insignificantly different from 
the 3.61 ± 0.18 mm2 of untreated wounds (Figure 5. 13B-C). Cx26 asODN scaffold-treated 
wound areas were significantly lower than uncoated scaffold-treated wounds (4.47 ± 0.34 
mm2, P < 0.001), yet those wounds had considerably larger quantified areas than even 
untreated wounds. Similar to Cx43 asODN only scaffolds, the combined Cx26/43 
scaffolds resulted in a significant reduction in the measured granulation tissue area 
compared to all control wounds. These observations were repeated at D15 – Cx26 asODN 
coated scaffolds resulted in a granulation tissue area of 1.73 ± 0.24 mm2, which although 
smaller than untreated wounds (2.29 ± 0.09 mm2) was insignificant, and significantly 
smaller than uncoated scaffold-treated wounds (Figure 5. 14B-C). The combined Cx26/43 
asODN scaffold again resulted in a significant reduction in granulation tissue area (1.34 ± 
0.10 mm2), to a level similar to that found using Cx43 asODN only scaffolds (1.39 ± 0.07 
mm2). Across all treatments at D10 and 15, only scaffolds containing Cx43 asODN (either 
as Cx43 only or Cx26/43 combined applications) appeared to significantly reduce the area 
of granulation tissue relative to untreated wounds. 
5.62 – The effect of the combined Cx26/43 asODN scaffold on the presence of 
myofibroblasts 
While Cx26 asODN alone did not appear to significantly improve the area of wound 
granulation tissue, it was unclear whether the Cx26 asODN in the combined Cx26/43 
asODN scaffold had a synergistic effect in reducing the size of the wound gap. As such, 
the two treatments that were found to significantly reduce the size of granulation tissue 
area (Cx43 asODN and the combined Cx43/26 asODN scaffold) were compared for α-
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SMA staining. This was to determine whether there were potentially differences in the 
number of α-SMA positive contractile myofibroblasts relative to control uncoated scaffolds 
that had been applied to wounds made on the same animals (Figure 5. 15). Staining 
revealed a similar sized α-SMA positive region in the combined Cx26/43 asODN scaffold-
treated wounds (0.39 ± 0.03 mm2) to the Cx43 asODN only scaffolds (0.357 ± 0.07 mm2). 
The combined Cx26/43 asODN scaffolds resulted in quantification of an SMA positive 
positive region that was 57% smaller than that measured in control scaffold-treated 
wounds (0.907 ± 0.09 mm2); a difference that was statistically significant (P < 0.001). The 
localisation of -SMA staining did not appear to be more or less centrally located in wounds 
treated with the combined asODN scaffolds. The included Cx26 asODN sequences in the 
Cx26/43 scaffolds did not appear to further promote the reduction in size of the α-SMA 
positive region in the late time point wounds, in contrast to re-epithelialisation in which 
combining asODN sequences resulted in the furthest levels of re-epithelialisation. 
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Figure 5. 13 – Full-thickness wounds treated with scaffolds at D10. 
Full-thickness wounds were either left untreated or treated with a scaffold. Wounds were 
harvested at D10. (A): A simplified wound diagram to illustrate the granulation tissue 
region swhich was measured in (B). (B): Wounds either left untreated or treated with a 
control scaffold (red bars) or a coated scaffold containing asODN (green bars) were 
measured for granulation tissue/wound area. (C): Typical H&E stained images illustrating 
the quantified granulation tissue area of the individual wounds in (white dots). Eight rat 
wounds were assessed (* = P < 0.05, ** = P < 0.01, *** = P < 0.001), scale bar = 100 μm. 
Data is plotted as means + SEM, and significance stars are coloured to match the 
treatment that is significantly different (e.g. dark red star = significantly different to Cx43 
sODN scaffold-treated wounds). 
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Figure 5. 14 – Full-thickness wounds treated with scaffolds at D15. 
Full-thickness wounds were either left untreated or treated with a scaffold. Wounds were 
harvested at D15. (A): A simplified wound diagram to illustrate the granulation tissue 
region which was measured in (B). (B): Wounds either left untreated or treated with a 
control scaffold (red bars) or a coated scaffold containing asODN (green bars) were 
measured for granulation tissue/wound area. (C): Typical H&E stained images illustrating 
the quantified granulation tissue area of the individual wounds in (white dots). Seven rat 
wounds were assessed (* = P < 0.05, ** = P < 0.01, *** = P < 0.001), scale bar = 100 μm. 
Data is plotted as means + SEM, and significance stars are coloured to match the 
treatment that is significantly different (e.g. dark red star = significantly different to Cx43 
sODN scaffold-treated wounds). 
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Figure 5. 15 – α-SMA expression in D10 scaffold-treated wounds. 
Rat full-thickness wounds treated with either control coated scaffolds or Cx43 asODN 
coated scaffolds were harvested at D10 and stained for both α-SMA (green) and Hoechst 
(blue).  
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(A): The green SMA+ region outlined in (B) was quantified for two different treatments on 
the same animals; a coated collagen scaffold without asODN and a coated scaffold coated 
with Cx43 asODN. This region was defined as positive stain in the wound gap above the 
blood vessel dense panniculus carnosus. A total of n=8 animals were assessed, data is 
plotted as means + SEM (*** = P < 0.001). 
(B): Typical immunofluorescence montage images illustrating the measured region of α-
SMA in the wound (yellow dots) as well as the initial wound margins (red dots). scale bar = 
500 μm). 
 
5.7 – Discussion 
Following the results of the previous two chapters it was observed that Cx26, as well as 
Cx43, were each strongly upregulated in keratinocytes at the wound edge when wound 
healing was perturbed by the presence of a scaffold. When Cx43 was upregulated, which is 
a common characteristic of chronic ulcers and slow-to-heal diabetic wounds, Cx26 was 
frequently also significantly upregulated beyond the normal levels encountered during acute 
wound healing. It was unclear whether Cx26 expression was beneficial during acute wound 
healing, or whether Cx26 knockdown would have a negative effect on healing. It has been 
shown that Cx30 null mice are not wound healing impaired, and it was suggested that Cx26 
may rescue this effect (Kretz et al., 2003). So it may be possible that Cx26 may not be 
necessary during wound healing due to a rescue effect of Cx30. While it has been shown 
that Cx26 may be important in controlling keratinocyte differentiation, it is unclear why 
Cx26 is strongly upregulated at the wound edge during re-epithelialisation (Coutinho et al., 
2003, Lucke et al., 1999). To determine whether Cx26 knockdown has a positive effect on 
scaffold-assisted wound healing, two novel Cx26 asODN sequences designed in the CoDa 
Theraputics Inc. laboratory in New Zealand were applied to scaffolds following preliminary 
using the emulsion technique developed in the previous chapter.  
Application of Cx26 asODN scaffolds to wounds did not appear to macroscopically inhibit 
wound closure, as wounds were similar in size to untreated wounds (Figure 5. 1). Similar to 
Cx43 asODN coated scaffolds, and to some extent the control scaffolds, the Cx26 asODN 
scaffolds did not prevent wound closure which was the opposite effect to that of the 
uncoated scaffolds. This could again be due to the fact that the coated scaffolds were often 
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only loosely associated with the wound edge and readily detached during tissue processing, 
to the extent that wound contraction may occur normally underneath the scaffold. The 
combined Cx26/43 asODN coated scaffold-treated wounds were also reduced in size to a 
similar degree as the other bioactivated scaffolds, although hair regrowth could often mask 
the actual size of the wound at D5. Unlike Cx43, Cx26 knockdown has not previously been 
linked to a reduction in wound area, and it still remains unclear how Cx26 knockdown 
could mechanistically affect wound closure. 
Microscopic assessment of wounds treated with the Cx26 asODN coated scaffolds 
revealed significant differences in wound re-epithelialisation relative to wounds treated with 
scaffolds coated without asODN or with a Cx43 sODN sequence that does not cause 
targeted mRNA degradation (Figure 5. 2, Figure 5. 3, & Figure 5. 4). The observation that 
Cx26 asODN improves re-epithelialisation in vivo is a finding that has, to the best of my 
knowledge, not previously been reported before. The finding that Cx26 asODN 
application reduced epithelial thickening appears somewhat logical, since a somewhat 
‘opposite’ study in which Cx26 was ectopically overexpressed resulted in the opposite 
effect of keratinocyte hyperproliferation and epithelial thickening (Djalilian et al., 2006). 
Hyperproliferation of the epidermis is also evident in individuals that have any one of a 
number of loss-of-function mutations in the Cx26 gene GJB2, and is commonly linked to 
deafness. A possible explanation for this hyperproliferation has been proposed following 
assessment of mice with a D66H Cx26 loss-of-function mutation, which are found to 
contain increased numbers of keratinocytes undergoing cell death (Bakirtzis et al., 2003). It 
has been reasoned that Cx26 may affect hyperproliferation through the triggering of a 
proliferative rescue response following the apoptosis of cells within the epidermis. 
Alternatively, it has also been suggested that overstimulation of Cx26 can lead to 
hyperthickening (Bakirtzis et al., 2003). It is interesting that Cx26 mutations, resulting in 
loss of Cx26 function, result in perturbed wound healing and epithelial thickening 
(Labarthe et al., 1998, Lucke et al., 1999), while knockdown of Cx26 protein appears to 
have had the opposite effect in this study. A possible explanation for this difference is that 
mutated forms of the Cx26 protein may be incorporated into connexon hemichannels, 
even those composed of other connexins besides Cx26, and deregulate normal signalling 
responsible for keratinocyte differentiation (Rouan et al., 2001). 
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While re-epithelialisation measurements indicated that the Cx26 asODN sequences 
appeared to be effective in vivo, immunostaining with an anti-Cx26 antibody actually 
confirm this knockdown at D1, 3 and 5 in the leading edge epidermis (Figure 5. 7, Figure 5. 
9 & Figure 5. 11). In the previous chapters, Cx43 knockdown using Cx43 asODN also 
resulted Cx26 downregulation at D3 and D5 relative to uncoated scaffolds (Chapter 3 - 
Figure 3. 7, Figure 3. 8 & Chapter 4 - Figure 4. 10, Figure 4. 12). In the opposite fashion, 
here Cx26 asODN resulted in a significant downregulation of Cx43 at D3 and D5 relative 
to most of the control scaffolds (Figure 5. 9, Figure 5.11). This may be due to the evident 
acceleration of wound re-epithelialisation following Cx26 asODN application. It is known 
that keratinocyte Cx43 downregulation occurs in conjunction with cell migration, so it may 
be possible that Cx26 could indirectly affect Cx43 levels, although the mechanism by which 
this could occur is unknown. The finding that Cx26 can somehow interact with Cx43 has 
been supported by the findings of another study, however, where it was found that the 
Cx26 loss-of-function mutation ΔE42 resulted in a decrease in intercellular conduction of 
wild type Cx43 (Rouan et al., 2001). Despite this, while it has been shown that Cx26 can 
interact with Cx30 (Ahmad et al., 2003), it cannot form channels with Cx43 due to 
physiological differences between the connexins (Marziano et al., 2003). The effect of the 
ΔE42 mutant Cx26 on Cx43 may possibly occur through another interaction separate to 
the formation of gap junction channels, although such a pathway is currently unknown. 
While it may have previously been thought that because the Cx26 protein has a short 
cytoplasmic C-terminus tail it may not be able to interact with many other proteins in the 
way Cx43 does, a study has identified an interaction between Cx26 and the tight junction 
associated protein occludin (Nusrat et al., 2000). Through affinity pulldown assays, Cx26 
was found to specifically interact with the coiled-coil domain of occludin (Nusrat et al., 
2000). This provides a potential link between tight junctions and gap junctions through 
Cx26, which could explain why knockdown of Cx26 could improve wound re-
epithelialisation, since occludin regulates migration of epithelial cells during wound healing 
(Du et al., 2010).  
It was also noted that similar to Cx43 asODN, Cx26 asODN coated scaffolds had a 
noticeable effect in reducing the infiltration spread of cells with an inflammatory 
polymorphonuclear leukocyte morphology (PMNs) into the uninjured dermis. The effect 
of Cx26 on inflammation has partly been explored by the work by Djailian et al (2006). In 
the study, Cx26 was ectopically overexpressed and this led to increased hemichannel 
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activity, resulting in a marked increase in cellular release of ATP. Normally extracellular 
ATP is removed by conversion to adenosine, but excessive levels can result in its 
accumulation (Cauwels et al., 2014). Heightened levels of ATP have been demonstrated to 
have a pro-inflammatory effect, causing an increase in available pro-inflammatory cytokines 
such as IL-1 and, likely as a result of this, an increased number of CD4+ inflammatory cells 
such as leukocytes. Indeed, promoting ATP hydrolysis through supplementation with 
apyrase significantly reduced IL-1 levels and the quantified number of CD4+ inflammatory 
cells (Cauwels et al., 2014). ATP is also found to stimulate CD39+ Langerhans cells, which 
typically modulate inflammation in response to chemical irritants (Mizumoto et al., 2002). 
It is possible that uncoated scaffolds, which cause an upregulation of Cx26, could be 
promoting the invasion of inflammatory PMNs through elevations in pro-inflammatory 
ATP, while Cx26 asODN could be preventing its extracellular accumulation. It is 
important to note that at some time points, not all control coated scaffolds resulted in 
significantly higher levels of infiltrating PMNs relative to the Cx26 asODN applications, 
although levels were still markedly increased by at least 50%. It is possible that the reduced 
level of PMN infiltration observed using control coated scaffolds relative to uncoated 
scaffolds was due to the fact coated scaffolds tended to be only loosely associated with the 
wound edge, resulting in less contact with the wound. It appears that the potential anti-
inflammatory applications of Cx26 asODN may be most readily observed in situations 
where Cx26 is strongly upregulated, such as following uncoated scaffold application or in 
chronic ulcers (Sutcliffe et al. (publication submitted)). 
It was interesting to observe the effect of combining both the Cx26 asODN sequences and 
the Cx43 asODN sequence within a single scaffold. While neither PMN infiltration (Figure 
5. 6) nor granulation tissue area (Figure 5. 13 & Figure 5. 14) appeared to be further 
reduced following the addition of Cx26 asODN to Cx43 asODN, it was apparent that the 
use of asODN against both Cx26 and 43 resulted in significant downregulation of both 
connexins between D1 to D5 (Figure 5. 7 - Figure 5. 12). This was met by a consistent 
increase in re-epithelialisation distance at each time point assessed relative to the individual 
asODN scaffolds, with an increase as high as 27.9% at D5. Due to the observed trend it is 
possible that the use of both Cx26 and Cx43 asODN may have a synergistic effect, but it is 
important to note that the combined asODN scaffold did not significantly increase re-
epithelialisation over single asODN scaffolds. Further investigation would be required to 
determine if a synergistic effect was indeed occurring. It is perhaps less surprising that 
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Cx26 asODN did not significantly reduce the area of late stage granulation tissue at D10 
and D15 (Figure 5. 13 & Figure 5. 14), since Cx26 knockdown has not been linked to 
myofibroblast activity or their accelerated clearance from the wound, in contrast to a study 
that employed Cx43 asODN (Mori et al., 2006).  
 
Conclusions 
Application of the two recently developed Cx26 asODN sequences together using a 
scaffold coating caused significant knockdown of Cx26 in wound edge keratinocytes, a 
significant reduction in infiltrating PMNs relative to uncoated scaffolds and also 
significantly improved wound re-epithelialisation relative to a number of control scaffolds 
at the same time points. Considering that scaffolds are intended for application to chronic 
wounds where inflammation, wound re-epithelialisation and connexin expression can be 
perturbed, the delivery of Cx26 asODN to the wound in a sustained manner could be an 
effective treatment in addition to Cx43 asODN. Furthermore, it is possible that combining 
the asODN sequences in a scaffold may have a synergistic effect on wound re-
epithelialisation, which would be of further benefit in a chronic ulcer setting. It is even 
possible that Cx26 and Cx43 asODN could be incorporated alongside additional drugs in 
other therapeutic settings, where they could act as enhancers of scaffold biocompatibility. 
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6.1 – Introduction 
The findings of this study help to elucidate the previously unclear role of scaffolds when 
applied in an in vivo setting. In chapter 3 it was found that in an uncoated form, collagen 
scaffolds had a negative effect on the healing of acute full-thickness wounds, causing 
thickening of the epidermis at the wound edge, reduction of wound contraction and 
induction of wound edge Cx43 expression. Infusion of scaffolds with Cx43 asODN using a 
Pluronic gel had a positive effect in reducing Cx43 expression and wound edge epithelial 
thickening, but scaffolds did not appear to act as a cell supportive matrix and wound 
integration was not achieved. In chapter 4, a polymer coating technique was established 
and was found to result in Cx43 asODN elution from coatings over several days in vitro. 
Bioactivation of scaffolds in this way had a strong positive effect; application of the 
sustained release scaffolds to rat full-thickness wounds resulted in significant 
improvements to wound re-epithelialisation, and inflammation was reduced relative to 
uncoated scaffolds. Unlike bioactivation using Cx43 asODN in Pluronic gel, polymer 
coated scaffolds containing Cx43 asODN improved wound healing to a greater degree than 
even untreated wounds in some aspects that were investigated. Cx43 downregulation using 
coated scaffolds was also achieved over a longer time period than when using the 
transiently bioactivated scaffolds applied to mouse wounds in chapter 3. Finally, in chapter 
5 it was found that the polymer coating technique could also be used to deliver more than 
one therapeutic agent; in this case two novel asODN sequences to Cx26, which was also 
found to promote wound re-epithelialisation and reduce inflammation associated with 
scaffold use. Following these assessments, the results of this study were assessed in light of 
those derived from other in vivo and clinical scaffold studies. 
  
6.2 – Comparing project findings with the literature 
6.21 - Downregulation of connexins 43 and 26 
Downregulation of Cx43 in the acute and chronic wound model setting through the 
application of Cx43 asODN using a Pluronic gel has previously been shown to improve 
wound re-epithelialisation, reduce the severity of inflammation and promote a reduction in 
wound size (Mori et al., 2006, Qiu et al., 2003, Wang et al., 2007). The experimental results 
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of this study are in agreement with those general biological findings; Cx43 asODN coated 
scaffolds similarly improved wound healing across the same three aspects. Chronic wounds 
have been found to exhibit upregulation of Cx43 at the wound edge; a feature that has 
been noted to delay wound closure (Mendoza-Naranjo et al., 2012b). Using a polymer 
coating approach to entrap Cx43 asODN it was observed that asODN could be made to 
elute from collagen scaffolds over several days. The sustained delivery of asODN could be 
particularly beneficial in a slow-healing ulcer setting to modify deleteriously expressed 
proteins. A recently submitted journal article also identified Cx26 as strongly upregulated in 
both DFUs and VLUs, far beyond the normal levels that Cx26 is upregulated to in acute 
wounds (Sutcliffe et al., article submitted in 2014). To the best of my knowledge, this is the 
first comprehensive study of Cx26 asODN application in skin. One other study has used 
Cx26 siRNA in vitro to knockdown Cx26 in rat epidermal keratinocytes (REKs). Using an 
organotypic model of epidermis they reported that Cx26 knockdown had no effect on 
differentiation of REKs. Despite this finding, it appears that no pre-existing study has 
performed Cx26 knockdown using an in vivo wound healing model (Thomas et al., 2007). 
The two Cx26 asODN 20-mer sequences used in this study were combined into one 
scaffold coating due to the time constraints of individual testing and limited wound site 
availability. Testing of the two sequences individually in future would be necessary to 
identify the most effective sequence.  
Comparisons between the findings of Cx26 knockdown in this study and the literature are 
difficult to make due to the lack of similar studies of Cx26 knock down in vivo. Loss of 
function mutations in Cx26 have previously been found to have no effect on rat 
keratinocyte cell migration or differentiation in vitro (Thomas et al., 2007). Cx26 is able to 
form gap junction channels with Cx30, and it has been shown that the expression profile of 
Cx30 is similar to that of Cx26 (Coutinho et al., 2003). Cx30 knockout mice have no 
impairment to wound healing, and it has been proposed that Cx26 may substitute for it. It 
is equally possible that Cx30 may substitute the function of Cx26 when Cx26 is knocked 
down, although what role this is remains unclear (Kretz et al., 2003). A combined Cx26 and 
Cx30 asODN knockdown approach may help to identify whether at least one of the two 
connexins is required during wound healing. 
With regard to the effect of Cx26 knockdown on wound healing, as mentioned in the 
previous chapter, Cx26 expression has been linked to inflammation in wound healing. 
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Overexpression of Cx26 was found to lead to extracellular release of ATP, which can 
subsequently cause extracellular elevations in pro-inflammatory cytokines such as IL-1 
which can serve as chemoattractants for PMNs (Cauwels et al., 2014, Djalilian et al., 2006). 
It may be possible, then, that downregulation of Cx26 from the high levels encountered in 
wound edge keratinocytes may have contributed to the reduced level of PMN infiltration 
of the tissue. In addition to this, re-epithelialisation could have been improved in 
keratinocytes in response to Cx26 asODN due to attenuation of interactions between Cx26 
and the tight junction associated protein occludin. Pulldown assays revealed that the two to 
interact (Nusrat et al., 2000). It is possible that the downregulation of Cx26 could have led 
to changes in tight junction associations, which are normally rearranged in the cell during 
wound healing. It is also interesting that Cx26 asODN scaffolds caused a reduction in 
wound edge keratinocyte Cx43 expression at later time points, as it could indicate some 
level of interaction between the two proteins. Alternatively, this observation could be due 
to indirect effects on other mediators or intermediate signals. A possible interaction 
between the two has previously been reported when a Cx26 loss-of-function mutation 
decreased intercellular conduction of wild type Cx43, although it is currently unclear how 
such an interaction may occur (Rouan et al., 2001). Although combination of both Cx26 
and Cx43 asODN sequences in a scaffold significantly improved wound re-epithelialisation 
over untreated or control scaffold-treated wounds, the difference was not statistically 
significant over single asODN applications against Cx26 or Cx43. Despite this, the 
combined asODN scaffold consistently resulted in the highest levels of wound re-
epithelialisation at D1, 3 and 5, which may indicate a synergistic effect. However, further 
experiments would be required to validate such a claim. 
 
6.22 – Scaffold design 
In order to assess what the effect of scaffolds used clinically and experimentally had on 
wound healing it was necessary that the scaffold I developed was generated to resemble 
other types of scaffolds. This was particularly important so that the findings reported in 
this study were relevant to the scaffold types used today. The collagen scaffolds fabricated 
in this study using an electrospinning technique were fabricated according to a previously 
established protocol. Scaffold porosity and fibrosity was illustrated using SEM and FITC 
Pluronic gel infusion assays. Following these analyses it was evident that scaffolds were 
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permeable to the Pluronic gel used to deliver asODN, and that the thickness of fibres 
ranged from 0.03 - 4.12 μm. This diameter range of fibres measured coincide with that 
those generated for in vivo application as a full-thickness wound dermal substitute in guinea 
pigs. In that study, fibre diameter was measured to be between 0.25 - 2 μm (Jha et al., 
2011). Additionally, the same group investigated the effect of endothelial and osteoblast 
cell adhesion and morphology on the scaffolds in vitro, finding that larger diameters 
supported elongation of endothelial cells and penetration of the scaffolds. The in vivo 
images shown in the study, however, did not show the cellular infiltration of scaffolds, nor 
did they indicate the time point at which images were captured. Fibroblast adhesion and 
elongation has also been observed on electrospun PCL fibres with an average diameter of 
approximately 0.8 - 1 μm (Mijovic et al., 2012). Given the reported diameter ranges that 
appear to support cell adhesion in vitro, it would appear that the collagen scaffolds 
electrospun in this study were comparable to those used elsewhere. It is likely that the 
negative findings observed using uncoated scaffolds are the result of the differences 
between in vitro and in vivo environments.  
The use of electrospinning to fabricate collagen scaffolds, as performed elsewhere and in 
this study, has been noted that it may denature the polymer, resulting in gelatin that does 
not structurally resemble collagen present in the native ECM (Zeugolis et al., 2008). This 
argument has been further supported by the findings of Jha et al. (2011), which found that 
collagen fibres were altered following electrospinning of acid-soluble bovine collagen, such 
that they were enriched for the α2 subunit. However, despite this, the group found that 
cells adhered to the modified electrospun collagen, again indicating that the negative 
response to scaffolds in vivo is likely not due to the materials employed. 
Scaffolds were also crosslinked using EDC hydrochloride. The use of this specific 
crosslinker is preferred over traditional and toxic crosslinkers such as glutaraldehyde, 
particularly since it is a 'zero-length' crosslinker that is not incorporated into the polymer, 
such that it should be easier to remove following washing steps (Girardot and Girardot, 
1996). Despite this, even using a reduced concentration of crosslinker in this study (0.15% 
wt./v.) compared to the 15% (wt./v.) crosslinker used to develop scaffolds in a previous 
study did not overturn the negative effects encountered through scaffold use (Torres-Giner 
et al., 2009). This further increases the likeliness that dermal scaffolds are currently poorly 
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optimised for in vivo use, and not that the methods used to fabricate scaffolds in this study 
specifically caused a reaction. 
6.23 – Wound closure 
It is difficult to compare the retardation to wound re-epithelialisation witnessed following 
uncoated scaffold application in this study to the findings of other scaffold studies, since 
high power analyses of wound re-epithelialisation is not usually performed. As a typical 
example, an in vivo study of experimentally induced pressure ulcers made to mice involved 
the application of chitosan scaffolds to wounds, but wound closure was then measured 
macroscopically (Park et al., 2009). Although macroscopic images can give a general 
impression of wound closure, they lack the accuracy of microscopic evaluations since it is 
difficult to determine whether re-epithelialisation has taken place, especially under scabs. 
Also in rodents, wound contraction plays a far more important role in wound closure, yet 
this feature is less prevalent in the human wounds that scaffolds are ultimately intended to 
be applied to (Wong et al., 2011). Interpreting scaffold efficacy based on macroscopic 
wound closure alone in animal models is not a sufficient way to gauge how effective 
scaffolds would perform in a human chronic ulcer setting. 
In many cases, human clinical trials have primarily focused on whether wounds have closed 
or not within a specified period of time following scaffold application as the main means to 
assess scaffold efficacy (Karr, 2011, Marston et al., 2003, Veves et al., 2001). In this study, 
uncoated bovine acid-soluble collagen scaffolds were found to inhibit wound contraction, 
and this result correlates with previous animal studies by other groups (Ng and Hutmacher, 
2006, Soller et al., 2012, Yannas et al., 1989). The presence of a solid scaffold in the wound 
could present a physical obstruction to the contracting wound, such that wound closure is 
perturbed. Despite this, scaffolds in the present study that were polymer coated did not 
prevent wound closure, which may have been due to the considerable lack of integration of 
polymer coated scaffolds with wounds. However, it has been argued that while scaffolds 
may impair wound closure, they can at the same time accelerate the rate of granulation 
tissue development (Soller et al., 2012). Despite the authors measuring granulation tissue, 
neither quantification of re-epithelialisation nor assessment of leading edge cells was 
performed in the study, which would be necessary to support such claims. In the present 
study, granulation tissue was not positively affected by the application of uncoated or 
coated collagen scaffolds that did not contain asODN relative to untreated wounds. 
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Despite the results of this study that demonstrate scaffolds can delay wound contraction in 
mice, previous clinical applications of scaffolds to non-healing ulcers have been met with 
limited positive findings (Karr, 2011, Marston et al., 2003, Veves et al., 2001). Both 
scaffolds comprised of organised cell layers as well as dermal extracellular matrix 
substitutes have been applied to patient ulcers, although most data reporting is limited to 
wound closure rates and not detailed analysis of re-epithelialisation. The efficacy of 
Dermagraft, a single layer dermal scaffold consisting of both a polyglactin matrix and 
seeded fibroblasts, has been assessed in a randomised clinical trial, and wound healing was 
reported to be improved following application. The results of the trial in which 145 patient 
wounds were assessed showed that Dermagraft applications resulted in 30% of DFUs 
closing within 12 weeks, while only 18.3% of wounds receiving conventional treatment 
closed; a difference that was significant (Marston et al., 2003).  
Cellular scaffolds comprising both epidermal and dermal layers have also been reported to 
be effective in promoting wound closure. This includes Apligraf, which consists of human 
keratinocytes overlying a bovine collagen matrix that has been seeded with human 
fibroblasts. Again, wound closure in DFUs was found to be significantly improved in a 
randomised clinical trial; 56% of wounds treated with Apligraf healed relative to 38% of 
controls, while the average time to heal was also significantly lower (65 vs. 90 days) (Veves 
et al., 2001). As well as cellular scaffolds, dermal matrix only scaffolds similar to the 
uncoated collagen scaffold used in this study have been clinically tested on patient DFUs 
and VLUs, such as the foetal bovine collagen fibrous matrix PriMatrix. A review of 68 
patient ulcers found that DFUs treated with PriMatrix healed at greater than twice the 
speed of those treated with Apligraf (38 vs 87 days), with a similar outcome for VLUs (32 
vs. 63 days) (Karr, 2011). The in vivo findings obtained in this project suggest that dermal 
scaffolds perturb acute wound healing within at least the first 5 days, yet scaffold 
application to chronic ulcers over many months has been frequently reported to encourage 
wound closure. One explanation for this difference in findings could be that the application 
of a scaffold to an ulcer for several weeks could provide a buffer against the highly 
enzymatic and ECM-degradative environment, potentially allowing the development of 
new granulation tissue and ECM proteins (Cullen et al., 2002). In this way, a scaffold could 
improve the wound environment of an ulcer but not of an acute wound as in this study. 
Although chronic ulcers can exhibit high levels of inflammation, microbial infections of 
ulcers are also common, and in some cases there may be a reduced level of cellular 
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infiltration of chronic ulcers (Guo and Dipietro, 2010). In neuropathic diabetic skin, for 
instance, it has been shown that when neuropeptides such as nerve growth factor are 
depleted it can result in reduced cell chemotaxis and contribute to DFU formation. 
Importantly, denervated skin has been found to contain reduced levels of leukocyte 
infiltration, such that it is possible that, in specific situations, PMN infiltration could be 
beneficial to the healing of a chronic ulcer (Galkowska et al., 2006). In the vast majority of 
ulcers this would not appear to be the case, however, since prolonged and elevated 
inflammation is typically associated with the pathology of chronic ulcers (Pierce, 2001). In 
fact, it has been argued that the continued recruitment of neutrophils and macrophages to 
chronic ulcers leads to damage from released reactive oxygen species, cytotoxic enzymes 
and proteases (Grice and Segre, 2012). For these reasons, it appears more likely that the 
recruitment of additional PMNs to ulcers would be detrimental to ulcer healing. 
It has also been suggested that the scaffolds that have been previously used been to treat 
ulcers may be acting as a barrier for the wound bed against microbial infection and 
desiccation (Griffiths et al., 2004). This suggestion was made following the results of an 
Apligraf study, where it was found that Apligraf did not survive in acute wounds for longer 
6 weeks, and instead may promote wound healing by serving as a temporary barrier 
(Griffiths et al., 2004). Regardless of how scaffolds may affect chronic ulcer closure in the 
long term, there still remains a need to improve existing scaffolds for use as healing 
devices. With only 56% of DFUs healing following the use of Apligraf in one study as well 
as an average healing time of 65 days, the bioactivation of similar devices might confer a 
considerable improvement to efficacy (Veves et al., 2001). Certainly, in this study, the 
bioactivation of collagen scaffolds using Cx43 asODN and Cx26 asODN considerably 
improved the healing of acute wounds. 
Although wound edge epithelial thickening following scaffold application has not been 
thoroughly assessed throughout the existing scaffold literature, epithelial thickening can be 
observed in some cases. One group that produced electrospun collagen scaffolds and 
applied them to mouse full-thickness wounds claimed that their scaffolds promoted re-
epithelialisation, yet the supporting images were of particularly low quality and 
measurement of re-epithelialisation across multiple animals was not performed (Chong et 
al., 2013). Despite this, clear thickening of the leading edge epidermis could be observed in 
some of their images in which bioactivated scaffolds were applied. Although the thickening 
6. Discussion 
186 
 
of the leading edge epidermis following scaffold application has not been widely reported, 
this negative effect was repeatedly observed in this study using a variety of different 
scaffold types. Uncoated collagen scaffolds, when also applied to rats, significantly 
increased epithelial thickening. The finding that different scaffold types induced epithelial 
thickening, as well as observations in both mice and rats, increase the likeliness that this is a 
common feature associated with scaffold application as opposed to the effect of one 
particular type of scaffold. The thickening of the epidermis is not only associated with 
hyperproliferative skin conditions, but also slow-to-heal diabetic wounds (Labarthe et al., 
1998, Wang et al., 2007). The repeated observation that uncoated scaffolds induce epithelial 
thickening could suggest that scaffolds may prevent the transition of wound edge 
keratinocytes from an adherent to a migratory phenotype, since keratinocytes at the wound 
edge should normally migrate outwards in a thin process of cells (Laplante et al., 2001). 
 
6.24 – Inflammation and the foreign body reaction 
It was apparent that uncoated scaffolds caused a significant increase in the numbers of 
inflammatory cells with the characteristic morphology of neutrophils infiltrating the 
uninjured tissue. In this study, scaffolds were fabricated using bovine collagen, owing to it 
being both readily available as well as frequently selected to produce other commercial and 
experimental scaffolds (Clark et al., 2007). While this meant that the scaffolds fabricated in 
this study more closely resembled other scaffolds, in theory there was the potential that the 
elevated inflammatory response observed following uncoated scaffold application could 
have been due to a cross species immunogenic reaction to bovine collagen in mice and rats 
(Menkin, 1930, Opie, 1924). While this is possible, a review of collagen immunogenicity 
found that collagen is only mildly immunogenic, and had in fact been incorrectly believed 
to be non-immunogenic until 1954 (Lynn et al., 2004, Watson et al., 1954). It was found 
that pepsin-extracted collagen from calf skin only induced inflammatory reactions in less 
than 3% of human patients it was injected into humans for cosmetic purposes (Lynn et al., 
2004). While pepsin-derived collagen differs in structure from the acid soluble collagen 
used in this study, the manufacturer Kensey Nash reports that its materials are processed to 
remove antigenic components, which could include processing using pepsin to remove 
terminal telopeptides in collagen that may be more likely to elicit inflammatory responses 
(Kensey-Nash, 2014). For this reason, it appears unlikely that the increased number of 
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infiltrating PMNs observed in the intact dermis across all animals studied is due to a cross-
species reaction with collagen. 
It has been previously demonstrated that implantation of biodegradable scaffolds can cause 
an increase in PMN infiltration in the surrounding tissue, as well there being a visible 
association of PMNs with the scaffolds noted (Rucker et al., 2006). Interestingly, the same 
group found a collagen-chitosan hydrogel induced a more severe inflammatory response 
over 15 days compared to a biodegradable scaffold made of PLGA. The finding that a 
hydrogel was less biocompatible is in direct contrast to the findings within this study, in 
which alginate hydrogel applications resulted in fewer PMNs invading both the dermis and 
wound bed. Where this study may agree with the results of my project is that the most 
severe response was found using a collagen application, while the PLGA scaffold was 
better tolerated. This mirrors the findings of my study, where exposed uncoated collagen 
scaffolds were found to induce a far more severe reaction than scaffolds that had an outer 
coating of PLGA. Although it has been argued that collagen is only mildly immunogenic 
(Lynn et al., 2004), uncoated scaffolds in this study are found to be rapidly degraded at the 
wound, and have been considerably broken down by D5.  
The longer-term effects (D10 & D15 after wound treatment) of the polymer coated 
scaffolds were assessed in this study. I found that the coated scaffolds were no longer 
visible within wounds at D10 and D15. This may possibly have been due to the hydrolysis 
and degradation of the inner scaffold and/or dislodgement of scaffolds from the wound. 
As well as this, the uncoated scaffolds in this study were found to be rapidly degraded, such 
that they would not be present in the wound at the later time points.  
It has, however, been demonstrated that the long-term application of commercial collagen 
sponges can cause a foreign body reaction (Cegielski et al., 2008). In particular, this 
response involves the fusion of macrophages to form foreign body giant cells, which 
associate with the scaffold and can accelerate its degradation, as well as contribute to 
inflammation. The foreign body reaction is not exclusive to scaffolds, and has been noted 
to occur on a variety of implants and medical devices (Anderson et al., 2008). The 
formation of foreign body giant cells has also been found to contribute to device failure 
(Zhao et al., 1991). In the present study, the polymer coated asODN containing scaffolds 
appear to behave more as a form of advanced dressing than a wound integrating scaffold; 
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as they were not observed to integrate with the wound. As such, if they were to be 
developed for clinical use it is possible that they could be frequently replaced before cells 
adhering to scaffolds could advance to giant cells, unlike, for instance, subdermal implants 
that remain within the skin for several months. 
 
6.3 – Additional therapeutic candidates for scaffold bioactivation 
In this study, the bioactivation of scaffolds using asODN to Cx43 and Cx26 was found to 
improve wound healing when applied either transiently using a Pluronic hydrogel, or in a 
sustained manner using a polymeric emulsion coating approach. In Chapter 5, it was 
apparent that the scaffold coating could be used to deliver more than one asODN 
sequence, and in doing so both Cx43 and Cx26 were found to be downregulated in the 
combined asODN scaffold-treated wounds. The ability to deliver multiple sequences in a 
sustained manner leads to the interesting possibility that the novel coating approach could 
be used to deliver more than one therapeutic agent, in an effort to target multiple 
perturbed aspects of chronic wound healing. In particular, a number of biological agents 
including growth factors, peptides and asODN sequences have already been investigated 
for their effects on wound healing, which could potentially be incorporated into a scaffold 
coating, as discussed below. 
6.31 – Growth factors 
A considerable number of studies have bioactivated scaffolds using growth factors as a 
means to improve wound healing or tissue regeneration. Alginate hydrogels have been 
designed to incorporate growth factors, including vascular endothelial growth factor 
(VEGF). Following application of VEGF hydrogels, it was found that angiogenesis was 
promoted in hypoxic ApoE-/- mouse hindlimbs relative to bollus injections of VEGF, and 
that the hydrogels resulted in a sustained delivery of the growth factor (Silva and Mooney, 
2007). Chitsoan hydrogels incorporating fibroblast growth factor-2 (FGF-2) have also been 
applied to full-thickness incisional wounds, which appeared to demonstrate an 
improvement to wound closure (Obara et al., 2003). The authors also argued that the 
bioactivated hydrogels improved re-epithelialisation, although the provided images of the 
wounds were extremely low power and unclear. Studies using growth factors in chronic 
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ulcers have also been investigated, including application of a collagen-gelatine scaffold 
sponges containing basic FGF (bFGF), a growth factor that promotes fibroblast 
proliferation and angiogenesis. It was reported that wound closure and granulation tissue 
formation was significantly enhanced in ulcers that had not healed in over 4 weeks, 
although assessment of cellular interactions with scaffolds were absent (Morimoto et al., 
2013). Growth factor deficiency is common in chronic ulcers, which can be attributed to 
the overactivity of degradative MMPs. Based on these findings, it appears that 
supplementing ulcers with growth factors using the sustained delivery coated scaffold could 
improve healing of chronic ulcers.  
The potential for growth factors to improve chronic wound healing is supported to some 
degree by studies in which growth factors have been directly administered to ulcers (Brown 
et al., 1991, Steed, 2006, Tsang et al., 2003, Tuyet et al., 2009). One of the most frequently 
utilised growth factors in the treatment of chronic ulcers is epidermal growth factor (EGF). 
EGF is implicated in keratinocyte migration, fibroblast proliferation and granulation tissue 
formation (Hardwicke et al., 2008). Across a number of DFU clinical trials, EGF 
applications have been reported to improve wound closure and to promote the 
development of granulation tissue, although re-epithelialisation assessments were again 
absent in these reports (Brown et al., 1991, Tsang et al., 2003, Tuyet et al., 2009). Platelet-
derived growth factor (PDGF) has also been used to treat DFUs, reporting outcomes of 
reduced time to heal and enhanced wound closure relative to placebo treatments (Steed, 
2006). 
While some studies have argued that growth factors could improve ulcer healing, a recent 
review of dressing and scaffold studies declared that growth factor applications did not 
demonstrate a significant improvement to ulcer wound healing over scaffold only 
treatments (Palfreyman et al., 2007). The report also highlights bias in scaffold studies and 
a lack of significance reporting, indicating that many current clinical studies should be 
interpreted with caution. Additionally, with regards to the use of growth factors over 
asODN sequences as therapeutic agents, targeted knockdown of specific proteins is not 
achieved using growth factors as they affect a multitude of proteins and processes. As well 
as this, safety concerns have been raised regarding the use of certain growth factors, such 
as the involvement of EGF and insulin growth factor-1 (IGF-1) in promoting tumour 
development, although a review of clinical evidence suggests that tumour initiation as a 
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result of growth factor application is unlikely (Berlanga-Acosta et al., 2009, Sandhu et al., 
2002). Nevertheless, owing to the number of processes that growth factors can affect, it 
has been argued that they may be best reserved for situations where other treatments have 
failed (Berlanga-Acosta et al., 2009). The potential use of growth factors in a scaffold 
coating approach alongside the previously evaluated asODN sequences should therefore be 
carefully considered. 
6.32 – Peptide therapy 
The use of peptides, such as antimicrobial peptides used in scaffold bioactivation, could 
also be effective in the case of those chronic ulcers with a high bacterial content. 
Endogenous cationic antimicrobial peptides include cathelicidins, defensins and histatins, 
and have been found to be active against a broad spectrum of bacteria and fungi (Bals, 
2000). The development of synthetic cationic peptides, for example such as the peptide 
KSL-W, appears to hold greater promise, since it requires an even lower minimum 
inhibitory concentration to be effective (Concannon et al., 2003). Incorporation of the 
KSL-W peptide into PLGA microspheres has been shown to result in peptide elution over 
4-7 days when incubated in a 20% Pluronic F-127 gel (Machado et al., 2013). Of interest, 
the in vitro application of the KSL-W peptide in conjunction with a biofilm degrading 
enzyme (DispersinB®) has been found to inhibit the growth of biofilm embedded bacteria 
that are found in chronic wounds, including MRSA and Pseudomonas aeruginosa (Gawande 
et al., 2014). The combined use of an antimicrobial peptide and biofilm-degrading enzyme 
could be particularly effect in treating chronic ulcers, since biofilm development often 
underlies the ulcer resistance to antibiotics. It is important to note, however, that KSL-W 
has been found to promote neutrophil chemotaxis, which may be counterproductive in an 
already highly inflammatory wound environment. That said, the KSL-W peptide was also 
found to reduce oxygen radical production, which could be beneficial to ulcer healing 
(Williams et al., 2012). 
The targeting of connexin expression, which is clinically important to the treatment of 
chronic ulcers, has also been achieved through the use of mimetic peptides. Unlike the use 
of asODN, which prevents translation of connexin mRNA transcripts to produce protein, 
mimetic peptides are peptide sequences that are complementary to the conserved 
extracellular loop regions of the connexins. These mimetic peptides prevent the opening of 
connexon hemichannels, and also prevent the docking of connexons to form gap junctions 
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(Evans and Boitano, 2001). It has also been suggested that mimetic peptides can block 
GJIC without affecting the connexin structure. Two mimetic peptides have been developed 
to target the extracellular loop of Cx43 (GAP27) and Cx32 (GAP26), although the 
conserved nature of the extracellular loop that they target means that they have been found 
to target multiple connexins (Dahl, 2007, Spray et al., 2002, Warner et al., 1995). 
Application of GAP27 and GAP26 in vitro was found to reduce GJIC in fibroblasts within 
1.5 h (Wright et al., 2009), and accelerate keratinocyte and fibroblast migration (Pollok et 
al., 2011, Wright et al., 2009). Despite this, early passage cell cultured human diabetic 
keratinocytes and fibroblasts were not affected by GAP27, which appears at odds with the 
finding that Cx43 asODN promoted diabetic rat keratinocyte migration in vivo (Pollok et 
al., 2011, Wang et al., 2007). An alternative approach to targeting connexin expression 
using peptides is to target the Cx43 C-terminal tail to prevent interactions with other 
proteins. The internalisation protein antennapedia has been linked to the last 9 amino acids 
of the Cx43 tail (RPRPDDLEI) to produce the synthetic peptide ACT1. ACT1 is reported 
to out-compete interactions between the cytoplasmic tail of Cx43 and the PDZ2 domain of 
ZO-1, as well as stabilising Cx43 in the membrane and resulting in large plaque formation 
(Hunter et al., 2005). The use of ACT1 has been reported to accelerate wound re-
epithelialisation and reduce scar tissue formation, similar to Cx43 asODN (Ghatnekar et 
al., 2009, Rhett et al., 2008). More recently, clinical trials investigating the effect of ACT1 
found the peptide significantly enhanced wound closure relative to compression bandage 
therapy alone, and reduced the time taken for 50% and 100% ulcer re-epithelialisation to 
occur (Ghatnekar et al., 2014). It is interesting that a peptide that results in large Cx43 
plaque stabilisation in the membrane has similar effects to Cx43 asODN application, since 
asODN instead reduces the level of Cx43. ACT1 may produce similar effects to Cx43 
asODN through prevention of Cx43 interactions with other proteins, which could also be 
reduced in the event of Cx43 downregulation using asODN. Connexin-targeting peptides, 
as well asODN, could be promising therapeutic agents to bioactivate scaffolds that might 
be used to treat chronic ulcers. 
6.33 – Antisense therapy 
A number of other sequences have been applied in a wound healing setting without a 
scaffold that could be beneficial to ulcer healing. The application of siRNA sequences 
specific to MMP-9 were incorporated into a cationic polymer and reported to improve 
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wound closure, although the effect on re-epithelialisation or fibroblast migration was not 
demonstrated in vivo (Li et al., 2014). MMP-9 knockdown was also reported in fibroblast 
cells in vitro. The targeting of MMP activity could be particularly effective in chronic ulcers 
where MMP activity is often considered to be deleteriously upregulated, resulting in 
degradation of the ECM and growth factors (Mast and Schultz, 1996, Wysocki et al., 1993). 
Targeting MMP expression has also been achieved in vitro indirectly. Through application 
of asODN specific to TGF-ß1, it has been found that MMP-1 and MMP-9 expression was 
significantly reduced in keratinocytes and fibroblasts (Philipp et al., 2005). However, it has 
also been demonstrated that TGF-ß1 can upregulate both MMPs and their inhibitors, 
TIMPs (Gomes et al., 2012). In this case, knockdown of TGF-ß1 in a chronic ulcer setting 
may have the deleterious effect of removing TIMPs that are necessary to prevent matrix 
degradation. Another study that delivered TGF-ß1 siRNA to wounds through bioactivation 
of collagen-chitosan/silicone membranes argued that wound skin regeneration and scar 
reduction was improved (Liu et al., 2013). It was clear that TGF-ß1 downregulation was 
achieved in the tissue samples measured, although the study did not conclusively show that 
wound closure or scarring was improved. This finding supports the use of scaffold-like 
matrices as delivery devices for interference therapy. 
Another interesting candidate protein that could be downregulated through scaffold 
bioactivation is the glycoprotein osteopontin (OPN). Expressed as both extracellular and 
intracellular variants, the complete knockout of OPN has been shown to result in viable 
mice with no impediment to wound healing, other than disorganisation of deposited ECM 
fibres following incisional wounding (Liaw et al., 1998). While it has been argued by the 
authors that OPN may play an important role in tissue remodelling and wound resolution, 
a second study identified that knockdown using asODN to OPN appears to instead have a 
favourable effect on healing. OPN knockdown was found to reduce scarring and 
granulation tissue deposition, but more importantly in the context of that which would be 
most beneficial in an ulcer setting is that it accelerated wound closure (Mori et al., 2008). 
Crucially, OPN upregulation occurs in wounds and appears to be associated with 
inflammation (Cooper et al., 2005). In a chronic ulcer, where inflammation is often severe 
and protracted, it is possible that OPN could be deleteriously upregulated, although further 
study would be required to confirm this. Indeed, blocking platelet-derived growth factor 
(PDGF), a growth factor present in the conditioned media of inflammatory macrophages 
and mast cells, prevented OPN upregulation (Mori et al., 2008). These findings highlight 
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both OPN and PDGF as potential targets for knockdown in addition to connexins to 
promote wound healing.  
The development of a polymer coating to deliver Cx43 and Cx26 asODN had the effect of 
promoting wound healing across a number of different assessed areas, yet it is evident that 
there are number of other therapeutic agents that could be incorporated into the scaffold 
coating in conjunction with a cargo of connexin antisense sequences. 
 
6.4 – A revised role for dermal scaffolds in wound healing 
A number of scaffolds have been developed for use in treating various types of chronic 
ulcers as well as full-thickness burns. In the design of these products, it is often considered 
important that they mimic the native tissue, and in the case of acellular dermal scaffolds 
this involves the design of a fibrous matrix that can support fibroblast adhesion and 
proliferation as well as integrate with the wound (Chong et al., 2007). Scaffolds are also 
developed to be well tolerated within the wound, eliciting only a minimal inflammatory 
response, while also not causing a severe foreign body reaction (Figure 6. 1A). The current 
understanding that dermal scaffolds may serve as useful wound regenerative devices is 
perhaps being more readily accepted due to in vitro findings, in which scaffolds are often 
reported to accommodate seeded cells (Mo et al., 2004). Following detailed microscopic 
analysis of in vivo experiments in my study, however, it appears that collagen scaffolds, as 
well as alginate dressings and microspheres, do not encourage classical wound regeneration 
across a number of different variables that were assessed (Figure 6. 1B). The full-thickness 
wound application of an electrospun collagen scaffold fabricated in a similar method to 
previous studies (Torres-Giner et al., 2009) led instead to thickening of the epidermis at the 
wound edge in both mice and rats, and Cx43 and Cx26 were strongly upregulated in these 
regions. These findings are more in line with observations of diabetic rat wounds and 
chronic human ulcers, in which healing is perturbed (Mendoza-Naranjo et al., 2012b, Wang 
et al., 2007). The implication that scaffolds instead negatively impact wound healing is 
further supported by the association of PMNs with the scaffold and elevated levels of 
inflammation within the dermis (Chapters 3-5), (Gilmartin et al., 2013). Although this 
project made use of acute full-thickness wound models, the findings strongly support that 
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unmodified scaffolds could, instead of promoting chronic ulcer healing, have a detrimental 
effect on multiple aspects of healing. 
The desire to produce a wound-integrating dermal scaffold could also not be achieved by 
addressing the deleterious overexpression of Cx43 using a Cx43 asODN Pluronic gel 
(Figure 6. 1C), (Gilmartin et al., 2013). Despite successfully reducing Cx43 levels in 
keratinocytes at the wound edge, fibroblast attachment and proliferation was not 
significantly observed within scaffolds, although inflammatory cell invasion was reduced. 
Keratinocyte migration also occurred underneath scaffolds in a manner similar to a scab. 
Although there was some improved biocompatibility of the scaffold, scaffolds did not act 
as a replacement dermal matrix as desired. These findings strongly argue against the current 
understanding that scaffolds may behave as good substitutes for the dermis. Despite these 
findings in full-thickness animal models, moderate successes have been reported following 
clinical use of scaffolds over several months (Schonfeld et al., 2000, Karr, 2011). It has 
been demonstrated that even cellular scaffolds do not integrate with wounds and serve 
more as a temporary barrier that could promote ulcer healing (Griffiths et al., 2004). 
Although scaffolds may not be useful as a dermal substitute in chronic ulcer healing, it is 
possible that scaffolds could adopt a new role with regards to promoting wound healing. 
Through the development of a novel Cx43 and Cx26 asODN scaffold coating technique, 
the results of this project suggest that scaffolds may better serve as a drug delivery device 
that does not integrate with wounds and instead acts more as a dressing overlying the 
wound (Figure 6. 1D). In this way, restoration of the epithelial barrier would not be 
obstructed while proteins that are aberrantly upregulated in cells within the ulcer could be 
continuously targeted through sustained drug delivery. 
 
6.41 - Study limitations 
While a number of results were obtained throughout the course of the project, the study 
did have certain limitations. Application of coated scaffolds to wounds for longer than 5 
days (chapters 4-5) may have been affected due to the transient nature of Tegaderm film 
adhesiveness. In future, cyanoacrylate glues could be used, as they have been in other 
scaffold studies, to fix scaffolds in place on the wound (Duffy et al., 2005). The regrowth 
of animal hair, as well as variation in the length of time that Tegaderm remained  
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Figure 6. 1 – Interpretation of the function of uncoated and bioactive scaffolds 
(A): A model outlining the previously believed mode of scaffold action. Scaffolds were 
typically considered to serve in a similar capacity to native extracellular matrix, acting as a 
scaffold for fibroblast attachment and proliferation, while keratinocytes migrated over the 
matrix. (B): The actual observed behaviour of wounds in response to uncoated collagen 
scaffold application. Keratinocytes aggregate as thickened non-migratory bulbs at the 
wound edge in which Cx43 and Cx26 is strongly upregulated. Polymorphonuclear 
leukocytes (PMNs) as opposed to fibroblasts are found to associate with the scaffold, while 
PMNs are also found to infiltrate the dermis of uninjured tissue. (C): Transient 
bioactivation of collagen scaffolds using a Cx43 asODN Pluronic gel (green) reduced 
epithelial thickening and PMN infiltration, while epithelial migration occurred underneath 
scaffolds in a manner similar to a scab. (D): The function of sustained release polymer 
coated scaffolds bioactivated using both Cx26 and Cx43 asODN. Coated scaffolds were 
only loosely associated with the wound edge, and keratinocyte migration was significantly 
enhanced. Epithelial thickening was again prevented relative to uncoated scaffolds, while 
elevated PMN infiltration of the dermis was similarly prevented. In all cases, keratinocyte 
migration was not found to occur over scaffolds. 
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adherent to the animal back, meant that re-application of Tegaderm was not possible. At 
D10 and D15, wounds typically showed no signs of scaffolds, although it was unclear 
whether this was due to the hydrolysis of the inner scaffold over time or the loss of 
scaffolds from the open wounds. Another limiting factor regarding coated scaffolds that 
has previously been discussed is the fact that the polymer coated scaffolds sectioned very 
poorly using a cryostat. Because of this, coated scaffolds could not typically be visualised in 
H&E tissue sections, although scaffold presence was confirmed macroscopically prior to 
histological processing. 
In terms of experimental limitations, the combination of two novel Cx26 asODN 
sequences was performed throughout chapter 5 due to the limited availability of wounds (4 
per animal) as well as the time remaining in the project. Testing of the sequences 
individually in future could be performed in order to identify the most effective sequence. 
With regards to the characterisation of changes in wound edge connexin expression 
throughout the thesis, it has previously been shown that only a limited number of 
keratinocytes at the leading edge typically dynamically change in connexin levels during 
wound healing (Qiu et al., 2003). It would be extremely difficult to separate out these small 
number of cells from the rest of the tissue in order to assess changes in connexin protein 
quantity using western blotting approaches, for instance. The use of an immunofluoresnce 
staining approach was therefore used to characterise connexin expression throughout the 
project. This technique has been similarly practiced throughout a number of previous 
studies and additionally permits identification of the localisation of protein expression 
(Davis et al., 2013, Mendoza-Naranjo et al., 2012a, Zhai et al., 2014). 
 
6.5 – Future experiments 
6.51 – Performing a systematic review of scaffold-related literature 
Over the course of the study it became clear that uncoated solid collagen scaffolds had the 
effect of inhibiting wound closure and re-epithelialisation, while also resulting in connexin 
misexpression typical of chronic wounds. These findings indicate a potential novel role for 
unmodified scaffolds as inducers of chronic-like wounds. Scaffolds could, in this case, 
instead be used as a tool to generate a chronic wound model. This possibility is particularly 
attractive due to the limited number of existing chronic wound animal models, which can 
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also be also be expensive and time consuming to develop (Ansell et al., 2012). Scaffolds can 
be relatively inexpensive to fabricate and the negative effects of scaffold application in this 
study was found to be detectable within 24 hours. 
As a follow on study to this thesis, a series of future experiments to develop scaffolds as a 
chronic wound model would first require investigation into the most appropriate material 
that could be used to generate scaffolds most likely to elicit a chronic-like wound. 
Additionally, the scaffold form (such as an electrospun scaffold or hydrogel) would need to 
be selected based on its potential to cause chronic wound-like symptoms. At the outset of 
this thesis, collagen was selected as the base scaffold material while elctrospinning was 
chosen as the method to fabricate the matrices. In both cases, these choices were made 
following literature searches of both animal and human in vivo scaffold studies, as well as in 
vitro studies that reported scaffold fabrication (Buttafoco et al., 2006, Huang et al., 2003). 
Additionally, Dr Suwan Jayasinghe at UCL had both the means and experience to assist 
with the initial setup of electrospinning collagen. The primary intention of the literature 
searches was to identify one of the most commonly applied scaffolds that could be 
affordably mimicked in the laboratory, such that the results obtained in this study could 
address current developers of scaffolds and biomaterials journals. Collagen is not only used 
in a large proportion of commercial scaffolds, it is often selected for use in animal studies 
(Buttafoco et al., 2006, Huang et al., 2003, Shevchenko et al., 2010). Similarly, 
electrospinning was commonly reported throughout the literature as a relatively simple 
technique capable of producing fibrous matrices in an effort to mimic some of the 
properties of the native dermis (Huang et al., 2003). Importantly, this technique was also 
available to us to use in the UCL mechanical engineering department. 
In a series of future experiments to develop a scaffold chronic wound model, the initial 
justification for using scaffolds, choice of scaffold material and method of scaffold 
fabrication would instead be based on a more rigorous approach than that undertaken in 
this thesis. In particular, performing a systematic review of existing randomised controlled 
trials (RCTs) in which scaffolds were applied to wounds would more accurately help 
identify the type of scaffold that is more likely to induce a negative effect on healing, and 
therefore be more useful in the setup of a chronic wound model. Performing a systematic 
review using Cochrane methodology will provide a comprehensive overview of the effects 
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of different kinds of scaffolds on wound healing, making it possible to make an informed 
choice of scaffold. 
A Cochrane review consists of multiple sections. An abridged background and justification 
for performing the review, which would later be expanded on, is as follows: 
Background 
Chronic ulcers remain difficult to treat and have a major impact patient quality of life, while 
also costing the UK over £3 billion annually (Posnett and Franks, 2008). The assessment of 
chronic wounds at a preclinical level is hampered by the limited availability of animal 
models that realistically recapitulate chronic wounds (Ansell et al., 2012). Current models of 
impaired healing consist of animals that are diabetic, aged, treated with bacteria or 
subjected to anoxic insults. In the case of localised anoxia, this can be achieved through the 
application of magnets to form a pressure ulcer (Ansell et al., 2012). The generation of aged 
animals can be expensive, while diabetic wounds still heal, albeit slower, unlike many 
chronic wounds. The development of a new and affordable model that can better mimic 
chronic wounds would be extremely useful in preclinical studies as a tool for drug testing. 
A previous study has highlighted the potential for solid scaffolds to act as inducers of 
chronic-like wounds, features present in human chronic wounds. Most notably, wound re-
epithelialisation was significantly perturbed, alongside severe thickening of the epidermis 
and misexpression of connexin proteins at the wound edge (Gilmartin et al., 2013). 
Why it is important to do this review 
Development of a scaffold capable of inducing chronic-like wounds requires prior 
investigation into the most appropriate materials and scaffold types that could be used to 
make a scaffold. While a systematic review of various wound dressings and scaffolds for 
healing wounds has been performed, this was not a Cochrane review. Additionally, it does 
not assess the endpoints required in order to identify the types of scaffolds have the 
strongest negative effect on wound healing (Snyder et al., 2012). 
The objectives of the Cochrane review would be as follows: 
1) To provide pooled observations and effect estimates (meta-analysis) of outcomes 
of the effects of different scaffold types on wound healing (including inflammation 
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via real time (RT)-PCR analysis/inflammatory cell counts, wound re-
epithelialisation and measurements of granulation tissue formation) 
2) To compare these estimates between different scaffold types in order to determine 
which scaffold type is most likely to elicit a negative reaction. 
With regards to the methods section of the systematic review, this review will capture 
RCTs involving adult patients in which scaffolds (or ‘advanced dressings’) have been 
applied to chronic ulcers. When assessing RCTs for inclusion in the review, guidelines on 
reporting trials available on the EQUATOR (Enhancing the Quality and Transparency of 
Health Research; http://www.equator-network.org) network, which will be complied with 
where applicable during the data extraction process. The EQUATOR network was 
established with the primary goal to compile multiple guidelines concerning the reporting 
of healthcare studies. These guidelines, such as the PRISMA guidelines, are available from 
the EQUATOR website, and include a checklist of information to report when assessing 
other meta-analyses or systematic reviews (Moher et al., 2009). These include requirements 
for the reporting risk of bias present in studies as well as patient numbers, information 
sources and search strategies. Several other key reporting guidelines are also catalogued by 
the EQUATOR network. These include CONSORT, STROBE, STARD, COREQ, 
ENTREQ, SQUIRE, CARE, SAMPL and SPIRIT. 
Search strategy 
Searching for RCTs should be performed separately by two individuals. MEDLINE, The 
Cochrane Library, EMBASE and ISI Web of Science will be used to perform the searches. 
RCTs will be searched for using the following keywords. As an example, the number of 
search records found using MEDLINE (prior to excluding any studies) is stated in square 
brackets after each search string, below: 
'Randomized controlled trial' AND 'ulcer' AND 'matrix' [45 results] 
‘Randomized controlled trial’ AND ‘scaffold’ [55 results] 
‘Randomized controlled trial’ AND ‘ulcer’ AND ‘dressing’ [501 results] 
'Randomized controlled trial' AND 'dermal' AND 'substitute' [23 results] 
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Searches will also be performed by substituting 'RCT' with 'CCT' in the search string. It is 
anticipated that additional search terms will be added to this list following general searches 
of scaffold studies to identify more scaffold-related search terms.  
Study exclusions 
Both RCTs and controlled clinical trials (CCTs) will be included, regardless of whether 
blinding took place or sample size. Cohort or case-control studies will not be included. 
Studies that do not involve the primary application of scaffold structures to wounds (e.g. 
systematic reviews) will also be excluded. Searching for 'scaffold' can also return results that 
focus on bone/cartilage repair or blood vessel stents. These focus on a different type of 
‘scaffold’, separate to dermal scaffolds, as and such will also be excluded. 
Retrieving records 
As an example of performing searches, the relevant RCTs/CCTs for the search string 
'randomized controlled trial' AND 'ulcer' AND 'matrix' are presented below using 
PubMed to search: 
Search: 'randomized controlled trial' AND 'ulcer' AND 'matrix' [45 results] 
Exclusions: [22 publications - non scaffold related, not RCT/CCTs] 
Included: [23 publications]. After excluding publications, 23 records remained that met all 
inclusion conditions. These studies were as follows: 
1. The effects of sulodexide on both clinical and molecular parameters in patients with 
mixed arterial and venous ulcers of lower limbs. Serra R et al. (Drug Des Devel Ther. 2014 
May 13;8:519-27) 
2. The influence of patient and wound variables on healing of venous leg ulcers in a 
randomized controlled trial of growth-arrested allogeneic keratinocytes and fibroblasts. 
Lantis JC 2nd et al. (J Vasc Surg. 2013 Aug;58(2):433-9) 
3. [Dynamic changes of MMP-1, MMP-9 and TIMP-1 in the refractory diabetic dermal 
ulcers treated by autologous Platelet-rich gel]. He LP et al. (Sichuan Da Xue Xue Bao Yi 
Xue Ban. 2012 Sep;43(5):757-61) 
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4. Randomised, controlled pilot to compare collagen and foam in stagnating pressure 
ulcers. Piatkowski A et al. (J Wound Care. 2012 Oct;21(10):505-11) 
5. A prospective, single-center, nonblinded, comparative, postmarket clinical evaluation of 
a bovine-derived collagen with ionic silver dressing versus a carboxymethylcellulose and 
ionic silver dressing for the reduction of bioburden in variable-etiology, bilateral lower-
extremity wounds. Manizate F et al. (Adv Skin Wound Care. 2012 May;25(5):220-5) 
6. Wound stimulation by growth-arrested human keratinocytes and fibroblasts: HP802-247, 
a new-generation allogeneic tissue engineering product. Goedkoop R et al. (Dermatology. 
2010;220(2):114-20) 
7. Randomized comparison of OASIS wound matrix versus moist wound dressing in the 
treatment of difficult-to-heal wounds of mixed arterial/venous etiology. Romanelli M et al. 
(Adv Skin Wound Care. 2010 Jan;23(1):34-8) 
8. Assessment of the antimicrobial effectiveness of a new silver alginate wound dressing: a 
RCT. Trial C et al. (J Wound Care. 2010 Jan;19(1):20-6. Erratum in: J Wound Care. 2010 
Mar;19(3):109) 
9. Clinical effectiveness of an acellular dermal regenerative tissuematrix compared to 
standard wound management in healing diabetic foot ulcers: a prospective, randomised, 
multicentre study. Reyzelman A et al. (Int Wound J. 2009 Jun;6(3):196-208) 
10. Clinical assessment of the effect of a matrix metalloproteinase inhibitor on aphthous 
ulcers. Skulason S et al. (Acta Odontol Scand. 2009;67(1):25-9) 
11. Effect of oxidised regenerated cellulose/collagen matrix on proteases in wound exudate 
of patients with chronic venous ulceration. Smeets R et al. (Int Wound J. 2008 
Jun;5(2):195-203) 
12. Evaluation of the nano-oligosaccharide factor lipido-colloidmatrix in the local 
management of venous leg ulcers: results of a randomised, controlled trial. Schmutz JL et 
al. (Int Wound J. 2008 Jun;5(2):172-82) 
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13. The lack of reliability of clinical examination in the diagnosis of wound infection: 
preliminary communication. Serena TE et al. (Int J Low Extrem Wounds. 2008 
Mar;7(1):32-5) 
14. Effect of amelogenin extracellular matrix protein and compression on hard-to-heal 
venous leg ulcers: follow-up data. Romanelli M et al. (J Wound Care. 2008 Jan;17(1):17-8, 
20-3) 
15. Synergistic action of protease-modulating matrix and autologous growth factors in 
healing of diabetic foot ulcers. A prospective randomized trial. Kakagia DD et al. (J 
Diabetes Complications. 2007 Nov-Dec;21(6):387-91) 
16. Effect of amelogenin extracellular matrix protein and compression on hard-to-heal 
venous leg ulcers. Vowden P et al. (J Wound Care. 2007 May;16(5):189-95) 
17. The effect of amelogenins (Xelma) on hard-to-heal venous leg ulcers. Vowden P et al. 
(Wound Repair Regen. 2006 May-Jun;14(3):240-6) 
18. Mitogenic bovine whey extract modulates matrixmetalloproteinase-2, -9, and tissue 
inhibitor of matrixmetalloproteinase-2 levels in chronic leg ulcers. Varelias A et al. (Wound 
Repair Regen. 2006 Jan-Feb;14(1):28-37. Erratum in: Wound Repair Regen. 2007 Jan-
Feb;15(1):163) 
19. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for 
diabetic ulcers. Niezgoda JA et al. (Adv Skin Wound Care. 2005 Jun;18(5 Pt 1):258-66) 
20. Effectiveness of an extracellular matrix graft (OASIS WoundMatrix) in the treatment of 
chronic leg ulcers: a randomized clinical trial. Mostow EN et al. (J Vasc Surg. 2005 
May;41(5):837-43) 
21. Can a tissue-engineered skin graft improve healing of lower extremity foot wounds 
after revascularization? Chang DW et al. (Ann Vasc Surg. 2000 Jan;14(1):44-9) 
22. Promotion and acceleration of diabetic ulcer healing by arginine-glycine-aspartic acid 
(RGD) peptide matrix. RGD Study Group. Steed DL et al. (Diabetes Care. 1995 
Jan;18(1):39-46) 
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23. Accelerated healing of chronic sickle-cell leg ulcers treated with RGD peptide matrix. 
RGD Study Group. Wethers DL et al. (Blood. 1994 Sep 15;84(6):1775-9) 
 
Data to be extracted from retrieved publications 
The following data will be extracted: 
1. Year and language of publication 
2. Country 
3. Date range that the trial took place 
4. Inclusion and exclusion criteria (e.g. age, sex, grade of wound, diabetes) 
5. Number of participants (both those screened and those only included in trial) 
6. Details of procedure/treatment schedule 
7. Outcomes. The following outcomes will be extracted: 
 Primary outcome: percentage wound area reduction at 12 weeks from baseline 
 Secondary outcome: re-epithelialisation percentage at 12 weeks from baseline (if 
such evaluation is performed) 
 Secondary outcome: inflammatory reaction quantification (percentage increase in 
inflammatory markers/cells over controls if molecular approaches used, otherwise 
observational findings) 
8. Methods employed to reduce bias 
9. Trial funding and source 
Hetereogeneity 
In order to determine whether the data extracted would be suitable for statistical meta-
analysis, extracted results will be subjected to heterogeneity assessments. In particular, 
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heterogeneity will be assessed visually using forest plots, χ² tests. An additional method is 
the interpretation of the I2 statistic, which is calculated using the effect (Higgins et al., 
2003). Using the Cochrane guidelines, meta-analysis will only be performed if the returned 
I2 statistic is over 75%, in line with the recommendations of the Cochrane handbook 
(Higgins and Green, 2011b). 
Meta-analysis 
If specific outcome data is suitable for meta-analysis, the software program RevMan will be 
used to perform the analyses. The Cochrane handbook details common approaches to 
meta-analysis depending on the data obtained. In particular, the handbook outlines the 
available meta-analysis methods in RevMan when dealing with both dichotomous and 
continuous data; both fixed- or random-effects methods (Higgins and Green, 2011a). A 
results summary table can additionally be generated using GRADEpro software in order to 
grade the quality of evidence for each outcome. This is particularly important as it allows 
one to take into account the risk of bias within the data pool. 
It is anticipated that performing a systematic review with meta-analyses will help highlight 
the scaffold types and materials most commonly associated with causing a negative 
reaction, or least frequently improving healing. This information would be useful when 
generating a new scaffold with the purpose of generating a novel chronic wound model. 
6.52 – Establishment of a novel chronic wound model 
Following the completion of a review using Cochrane methodology, it is anticipated that a 
number of different scaffold materials and fabrication methods will be identified as suitable 
to produce scaffolds that will perform well as inducers of chronic-like wounds. The first 
step would be to further research the scaffold processing techniques identified throughout 
the review, such that they could be employed to generate scaffolds composed of different 
materials. The different scaffolds would then be eligible for application to full-thickness 
excisional wounds made to the backs of rats, as performed in this thesis. The number of 
rats that produced significant results in the previous series of scaffold experiments would 
again be used in the planned experiments (n=8). The time points of D1, D3 and D5 will be 
selected as cull points to compare the time taken for different scaffolds to induce epithelial 
thickening, inflammation and Cx43/Cx26 expression. These time points will also allow 
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result comparisons to be made to the collagen scaffold experiments performed in this 
thesis. 
In the first chapter of this thesis, collagen scaffolds were found to be largely degraded by 
day 5. The loss of the scaffold from the wound after such a short period of time would not 
be ideal in the generation of a chronic wound model. Polymer coated collagen scaffolds, on 
the other hand, appeared to shift from the position in which they were placed within the 
wound. One method to correct this problem could be to superglue scaffolds onto wounds 
(Duffy et al., 2005). This would prevent loss of the scaffold from the wound at later 
timepoints. Additionally, the use of higher ratios of lactide to glycolide PLGA or PCL only 
scaffolds, in combination with superglue, would result in scaffolds that remained within 
wounds for longer periods of time. These scaffolds could be applied to wounds in the same 
manner as the collagen scaffolds, but would allow time points of 30 days and beyond to be 
assessed. 
Assessments 
Light microscopy 
As performed in this thesis, re-epithelialisation and wound edge epithelial thickening would 
be measured at D1, D3 and D5. Additionally, measurements will also be recorded at D10, 
D15 and D30, as it is anticipated that the continued presence of a scaffold will postpone 
re-epithelialisation. These time points would help identify the scaffolds that had the most 
severe impact on re-epithelialisation. A delay to wound healing on the scale of a month or 
more would suggest that scaffolds were capable of inducing a 'chronic-like' to partially 
recapitulate human chronic wounds. If, at D30, the continued presence of a scaffold has 
prevented re-epithelialisation from occurring, longer time points can be considered. In 
addition to re-epithelialisation and wound edge thickening, the histological assessment of 
inflammatory cells invading the dermis will again be performed on the same tissue to 
explore whether specific scaffold materials and forms are more likely to induce chronic 
wound-like inflammation. In addition, the visual detection of foreign body giant cells 
(FBGCs), which are fused macrophages formed in response to a foreign body, can also be 
performed. FBGCs typically form after a number of weeks in response to a present foreign 
body (Cegielski et al., 2008). The detection of these cells at the D15 and D30 time points 
would help further confirm the inhibitory effect of scaffolds used in this model. 
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Inflammation 
In addition to the microscopic assessment of scaffold-treated wounds, performing real-
time (RT) PCR on digested wound tissue following scaffold application would provide a 
more conclusive means of quantifying inflammation. The protocol to enzymatically 
degrade tissue followed by RNA purification has been outlined in previous studies (Jackson 
et al., 1990, Peirson and Butler, 2007), and would be followed to extract RNA from 
scaffold-treated wounds. The wounds examined histologically in the previous light 
microscopy section would first be bisected; one half would be fixed, frozen and 
cryosectioned while the other half would be stored in RNAlater and used for RNA 
extraction. This step would be performed using wound tissue harvested from all planned 
time points (D1, D3, D5, D15, D30 and potential future time points beyond 30 days).  
Numerous studies have quantified pro-inflammatory cytokine gene expression in order to 
investigate inflammation more rigorously than is possible using histological approaches. In 
particular, expression of the pro-inflammatory cytokines IL-1, IFN-γ and TNF-alpha are 
often studied, corresponding with classically activated pro-inflammatory M1 macrophages 
(Autenrieth et al., 1997, Gougeon et al., 2013). Determination of expression of these genes 
relative to a stably expressed housekeeping gene will allow comparisons of wound 
inflammation following treatment with different kinds of scaffolds. On the other hand, 
increased expression of IL-10 and TGF-ß is more commonly associated with alternatively 
activated (M2) macrophages, responsible for tissue repair and attenuation of pathological 
inflammation (Mosser, 2003). Detection of a higher ratio of M1 to M2 cytokine expression 
may therefore serve as a useful indicator of inflammation in the wound bed following 
scaffold treatment. 
Enzyme-linked immunosorbant assays (ELISA) 
A common feature of chronic diabetic wounds is a reduced stability of the transcription 
factor hypoxia inducible factor-1 (HIF-1). The α subunit of HIF-1 is tightly regulated by 
cell oxygen availability; under normoxic conditions, HIF-1α has a rapid turnover of less 
than 5 minutes (Hofer et al., 2002). Under hypoxic conditions, HIF-1α escapes 
proteasomal degradation and translocates to the nucleus, whereupon it dimerises with the ß 
subunit. The assembled HIF-1 transcription factor can then act to regulate expression of a 
large number of genes, and importantly can drive VEGF expression to promote 
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angiogenesis (Forsythe et al., 1996). A reduced level of HIF-1 stability as found in diabetic 
skin can therefore result in a reduced response to anoxia, promoting the maintenance of 
the anoxic environment due to limited resultant angiogenesis (Botusan et al., 2008). In the 
case of the scaffold experiments that are planned to be performed, it may transpire that the 
placement of large solid scaffolds creates a localised region of anoxia, on account of the 
limited cellular penetration of scaffolds experienced throughout this thesis. Indeed, H&E 
staining revealed that vascular smooth muscle cells were not present within intact scaffolds. 
As such, scaffolds may be capable of creating an anoxic environment that is characteristic 
of chronic wounds. Anoxia could be detected in scaffold-treated wounds by measuring 
HIF-1α activity through ELISA. Commercially available ELISA plates containing the HIF-
1α response element adherent to individual wells within a plate allow the addition of 
nuclear extracts (kit available from: http://www.abcam.com/hif-1-alpha-transcription-
factor-assay-kit-ab133104.html). Detection of an increased level of HIF-1α would suggest 
that the wound environment is anoxic. Performing ELISA on nuclear extracts obtained 
from harvested scaffold-treated wound cells will be a useful step to confirm whether 
scaffolds can again induce features characteristic of human chronic wounds. 
Western Blotting 
Western Blotting may also be used to detect the levels of Tissue Inhibitors of matrix 
Metalloproteinases (TIMPs) in scaffold-treated wounds. In acute healing wounds, TIMPs 
act to inhibit the activity of MMPs such that the balance between deposition and 
degradation of new matrix proteins is finely tuned (Nagase et al., 2006). In chronic ulcer 
fluid, TIMP levels have been found to be significantly reduced, which may partially 
underlie the often severely degraded ECM present in these ulcers (Nwomeh et al., 1999). A 
decrease in TIMP protein in harvested wound tissue following scaffold treatment may 
suggest that scaffolds have the potential to disturb the normal balance between MMP and 
TIMPs, similar to the situation in chronic wounds. This could be due to the presence of a 
polymer scaffold that is systematically targeted for degradation. Western Blotting using 
anti-TIMP and anti-MMP antibodies on whole-cell protein extracted from wound tissue 
may therefore also be used to confirm whether the ratio between the two is altered, similar 
to chronic wounds. 
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Detection of cell death 
It has been previously shown in VLUs that extensive cell death occurs relative to healthy 
skin, in conjunction with hypoxia and oxygen reperfusion. This was demonstrated through 
the use of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
staining; fragmented DNA staining, characteristic of apoptosis, was found to be elevated in 
VLUs (Herouy et al., 2004). To establish whether the application of a scaffold may be 
causing a chronic-like wound by similarly increasing the level of apoptosis in the wound, 
wounds treated with scaffolds will be harvested, frozen and cryosectioned. Tissue will then 
be TUNEL stained. Using this method, it can be detected whether scaffolds induce 
apoptosis similar to in chronic ulcers, and in which specific cell types. 
Impaired granulation tissue deposition using scaffolds 
During the course of wound healing, the major collagen type deposited at the wound bed is 
type III. As the wound matures, type III collagen is gradually hydrolysed and replaced by 
type I collagen (Klinge et al., 2000). It has been observed that in individuals where healing 
is perturbed, such as diabetics, the amount of collagen type I deposited at the wound is 
reduced (Black et al., 2003). This finding has been explained by the decreased numbers of 
fibroblasts present in diabetic wounds. In this thesis, applying an obstructive scaffold 
resulted in very few non-inflammatory cells infiltrating the wound. It is possible, therefore, 
that collagen scaffolds may be recapitulating healing impaired diabetic wounds by similarly 
preventing fibroblast infiltration of the wound bed, resulting in decreased collagen 
deposition. It has been shown previously that the application of Cx43 asODN to wounds 
accelerates fibroblast migration both in vitro and in vivo (Mori et al., 2006). This may 
explain why the coating of scaffolds with Cx43 asODN resulted in faster contraction of 
granulation tissue at D10 and D15; due to an increased number of fibroblasts migrating 
into wounds and depositing collagen. 
In order to determine whether the scaffold chronic-like wound model limits collagen 
deposition in the newly forming granulation tissue, staining for collagen type I can be 
performed. Immunostaining for collagen I can be performed on untreated wounds, 
scaffold-treated wounds and Cx43 asODN coated scaffold-treated wounds. Comparing 
staining levels between the different treatments will highlight whether the scaffold is 
preventing collagen I deposition relative to untreated wounds. Additionally, quantifying 
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collagen I deposition in Cx43 asODN scaffold-treated wounds can help identify whether 
Cx43 asODN improves collagen deposition in the wound. 
In addition to this, the orientation of deposited collagen fibres can also be assessed to 
gauge the extent of scarring in wounds following scaffold placement. In normal skin, 
collagen is normally arranged in a basket-weave formation. In scarred tissue, however, 
collagen fibres are typically aligned with each other (Gurtner et al., 2008). Following 
scaffold application, assessment of collagen fibre alignment can be performed to assess the 
extent of scarring encountered using scaffolds. Excessive scarring may indicate that the 
scaffold is capable of reproducing a poorly healing wound. 
6.53 – Continued development of the polymer coated drug-eluting scaffold 
Characterising the role of Cx43 asODN coated scaffolds in reducing inflammation 
In this thesis, although Cx43 asODN coated scaffolds were shown to reduce inflammatory 
PMN recruitment, it was not demonstrated how Cx43 knockdown resulted in this effect. It 
has been separately shown in the lung that decreasing Cx43 channel conductivity with the 
blocking peptide 43Gap26 reduced neutrophil adhesion to endothelial cells, ultimately 
lowering the migration of neutrophils to the site of inflammation in the lung (Sarieddine et 
al., 2009). Cx43 is expressed on the surface of neutrophils and endothelial cells, such that 
the knockdown of Cx43 reduces communication between the two cell types. It is possible 
that a similar situation occurs during wound healing; Cx43 knockdown may reduce the 
recruitment of PMNs by reducing PMN to endothelial cell communication (and 
subsequently adhesion), resulting in decreased PMN transmigration to the site of injury. In 
order to test this hypothesis, similar in vitro experiments to those performed by Sarieddine 
et al. (2009) could be performed. In their study, they utilised lung alveolar epithelial murine 
pneumocyte monolayers that had been treated with the Cx43 blocking peptide, to which 
they applied neutrophils. To perform a similar experiment relevant to wounding, 
neutrophils isolated from rat skin by density gradient ultracentrifugation or flow cytometry 
can be treated with the Cx43 asODN sequence used in this thesis. Following the seeding of 
these neutrophils onto separate skin keratinocyte and endothelial cell monolayers, cells can 
be rinsed then fixed, after which the adhesion of cells can be visualised using a light 
microscope to determine the frequency of adhering neutrophils within single field of views. 
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This approach would be necessary to identify whether Cx43 knockdown improved healing 
by reducing neutrophil adhesion and, as a result, transmigration to the wound site.  
Linking Cx43 knockdown to fibroblasts in the granulation tissue 
One of the areas that was lacking in this thesis was the assessment of granulation tissue 
deposition. While it was shown that the overall area of granulation tissue and wound size 
was reduced following Cx43 asODN coated scaffold application, it was not shown whether 
Cx43 knockdown in fibroblasts resulted in this effect. It has been elsewhere demonstrated 
in vitro that Cx43 knockdown in fibroblasts improves their migration through stabilisation 
of the GTPases Rac1 and RhoA (Machacek et al., 2009, Mendoza-Naranjo et al., 2012a). 
Acceleration of granulation tissue and collagen deposition may occurr as a result of 
enhanced fibroblast migration through activity of Cx43 asODN. However, differences in 
Cx43 expression were not detectable by eye following immunofluorescence staining of 
both mouse and rat wounds in this thesis, mainly due to the background fluorescence often 
present within the wound bed. 
One method to detect Cx43 levels in the wound bed would be to use an 
immunohistochemistry approach using horseradish peroxidase (HRP) instead of 
fluorescence conjugated antibodies, on account of the high background fluorescence in the 
wound. Another method to assess whether Cx43 asODN coated scaffolds reduced 
fibroblast Cx43 expression would be to use flow cytometry and Western Blotting. 
Harvesting scaffold-treated wound tissue at D1, D2, D3 and D5 can be performed, using 
the same approach as outlined in the previous sections. Enzymatic digestion of the wound 
tissue to release cells can be performed by following an enzymatic digestion protocol that 
has been successfully used in other studies (Seluanov et al., 2010). Fluorescence-Activated 
Cell Sorting (FACS) can then be performed to isolate cells expressing alpha smooth muscle 
actin (present on activated myofibroblasts) and PDGF-R. Both of these markers have been 
previously identified as effective in the isolation primary fibroblasts (Sharon et al., 2013). 
Following FACS, performing a Western Blot on the whole cell lysates of control scaffold 
vs Cx43 asODN scaffold treated wounds using an anti-Cx43 antibody would then reveal 
whether Cx43 asODN scaffolds knocked down Cx43 expression in vivo. This result would 
support previous in vitro findings that link Cx43 knockdown to enhanced migration in 
fibroblasts. 
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Using Cx43 asODN coated scaffolds to deliver other therapeutic agents 
As detailed in section 6.3, a number of additional therapeutic agents are available that can 
be used to coat scaffolds in the same manner performed in this thesis. In particular, growth 
factors such as VEGF (Silva and Mooney, 2007), antibacterial peptides like KSL-W 
(Williams et al., 2012) and anti-Cx43 peptides such as ACT1 (Ghatnekar et al., 2014). The 
combination of the existing Cx43 and Cx26 asODN sequence with these sequences in a 
sustained release scaffold coating could further enhance full-thickness wound healing. The 
testing of these agents in conjunction with Cx asODNs would involve the same full-
thickness wounding procedure that was performed on rats in this study. Four full-thickness 
wounds would be made to the backs of rats, and each wound would be treated with a 
scaffold coated in one of the new therapeutic agents. In addition, wounds can be coated in 
both Cx asODNs and another therapeutic agent, similar to how both Cx43 and Cx26 
asODN were combined in this study. This would be done in order to detect whether there 
could be a synergistic effect between Cx asODNs and the other therapeutic agents being 
tested. The same time points of D1, D3, D5, D10 and D15 will be first assessed to 
determine the effect of the therapeutic agents on inflammation, re-epithelialisation, 
granulation tissue formation and wound closure. It is anticipated that the existing coated 
scaffold may serve as a useful and translatable drug delivery device to improve wound 
healing. 
6.6 – Conclusions 
At the outset of the study, little was known in terms of the biological role of dermal 
scaffolds and in-depth assessment of the cellular response to scaffolds was lacking. 
Throughout the course of the project, it was discovered that a number of scaffolds 
appeared to be poorly optimised in their current state as they perturbed healing and 
induced characteristics of slow healing diabetic wounds. Bioactivation of scaffolds with 
Cx43 and Cx26 asODN using a polymer coating technique had the effect of improving 
wound healing, yet this was not through integration of scaffolds with wounds. It is possible 
that this objective could be achieved in the future with further optimisation of bioactive 
delivery from coated scaffolds. It appears that scaffolds may currently instead best serve as 
sustained drug delivery devices than behaving as a temporary matrix as they were perhaps 
intended. 
6. Discussion 
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Chronic ulcers pose a challenge to treat and existing standard treatments can be ineffective. 
The development of an easily applicable polymer coating to scaffolds resulted in sustained 
delivery of asODN that would be particularly useful in a chronic ulcer where connexin 
expression is known to be perturbed. A number of additional asODN and siRNA 
sequences, as well as peptides and growth factors could also be incorporated into scaffolds 
andinvestigated for their effect in vivo to produce an even more effective drug delivery 
scaffold. Interestingly, Cx43 and 26 asODN improved scaffold biocompatibility, such that 
a Cx asODN coating might also be applicable to a number of implantable devices and 
dressings that could benefit from improved biocompatibility. 
The developed Cx43 and Cx26 asODN coated scaffolds are potentially inexpensive, off-
the-shelf devices that overcome many of the pitfalls of more expensive complex cellular 
scaffolds. Following the results obtained in acute wounds, it is anticipated that sustained 
asODN delivery to chronic ulcers using coated scaffolds may promote ulcer healing. 
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